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Abstract
Colorectal cancer, the most common cancer in males and females who do not smoke,
is diagnosed in approximately 3,500 Scots each year. Despite having a large envi¬
ronmental contribution, the substantial genetic basis of colorectal tumours is still
poorly understood. In this project we have adopted a number of approaches to try
and further characterise this genetic contribution of colorectal cancer.
To begin to understand tumour progression, we first characterised the gene ex¬
pression changes observed in various tumours using SAGE, EST and microarray
data. Although many genes were identified as differentially expressed in cancers, lit¬
tle congruence was observed between tumour types and even expression platforms.
We next compared gene expression changes observed along chromosomes to local
chromatin structure, and showed that regions of constit.utively open structure gen¬
erally show an increase in gene expression in cancer. Despite the lack of congruence
between expression data shown previously, we illustrated that such a correlation be¬
tween gene expression change in tumours and chromatin structure can be observed
using various expression platforms and across a variety of tumours.
To further characterise the role of chromatin structure in tumours, we also investi¬
gated the rates of mutation and selection across chromatin categories. DNA damage
and repair is a key process in cancer progression and we have shown, through inter
species alignments, that although chromosomal regions of a relatively more open
chromatin structure undergo lower rates of mutation, levels of purifying selection on
synonymous sites are highest in regions of closed chromatin.
As part of the COGS/SOCCS group the role of DNA repair in colorectal cancer
was finally further investigated through a case-control association study. Tagging
SNPs in genes predicted to be associated with DNA repair were selected and sub¬
sequently typed by the group in approximately 1000 cases and 1000 controls. The
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In 2003 1,858 Scottish males and 1,507 Scottish females were diagnosed with col¬
orectal cancer and approximately 5% of all Scots will develop the disease at some
point in their lifetime. Despite dramatic reductions in mortality rates in recent years
only around half of these individuals are expected to survive five years 11]. World¬
wide, over a million cases of colorectal cancer will be diagnosed this year, accounting
for over 9% of all new cancer cases, a figure only exceeded by cancers of the lung
and breast. Rates of colorectal cancer incidence are not however constant across the
globe with two-thirds of all cases of colorectal cancer occurring in the most developed
countries. Survival rates are also markedly lower in the UK than in other Western
European countries, and this has been tentatively attributed to delays in treatment
and later stages at diagnosis [2],
The diagnosis of tumours at an early stage has however been shown to have a
dramatic affect on colorectal cancer survival rates. The Dukes and Modified Dukes
systems for staging colorectal tumours as well as the TNM (Tumour, Node Metas¬
tasis) staging systems, each defines a tumour according to factors such as degree
of invasion of the mucosa, progression to lymph nodes and metastasis. Patients di¬
agnosed at an earlier stage have a markedly improved prognosis than those with a
more developed tumour, with 83% of patients diagnosed at Duke's stage A (tumour
penetrated into mucosa of bowel wall only) surviving five years compared to only
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3% diagnosed at Duke's stage D (tumour spread to multiple organs) [3]. Diagnosing
tumours early on in their development can therefore dramatically increase survival
rates, and consequently the development of genetic tests for the identification of
individuals at risk from the disease is a priority in colorectal cancer research. Like¬
wise understanding the progression of tumours should assist in the development of
more affective interventions. There is consequently a need to further understand the
genetic mechanisms underlying colorectal cancer.
1.1.2 Molecular progression
Colorectal carcinogenesis has often been described as a multi-stage process involv¬
ing progressive genetic alterations along a relatively well characterised phenotypic
pathway [4, 5]. This step-wise progression from normal to tumour tissue is defined
by the adenoma-carcinoma sequence, whose first stage is characterised by the alter¬
ation of normal intestinal crypts to aberrant crypt foci (ACF) or microadenomas,
often as a result of APC loss or mutations in the k-Ras gene. The size, number and
features of these aberrant crypt foci are in turn associated with the number of be¬
nign adenomas that characterise the next stage in tumour progression. Postmortem
studies have shown that in Western populations the incidence of these adenomas
is approximately 30-40% [4|. Upon the accumulation of certain genetic alterations
these adenomas are subsequently transformed into in situ tumours, and in the final
stage to metastatic carcinomas [6]. It should be noted however that this simplified
pathway of tumour progression is not applicable to all cases of colorectal cancers.
For example carcinomas have been shown to arise from lesions rather than adenomas
[7] and follow the inflammation-dysplasia-carcinoma sequence. However the types
and frequencies of mutations observed in these alternative routes of carcinogenesis
are believed to be analogous |8].
One of the earliest molecular events in the progression of almost all colorectal
tumours is loss of function of the APC gene product. Mutations in APC have
been identified in up to 80% of sporadic colorectal tumours and germline muta¬
tions in the gene lead to familial adenomatous polyposis [4]. The molecular events
that characterise the later stages of colorectal carcinogenesis can broadly be broken
down into two alternative pathways; microsatellite instability (MSI) and chromosome
instability (CIN) (although tumours with near-diploid chromosomes displaying no
microsatellite instability can be observed, they are relatively rare [9]).
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The microsatellite instable phenotype results from defects in DNA repair. Main¬
taining the integrity and accuracy of DNA and the genes it encodes is an important
step in avoiding cancer progression and a number of the genes associated with col¬
orectal cancer have been shown to be involved in DNA replication and repair. These
include various mismatch repair genes. These genes, involved in the correction of
single-base mismatches that arise during DNA replication, also eliminate insertion
deletion loops that result from gains or losses of short repeat units within microsatel¬
lite sequences. Defects in these genes lead to the accumulation of detectable ab¬
normalities at these microsatellite regions, and MSI is consequently a hallmark of
mismatch repair (MMR) deficiency. People with a deleterious germline mutation
or hyper-methylated promoters at a MMR gene display large numbers of instable
loci (microsatellite instability-high; MSI-H) and this is frequently seen in patients
with heriditary non-polyposis colorectal cancer (HNPCC). Around 10 to 15% of spo¬
radic colon tumours will also show at least some microsatellite instability (MSI-L)
110, 11, 12]. Although the development of tumours after the loss of efficient mismatch
repair is often simply the result of an accumulation of mutations in key genes such
as TP53, some tumour suppressors, such as TGFBR2 and BAX, contain microsatel-
lites within their coding regions. Loss or gain of nucleotides at these microsatellites,
resulting from this loss of efficient MMR, will lead to frameshifts inactivating the
corresponding gene [13, 14].
The CIN phenotype is characterised by the gain or loss of chromosomal regions
or even entire chromosomes and is observed in approximately 85% of colorectal tu¬
mours. Although the mechanism of CIN is poorly understood it has been associated
with various mitotic-spindle and DNA replication checkpoint genes. For example mu¬
tations in two genes that control the human mitotic checkpoint, BUB1 and BUBR1,
have been observed in several CIN colon cancer cell lines. Although it is suggested
that the CIN and MSI phenotypes may be a result of cancer rather than its cause,
examination of colorectal and endometrial cancers illustrates that there is an inverse
relationship between CIN and microsatellite instability, i.e. MMR deficient cancers
generally do not display chromosome instability and vice versa. The rate of tumour
progression is also faster in MSI cancers and it is therefore likely that CIN and MSI
are alternative routes to tumour development [14, 15].
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1.1.3 Major syndromes
It has been shown in numerous studies that individuals with a first-degree relative
diagnosed with colorectal cancer are two to three times more likely to develop col¬
orectal cancer than the general population [16, 17, 18]. This relative risk is increased
dramatically if two or more relatives have been diagnosed with colorectal cancer, and
especially if the onset of the disease was relatively early in their lifetimes. Where a
number of individuals from the same family are affected with the disease in this way,
there is strong evidence that a genetic syndrome may be responsible. Of the ma¬
jor colorectal cancer syndromes Familial Adenomatous Polyposis (FAP) displays the
highest absolute lifetime risk, with 90% of affected individuals developing colorectal
tumours by the age of 45 [19). The gene responsible for the majority of FAP cases is
APC, and mutations in this gene lead to individuals developing hundreds to thou¬
sands of adenomatous polyps in their colon and rectum that can each subsequently
develop into tumours. As FAP results from dominant mutations in the APC gene
and offspring of affected individuals are at a 50% risk of developing the disease, FAP
is a strong candidate for genetic screening within affected families [20].
A number of FAP patients (i.e. patients with multiple colorectal adenomas) do
however have no identifiable pathogenic germline mutations located in the APC gene
ORF (open reading frame) [21], and it has been shown that in approximately 7-8%
of affected individuals the FAP phenotype is caused by biallelic mutations at the
MYH gene (MYH-associated polyposis) [21, 22, 23]. MYH is involved in repairing
8oxoG:A mispairs that primarily result from oxidative damage. As oxidative damage
is particularly prevalent within the gut, inactivation of MYH is likely to make carriers
particularly susceptible to mutations that lead to colorectal tumours. Biallelic MYH
mutations are however relatively rare within the general population [24],
Hereditary Nonpolyposis Colorectal Cancer (HNPCC or Lynch Syndrome), like
APC associated FAP, is an autosomal dominant disorder with high penetrance. 80%
of affected individuals develop tumours by the age of 75 [25|. However, unlike FAP
patients, individuals with HNPCC do not display an abnormal number of colorectal
polyps. Consequently cases of HNPCC are more difficult to identify, especially as
the disorder can also lead to a number of other cancers complicating an individu¬
als family history. HNPCC results primarily from defects in the mismatch repair
pathway and significantly more affected individuals with this syndrome display ev¬
idence of microsatellite instability than is observed in all colorectal cancer patients
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[26]. Although there are at least 18 human genes associated with DNA mismatch
repair, defects in the MLH1 and MSH2 genes account for the majority of HNPCC
cases. Redundancy among the other 16 genes may account for their relatively low
contribution to the disorder [27, 11, 10].
Although together FAP and HNPCC account for the vast majority of cases of in¬
herited colorectal cancer in strongly affected families, there are a number of further
rare, inherited syndromes associated with colorectal tumours that include Peutz-
Jeghers syndrome (PJS) and juvenile polyposis syndrome (JPS). Peutz-Jeghers syn¬
drome is an autosomal dominant disorder that is characterised in affected individu¬
als by multiple hamartomatous and adenomatous gastrointestinal polyps as well as
melanin spots on the lips and buccal regions [28]. It is estimated that 93% of individ¬
uals with PJS will develop a noncutaneous cancer by the age of 64 with 39% of them
developing a tumour of the colon |29]. The majority of PJS cases have been shown
to be associated with germline mutations at the gene encoding the serine-threonine
kinase, STK11 [30]. Juvenile polyposis syndrome, that is also an autosomal domi¬
nant disorder, is a rare childhood-onset disease demonstrating with hamartomatous
polyposis, diarrhea and gastrointestinal tract bleeding. This disorder has been linked
with the SMAD4 and BMPR1A genes in up to 60% of cases [31, 32],
1.1.4 Major tumour suppressors and oncogenes
In 1986 Herrera et al. identified a deletion of 5q in a patient with familial adenoma¬
tous polyposis [33]. This initial discovery eventually led to the identification of one
of the key genes in colorectal cancer, the tumour suppressor APC. As mentioned,
mutations in APC have been identified in up to 80% of sporadic colorectal tumours
and certain germline mutations in the gene lead to familial adenomatous polyposis.
Further mutations in APC, such as I1307K, have also been potentially associated
with familial colon cancer. These mutations, unlike those underlying FAP, are not
thought to directly underlie the development of colorectal tumours despite families
carrying these mutations displaying elevated levels of colorectal cancer incidence.
Rather it is believed that these mutations act by promoting sporadic mutations at
other neighbouring parts of the gene. The T to A transversion underlying I1307K
leads to an unstable run of eight adenines (from (A)3T(A)4) and a somatic mutation
at this poly-adenine tract is observed in approximately 42% of tumours involving
I1307K carriers, compared to only 4% of controls (127 cases and 127 controls) [34].
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The majority of these mutations are an insertion of a single adenine leading to a
frameshift and mis-translation of downstream codons. APC is consequently a key
gene in colorectal cancer and as a result has come to be known as the "gatekeeper"
gene [35, 36].
The mode of action of APC is through the modulation of the /3-catenin protein. In
its wild-type form the APC protein inhibits /3-catenin. However certain mutations in
the APC gene can lead to its uncontrolled accumulation in the cytoplasm ultimately
leading to aberrant cell signal transduction and growth. It is believed this occurs
through the association of /3-catenin with certain T-cell transcription factors, leading
to aberrant expression of key Wnt responsive genes (e.g. c-myc, c-jun, Fra and cyclin
D1) [35, 37],
In 1988 Volgelstein et al. showed that a second region, located on chromosome
18, was lost in approximately 73% of colorectal carcinomas [38]. The DCC (deleted
in colorectal carcinoma) gene was later identified in this region and it was shown
that the expected survival time of patients was significantly reduced if this gene
was found not to be expressed. However recent evidence suggests that the DPC\
(SMAD^) gene, found 1.26Mb upstream of DCC, may also be a key gene from this
region [36]. Of 20 unrelated individuals with juvenile polyposis syndrome sequenced
at this gene, 5 were shown to carry the same exonic 4bp germline deletion. None of
240 controls examined carried the same mutation [31, 39].
Another tumour suppressor involved in colorectal cancer progression is p53. Up
to 75% of sporadic colorectal tumours contain a mutation in the p53 gene, and
affected patients have a significantly poorer prognosis in both terms of outcome and
survival time. Wild-type p53 is involved in DNA repair via the arrest of the cell
cycle at Gl (allowing corrections of the DNA to be made) as well as the induction
of apoptosis. Consequently mutations of the p53 gene can lead to the accumulation
of DNA damage as well as uncontrolled cell growth [36].
One of the apparently key oncogenes involved in colorectal carcinogenesis on the
other hand is KRAS. Activation of KRAS leads to the continuous transmission of
extracellular growth signals to the nucleus resulting in the uncontrolled growth of
affected cells. However the Src non-receptor tyrosine kinase, c-myc and c-erbB2 have
all also been associated with the colorectal cancer phenotype [36, 40].
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1.1.5 Low penetrance genes and polymorphisms
The major genetic syndromes discussed in 1.1.3 are thought to only account for 2-6%
of colorectal cancer cases [411, despite twin studies suggesting that up to 35% of cases
have some form of heritable contribution [42]. In agreement with this, a substantial
number of colorectal cancer cases have been shown to be familial in nature, i.e.
cases are observed between related individuals more often than would be expected
by chance, but in such a way that they can not be explained by the patterns of
inheritance associated with the FAP or HNPCC syndromes [36]. Relatives of patients
with supposedly sporadic cases of colorectal cancer have also been shown to be at
an increased risk of developing the disease than the general population. There is
therefore a substantial genetic contribution to colorectal cancer not accounted for
by the high penetrance genes associated with the major genetic syndromes, and
although there may still be further high penetrance genes to be discovered, it is
likely that combinations of lower penetrance alleles account for most of this unknown
genetic contribution [41].
Despite substantial effort in recent years to identify low-penetrance genes involved
in colorectal cancer, few genes have been unequivocally associated with the disease.
The low penetrance nature of the genes means they will rarely cause multi-case
families such as those observed with FAP or HNPCC and consequently case control
studies, where the frequencies of polymorphisms in affected individuals are compared
to those in unaffected controls, have become the method of choice for detecting
these alleles. However, few polymorphisms shown to be associated with colorectal
cancer have been replicated across studies and this is at least partly the result of the
insufficient sample sizes and the lack of sufficiently rigorous statistical testing used in
these analyses. Variants that have however been shown to be significant in more than
one study include a rare VNTR (Variable Number of Tandem Repeats) allele in the
HRAS-1 oncogene, the polymorphism associated with the rapid acetylator phenotype
of the N-acetyltransferase NAT2 and a synonymous change in the MTHFR gene
involved in folate and methionine metabolism [43, 41, 44], Models of the contribution
of low penetrance alleles to the onset of colorectal tumours have however predicted
there may be hundreds of rare polymorphisms with some form of association with
the onset of colorectal cancer.
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1.1.6 Genetic testing/screening
The use of screening techniques such as faecal occult blood testing (FOBT) and sig¬
moidoscopy have been shown to reduce colorectal cancer mortality rates by between
15 and 50%, and the NHS has recently announced that from 2006 all individuals
aged between 60 and 69 will be given the opportunity to be tested for colorectal
cancer using FOBT. This technique, that detects small amounts of blood in a pa¬
tients faeces that may result from polyps or tumours, although less effective than
sigmoidoscopy or colonoscopy is less invasive and has been shown to display the
highest participation rates [45]. Individuals from high risk families such as those
with HNPCC or FAP are also offered regular screening (generally via colonoscopy).
However faecal blood detected by FOBT is not necessarily an indication of a tumour;
likewise FOBT and sigmoidoscopy have been shown to miss a substantial number of
tumours and a negative test is not a guarantee that a patient is free from colorectal
cancer. It has therefore been proposed that genetic testing should precede or be used
in conjunction with these screening procedures. For example, 50% of the offspring of
a single FAP patient will not carry the APC mutations associated with the disorder
and therefore may prefer to not undergo regular invasive screening if genetic tests
prove this is the case. Likewise the genetic screening of the general population for
mutations associated with colorectal cancer could be used to identify high risk indi¬
viduals for whom regular screening would be particularly beneficial. For this type
of genetic testing to be cost effective however, mutations that confer a substantial
relative risk and that are relatively common in the population need to be identified.
1.1.7 Environmental factors
As mentioned, the incidence of colorectal cancer is higher in developed countries
than in the developing world and this has been attributed to the differences in diet
and other environmental factors observed between these regions. Various studies
have shown that the incidence of colorectal cancer in immigrants to the USA from
countries such as Japan, whose incidence of colorectal cancer is relatively low, can
increase rapidly to match or even surpass that of the host population [46], There is
therefore strong evidence that dietary and environmental factors contribute substan¬
tially to the development of colorectal tumours. However the evidence as to what
factors affect the rates of colorectal cancer is often weak and contradictory, a result
of the complex interplay of many dietary, genetic and environmental factors and the
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difficulty of isolating the specific contributing factor.
One of the factors with the strongest finks to colorectal tumours however are
Nonsteroidal Antinflammatory Drugs or NSAIDs. NSAIDs, such as sulindac and
aspirin, have consistently been shown to have a protective effect with respect to can¬
cer development. A study by Chan et al. in 2005 showed that those women who
consumed more than 14 325-mg tablets of aspirin a week for at least ten years had a
53% decreased risk of colorectal cancer compared to women who took no aspirin [47].
Similar affects have been observed with other NSAIDs [48]. Although these results
initially appear promising, large doses of NSAIDs have been associated with side-
affects such as an increased risk of gastrointestinal bleeding, and consequently the
potential benefits from the long term use of high doses of NSAIDs are outweighed by
their inherent risk [48) (it has been predicted that the prevention of 1 or 2 colorectal
cancer cases per 10000 people will be at the cost of 8 cases of severe gastrointesti¬
nal bleeding). Further understanding of the mechanisms by which NSAIDs protect
against colorectal tumours may however lead to better treatments in the future.
Another factor potentially associated with colorectal cancer prevention is Hor¬
mone Replacement Therapy or HRT. A meta-analysis by Nanda et al. of a number
of observational studies concluded that recent use of HRT conferred a 33% reduc¬
tion in colon cancer risk (the protective affect of HRT appears to be lost after the
cessation of HRT treatment) [49]. This link between HRT and colorectal cancer is
further (tentatively) supported by the fact that the incidence of colorectal cancer
among females has fallen since the introduction of HRT but remained relatively sta¬
ble among males. A causal fink between HRT and colorectal tumour prevention has
however yet to be established and certain randomised controlled trials have found no
supporting evidence of a link between HRT and colon tumours. Given the potential
side-affects of sustained HRT, such as breast and endometrial tumours, the use of
estrogen itself is unlikely to be a viable treatment of colon cancer.
HRT has also been predicted to modify the association between body weight and
colorectal cancer risk. An association between body weight or BMI and colorectal
cancer has been observed in men in a number of studies but no such association
has been observed in women, and HRT has been proposed as an explanation of this
discrepancy [50|. Direct links between the intake of dietary factors such as fat, fibre,
vitamins or antioxidants are however generally weak or contradictory and further
work is required to elucidate the impact of diet on colorectal cancer incidence.
Other environmental factors with weak or contradictory evidence of modifying
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colorectal cancer risk include smoking, alcohol and physical activity [511. Conse¬
quently, despite the environment playing a large part in the progression of colorectal
tumours, the interplay between factors is likely to be complex and has yet to be fully
elucidated.
1.2 Bioinformatics and Cancer
Primarily due to the increase in large scale digital datasets, the roles of bioinformatics
and computational biology in oncology have expanded dramatically in recent years.
The advent of the genomic era has moved the focus of cancer research increasingly
to the global level and to the integration and analysis of complex datasets. This is
perhaps most apparent in the field of gene expression where there has been an explo¬
sion in genonre-wide analyses of tumour transcript levels. The role of bioinformatics
has however extended to all areas of cancer research and some examples of this are
discussed below.
An area in which bioinformatics has played a major role is cancer diagnostics.
The aim of cancer diagnostics is to identify and stage tumours, primarily through
the detection of specific proteins, RNA or other molecular markers in an affected
individual. For example, cancerous prostate cells produce abnormally large amounts
of the prostate-specific antigen (PSA) into the bloodstream, consequently a num¬
ber of tests have been developed that measure the levels of this protein in patients
[52], The initial identification of these molecular markers requires the comparison of
tissue/blood samples from normal and affected individuals and to identify protein
diagnostic signatures in the bloodstream mass spectrometry is commonly used. How¬
ever, the high dimensionality, substantial noise and complex spectra that characterise
mass spectrometry results means that mass spectrometry data requires substantial
computational processing to piece together the most parsimonious protein contents
of various tissue samples [53]. For example the sequencing of the human genome has
allowed the mass spectra of all potential proteins to be determined [54]. Likewise,
the characterisation of protein profiles that characterise tumour samples also gener¬
ally involves computational analyses such as those based on support vector machines
(SVM)[55],
Cancer diagnostics is not however restricted to the analysis of protein levels,
transcript levels have also been used to characterise tumours. For example bioin-
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formatics analysis of genome-wide gene expression studies has shown that certain
tumours can be sub-classified according to their expression profiles [56]. The role of
bioinformatics in gene expression and cancer is discussed further in chapter 2.
Bioinformatics has also been used extensively in disease gene identification. The
identification of genes associated with a disease traditionally involves the use of link¬
age or association studies. Not only are bioinformatic tools generally used in the
design of these studies (for example in picking tagging variants [57]) but as both
these techniques are limited in their resolution, so that often a number of potential
candidate genes remain, a number of bioinformatic approaches have been developed
to prioritise genes in candidate regions. The most common first approach to ranking
candidates is to identify if any of the genes of interest have a known function asso¬
ciated with the disease. This is most commonly achieved through Gene Ontology
(GO) term annotation. The gene ontology project is an attempt to assign certain
terms describing biological processes, cellular components and molecular functions
to all genes and gene products. A gene in a candidate region that is involved in a
key process associated with the relevant disease, is generally thought more likely to
be the gene of interest from that region. Programs that have been developed around
this principle include Freudenberg and Propping's disease clustering algorithm [58],
G2D [59], and POCUS [60]. (Gene Ontology terms, tag selection, association studies
and cancer are discussed further in chapter 5)
Gene Ontology terms and other annotations are also often used in conjunction
with expression data to identify disease genes (e.g. SUSPECTS [61]). For example,
although a number of genes may be differentially expressed in a particular disease,
only a subset of these will also be associated with key biological processes or path¬
ways. Further annotations that have been used in prioritising candidate genes in
this way include protein interaction data, domain annotations, PubMed reports and
eVOC annotations [62],
It has also been shown that disease genes may, as a group, have certain se¬
quence characteristics that mark them out from the rest of the genome. For example,
Lopez-Bigas and Ouzounis illustrated that proteins involved in hereditary disorders
tended to be longer, more conserved, phylogenetically extended and without close
paralogues [63]. Likewise CpG islands, long 3' UTRs, and large numbers of exons
have been associated with hereditary disease genes. Consequently programs such
as PROSPECTR [61] have been developed that allow the prioritisation of potential
disease genes according to their sequence characteristics.
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The recent rapid expansion in sequenced genomes has also further assisted in the
examination of candidate disease regions. Not only can disease genes/regions and
other annotations identified in model organisms be more readily transferred to the
human genome, but multi-species conservation can be a key tool in further refin¬
ing regions associated with the disease. For example, a number of ultra-conserved,
non-genic regions of the human genome have been potentially associated with dis¬
ease [64, 65]. Likewise conservation can be used to identify domains and regulatory
motifs within a region that may be involved in disease progression. Conservation
has also been used, primarily in monogenic diseases, to identify variants potentially
associated with disease. For example those non-synonymous changes in a gene that
are at a position that is particularly conserved across species are thought more likely
to be deleterious, particularly if the observed change is not observed in other homol¬
ogous transcripts [66]. Further criteria that have been used to predict potentially
deleterious polymorphisms include the affect of a polymorphism on splicing, domain
score predictions and protein structure [67]. SNP (single nucleotide polymorphism)
prioritisation is discussed more in chapter five.
The ever increasing number of sequenced genomes has also meant that bioinfor-
matics has begun to play an ever more important role in drug target identification
and validation. Until recently drugs were tested individually and generally influ¬
enced a previously known target. However the advent of the genomic era has led to
the acceleration of the drug discovery process. The first step in drug discovery, the
identification of a potential drug target, often involves identifying family members
and homologues of previously known drug targets and the subsequent classification
of these genes and their products according to their structural properties, locations
in the cell, evolutionary history [68] and expression profiles in both the target and
other organisms [69]. Once a group of potential targets has been identified, and the
molecular basis of the disease elucidated, it is then possible to predict computation¬
ally, drugs that will interact in an appropriate fashion with the target protein. If
an appropriate structure of the drug target has yet to be determined, a number of
algorithms have been developed that attempt to predict a protein's structure from
its amino acid sequence and its homology to proteins of known structure. Once a
suitable drug compound is determined, its activity is often further refined through
the computational analysis of the precise molecular structures responsible for the
drugs activity and potency.
The role of bioinformatics in cancer epigenetics is also expanding rapidly. Un-
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til recently there has been little data available on genome-wide epigenetic states in
the human cancer genome. However the dramatic reduction in costs of sequencing
and array technologies have led to a number of studies investigating the methyla-
tion patterns across the human genome. Although some studies have involved the
computational analysis of large bisulphite sequencing datasets [70, 71], genotyping
microarrays have allowed the investigation of epigenetic silencing on a truly global
scale. The underlying principle behind these studies being that where a copy of a
gene is silenced, all alleles corresponding to the transcripts from that gene will no
longer be expressed. In a similar fashion genotyping platforms have been used to
determine copy number variation in the human genome through looking at the ratio
of allele intensities obtained from DNA alone [72],
These however are only some of the many areas in which bioinformatics is playing
a key role in cancer research and given the wealth of data being generated in this





The link between cancer and gene expression has been well characterised. Several
of the most important genes in cancer progression can be classified as oncogenes or
tumour suppressors, whose aberrant expression through inappropriate methylation,
RNA degradation, mutations or copy number changes, can lead to tumour develop¬
ment. Although further analysis is generally required, as it is necessary to determine
those genes whose change in expression is the cause of the relevant tumour and not
simply its result, expression analysis can be a valuable tool for highlighting potential
candidate cancer genes.
The characterisation of gene expression has also proven a useful tool in identifying
those genes whose expression level is specific to a certain tissue or disease state,
analyses that can potentially allow for the development of specific therapies and
diagnostic tests. For example Alizadeh et al. [56] used gene expression profiles to
define two molecularly distinct sub-types of diffuse large B-cell lymphoma, likewise
van't Veer et al. [73] identified gene expression signature in breast cancer biopsies
associated with patients with a relatively poor prognosis.
Many genes associated with cancer also belong to one of several key pathways,
for example apoptosis, the cell cycle or DNA repair, likewise many of the key cancer
genes have been shown to interact [74], Analysis of expression signatures across
tissues can be used to identify those genes whose expression profiles are similar to
genes previously associated with the disease [75] and which themselves could be
involved in cancer progression.
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Further uses of gene expression analysis have included the identification of non¬
specific expression of a drug target that may result in undesirable toxicity and the
characterisation of copy number changes in tumours [76]. The investigation of tu¬
mour gene expression, and its comparison to expression levels in normal tissue, is
consequently a vital tool in further understanding the development and progression
of colorectal cancers.
In this analysis we investigated the expression of genes in normal and tumour
tissue samples via the analysis of Expressed Sequence Tags (ESTs). Our aim in
this study was to not only identify genes differentially expressed in various tumour
types, but to also identify differently expressed genomic regions, genes expressed
primarily in particular tissues of interest and gene coexpression. These data could
then subsequently be used in the prioritisation of genes for further examination in
association studies of colorectal and other cancers. For example, which genes are
expressed specifically in the colon and also show differential expression in colorectal
tumours and may therefore be specifically associated with colorectal cancer? What
genes are coexpressed with known tumour associated genes? Also what genes are
differentially expressed in not only colonic tumours but also other forms of cancer?
Out of interest we were also keen to compare these EST results to those from other
expression platforms. If we are to prioritise genes for candidate association studies
using expression data what difference does it make if other expression platforms are
used? Does the list of candidates dramatically change? What is the overlap between
platforms? Perhaps those genes that are consistently differentially expressed across
platforms are the true positives and therefore the truly interesting candidates.
2.1.1 Expressed Sequence Tags
ESTs are short, single pass reads of randomly selected cDNA clones that are a valu¬
able resource for the investigation of tumour gene expression. Although initially used
to identify the genes present in a genome of interest [77] they have been increasingly
used to characterise transcript expression profiles. Megy et al. for example identified
a number of genes overexpressed in the heart through the comparison of cardiac and
non-cardiac derived ESTs [78], Of the 35 genes deemed differentially expressed, five
had previously been associated with cardiac disorders and one was located in the lo¬
cus of a bleeding disorder. Expressed sequence tags can therefore play an important
role in elucidating potential disease gene candidates.
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ESTs are produced by first converting the mRNA content of a sample to cDNA
via reverse transcription. These more stable cDNA libraries are then typically cloned
into plasmid vectors and then sequenced from the 5' or 3' end to produce ESTs that
are generally a few hundred base pairs in length. It is important to note that although
3' ESTs by and large match the 3' of a transcript due to the reverse transcription
being primed by an oligo-dT sequence from their 3' end, the resulting cDNAs are
often incomplete and can lack a corresponding 5' end [77]. ESTs sequenced from the
5' end of a cDNA may therefore not necessarily represent the 5' end of the mRNA
but rather may derive from a more central portion of the gene.
The proportion of ESTs in a library matching a particular transcript should
be related to the levels of that transcript in the corresponding sample; as those
transcripts whose levels are high in a sample should be cloned into more vectors and
consequently sequenced more often. The use of ESTs to determine transcript levels
in this way is however dependent on the ability to unambiguously match ESTs to
the transcripts from which they were derived. The sequencing of ESTs can often be
of a poor quality and the large number of paralogues and homologous regions within
the human genome can make assigning ESTs to individual genes difficult. Likewise
many EST libraries have undergone normalisation or subtraction to amplify the
representation of genes of low expression. These libraries are therefore unsuitable for
use in gene expression studies as the link between EST numbers and gene expression
has been disrupted.
2.1.1.1 Statistical analysis
As most EST studies are unreplicated determining the significance of any observed
change in EST numbers between samples requires the use of appropriate statistical
tests. Although Fisher's exact and chi-square tests are often used in conjunction
with a Bonferroni multiple test correction in EST studies [79|, this type of analysis
is likely to be too conservative and exclude many genes that display true biological
changes in expression. Likewise, the use of the Fisher's exact test when both the row
marginal totals and column marginal totals are not fixed is controversial (in EST
studies only the number of clones sampled in each library is fixed) and therefore
Audic and Claverie developed a new statistical test specifically for use in tag based
gene expression studies [80]. The sole assumption of this test is that the observation
of any particular cDNA is rare, which is the case in most libraries where each cDNA
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is represented by at most only a few percent of all ESTs.
Whatever statistical test is used in a gene expression study it is necessary to
account for the large number of separate tests performed and to try and minimise
the number of false positives. Traditionally multiple testing has often been corrected
for by applying a Bonferroni correction, so that the probability of observing a single
false positive among all genes is less than 5%, however this is likely to be far too
conservative for gene expression studies, especially as the cost of a false positive in
a gene expression study is relatively low (individual gene expression levels can be
easily confirmed). An alternative to the Bonferroni correction is to calculate the q
value for each gene [81]; a measure based on the false discovery rate (rather than the
false positive rate as in traditional p values) that takes into account the number of
features being tested. The q value of a test represents an estimation of the number
of false positives that will be obtained if the respective test is called significant.
Not only can q values be thought of as less conservative than Bonferroni corrected
p values but they are also more informative as they predict the number of genes
among a given significant set that are likely to in fact show no difference in their
gene expression. A q value significance cutoff can consequently be set according to
the number of these genes that one is willing to accept.
2.1.2 Other expression platforms
In this analysis we attempted to confirm those genes deemed differentially expressed
in our study of EST libraries through comparisons with datasets derived on other
genome-wide expression platforms. Although each individual expression platform
has limitations and will generate a set of false-positives, we hypothesised that those
genes shown to be differentially expressed across platforms and samples are more
likely to be truly differentially expressed. We therefore compared the results from
our EST analysis to those derived from SAGE (serial analysis of gene expression)
and microarray studies.
2.1.2.1 Serial Analysis of Gene Expression
The SAGE technique for determining gene expression was first developed within the
Vogelstein-Kinzler colon cancer laboratory at the Johns Hopkins Oncology Centre
[82]. Like techniques based on ESTs, the SAGE method involves isolating unique
sequence tags from transcripts present within a tissue/sample, whose relative abun-
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dance should approximate to the expression levels of the corresponding mRNA. This
is achieved through a number of steps. First, the poly-A tails of mRNAs within
a sample of interest are captured on oligo-dT beads, and these captured mRNAs
are reverse transcribed to cDNA with the oligo-dT acting as a primer. To isolate
unique tags from each mRNA species the anchored cDNAs are then digested with a
restriction enzyme, usually Nlalll, so that only the bases following the final cutting
site of this enzyme are left attached to the magnetic beads. By attaching linkers that
contain the recognition site of a type II restriction enzyme, such as BsmFI, to the
resulting sticky ends, the ten base pairs immediately following the Nlalll site can be
isolated. To determine the mRNA content of the sample of interest these resulting
tags are then finally sequenced. This is achieved by first ligating pairs of tags tail to
tail to form ditags, amplifying these ditags by PCR (polymerase chain reaction) and
then releasing the linkers using Nlalll. The concatenation, cloning and sequencing of
these ditags then allows the expression levels of each mRNA species to be estimated.
This SAGE technique for determining gene expression generally has the same
advantages as methods based on ESTs; namely the results are digital in nature, no
pre-selection of genes is required and results are highly comparable between experi¬
ments and labs. The number of short SAGE tags per library are however generally
substantially higher than the number of (longer) ESTs produced per experiment, and
consequently SAGE can be more powerful at detecting genes with lower expression
levels. There are however a number of drawbacks to the SAGE technique, primarily
because this method for determining gene expression is strongly dependent on being
able to unambiguously assign a unique tag to each mRNA, which in practice is of¬
ten not possible. For example, some mRNAs simply do not contain the appropriate
restriction site, or the final site within the mRNA is immediately upstream of the
poly-A tail. Likewise imperfect digestion will lead to some tags being derived from
sites further upstream than the final site so that multiple tags correspond to the same
gene. Sequencing error and polymorphisms in these short lObp tags will also lead
to some being assigned to the wrong transcript, and tags are often generated that
are not lObp in length making the boundaries within ditags difficult to determine.
Blunt end ligation used within the SAGE protocol is also dependent on the corre¬
sponding terminal bases so that tag generation can be biased. Although protocols
have been determined to try and minimise these problems; for example repeating the
experiment with different restriction enzymes, producing longer tags and excluding
tags with low counts, these changes largely diminish the advantages of the SAGE
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technique [83].
The inherent problems of the SAGE technique can be illustrated using data from
one of the largest SAGE gene expression studies carried out to date (and the one
used in our analysis) that characterised the gene expression profiles within normal
human colorectal epithelium, colorectal tumours and pancreatic cancers [84], Of over
300,000 tags generated by this study over 70,000 were unique and 86% of transcripts
were represented by less than five tags. Consequently few genes can be deemed
significantly differentially expressed from this data, as there are simply insufficient
tags to provide the necessary power.
2.1.2.2 Microarrays
Microarrays have become increasingly popular for determining genome-wide expres¬
sion profiles, primarily because of their ease of use. Determining the expression
profiles in a variety of tissue samples can be done relatively quickly and at a rela¬
tively low cost. Determining gene expression through the use of SAGE or ESTs on
the other hand can require a substantial level of optimisation and sequencing.
The technology behind microarrays evolved from that of the Southern blot, where
the presence or absence of specific DNA sequences on a membrane is determined
through the addition of complementary, labeled probes. If the sequence of interest
is present, it will be bound by the probe and can consequently be visualised via its
corresponding label. The approach of microarrays is not however to add individual
probes to a DNA sample but rather to add the DNA or RNA sample to a collection
of thousands of probes, each of which corresponds to the complement of a section of
a transcript that may be expressed in the tissue of interest. By labeling the RNA
sample that is hybridised to the microarray with fluorescent dyes it is possible to
determine the expression levels of individual transcripts; as the more transcripts that
bind to the corresponding probes the greater the total fluorescence. In practice how¬
ever the relationship between transcript levels and fluorescence is not linear, in part
due to intensity-dependent effects, and microarray data must undergo substantial
processing.
The main stages of microarray processing are scanning/image analysis, normali¬
sation and transformation. The image analysis stage of microarrays involves deter¬
mining the fluorescence level of each spot/probe set on each array. In Affymetrix and
other types of arrays these intensities are then corrected for non specific hybridisa-
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tion by adjusting them according to the intensity of corresponding mismatch probes.
As probe intensity levels may differ between arrays for a number of non-biological
reasons (differences in RNA quantity, differences in labeling efficiency, scanner setup
etc) to allow for the comparison of intensities between arrays (or within two colour
arrays) it is necessary to normalise these intensities. A large number of different
normalisation procedures exist including loess, rma (robust multi-array) and vsn
(variance stabilising normalisation) but perhaps the simplest example is global me¬
dian normalisation in which the intensities on each array are simply scaled so that the
median intensity on each array is the same. Different normalisation procedures are
available as each makes different assumptions about the data and required outcome,
for example the choice of normalisation procedure can depend on whether or not the
expected levels of certain probes are known or whether the distribution of expression
levels is expected to be constant. Before or after normalisation microarray data are
often transformed to improve comparability and/or signal to noise ratios and the
simplest example of this is the log transformation. Microarray error distribution and
the advantages and disadvantages of the log transformation are discussed in more
detail in chapter 3.
The main problems associated with microarrays are primarily related to this re¬
lationship between probe-target binding and fluorescence. For example probes can
differ in their hybridisation efficiencies, so that some transcripts are less easily bound
by their corresponding probe and can be more easily released during the washing of
unbound RNA from the microarray. Likewise the incomplete dissociation of target
structures may inhibit target-probe binding. Certain RNAs may also bind inappro¬
priate probes or if a transcript's level is particularly high a probe set can become
saturated. Unlike the SAGE and EST techniques comparisons ofmicroarray datasets
between experiments and labs is also difficult and it is necessary to pre-specify the
content of a microarray so that the expression levels of unknown/unrepresented genes
will not be detected. With the advent of large scale sequencing technologies, it is




329 adult, human EST libraries were obtained from dbEST that were non-normalised,
non-subtracted and not obtained using the ORESTES (open reading frame ESTs)
technique [85] (although the ORESTES libraries provide a higher coverage of the
central, coding regions of transcripts, the approach leads to a certain level of pseudo-
normalisation [86]). Selected libraries contained a minimum of 250 sequences and
were grouped according to tissue and disease state. All 1,802,156 ESTs were sub¬
sequently RepeatMasked (http://www.repeatmasker.org/) and an initial attempt
made to identify them through Blasting [87] them against the Ensembl cDNA database
Ensembl genes were used in this analysis due to the support at Ensembl for down¬
stream analyses (Ensembl APIs, EnsMart etc). Any EST that matched an Ensembl
cDNA sequence with 95% identity over at least 100 base pairs was assigned to that
cDNA, a stringent enough threshold to exclude most sequence similar paralogues
(any paralogues that are above this threshold are much more likely to lead to the
loss of signal than to lead to spurious false positives). This high threshold was used to
ensure ESTs were not assigned to closely related paralogues. The remaining 527,951
ESTs were grouped together according to those that shared limited homology with
one another (again using the BLAST program as in Megy et ah; score > 40 and e-
value < 10~5) and formed into contigs using the CAP3 program [88]. A subsequent
attempt was made to assign these contigs to an Ensembl gene. Remaining ESTs
were discarded [78]. In the analyses in this chapter I focused on those ESTs we were
able to assign to a known gene. As in Megy et al. [78] BLAST rather than BLAT
[89] was used to assign ESTs to genes, however this is simply a result of the fact
that BLAT had only just been released when this analysis was undertaken. BLAT
would have undoubtedly been a better choice for this analysis (not least due to its
increased speed).
To identify potential differential gene expression between groups of ESTs (e.g.
prostate normal and prostate tumour) we utilised the Audic Claverie [80] and chi-
squared tests to compare the number of ESTs that had been assigned to a particular
gene or contig. The p values derived by these tests were subsequently used to cal¬
culate more informative q values through the use of the R statistics package [81].
Length corrections were not required as only ESTs primed from the ends of tran¬
scripts were used.
SAGE tag counts for pertinent libraries were obtained from the CGAP website
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Figure 2.1: Procedure for assigning ESTs to genes or transcripts
[90]. NCBI SAGEmap data [91] was used to map tags to Ensembl genes via Lo-
cusLink [92]. Those tags that mapped to more than one Ensembl gene were ignored.
As with the EST data, libraries were grouped together according to tissue and disease
state and counts were analysed using the same statistical tests.
Microarray data were obtained from the Gene Expression Atlas website for three
normal and five cancerous prostate experiments [93]. The average difference values
for each probeset on each chip had been scaled by GNF using the standard Affymetrix
scaling algorithm (i.e. the top and bottom 2% of probesets ranked by their average
intensity after perfectmatch-mismatch background correction were removed and the
remainder scaled so that their mean equaled 200). Values less than twenty were set
to twenty and averages made for each probe in each tissue type. Probes were mapped
to Ensembl gene IDs using data available at the Affymetrix website. Probes that
mapped to more than one Ensembl gene were excluded.
2.3 Results and Discussion
Having assigned as many ESTs as possible to either a gene or a contig it was possible
to analyse the distribution of their corresponding counts among the different tissues
and disease states. Analysis of the results in the corresponding appendix table1 high-
1 http://www.hgu.mrc.ac.uk/users/james.prendergast/appendixtable.xls
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lights that a number of the genes identified as differentially expressed in colorectal
cancer had previously been shown to be differentially expressed in colonic tumours.
For example Yow et al. showed that laminin receptor 1 was expressed approximately
9-fold higher in colon tumour tissue than in adjacent normal colonic epithelium [94],
a value that is in agreement with our observed change of x8.4. Likewise, galectin 4,
whose expression is believed to be restricted to the small intestine, colon and rectum
(we observed it in colon and pancreatic tissue) has been shown to be expressed 1.5 to
50-fold lower in colon adenocarcinomas than in adjacent normal mucosa [95]. This
value is also in broad agreement with our observed expression change of x5.1. The
large number of ribosomal proteins observed as differentially expressed in normal
and colorectal tumours, is also in agreement with observations made by Kasai et al.
[96] (recent publications have also indicated that defects in ribosomal proteins may
cause cancer in Zebrafish [97]). A number of the other genes that were shown to be
differentially expressed had previously been shown to be associated with the onset of
various cancer in humans. For example both EGR1 and NDPKB, whose expression
were shown to be significantly lower in colon tumours than in normal colonic tissue,
are putative tumour suppressors [98, 99]. Likewise HMGIY, whose expression was
not seen at all in normal colon, is a c-MYC target and potential oncogene that has
been shown to be associated with nuclear factor kappa-B [100]. Further interesting
genes include trefoil factor 3, the trefoil family of proteins has been strongly associ¬
ated with tumour progression [101], and ubiquitin which regulates many key cancer
associated genes through ubiquitination[102].
To ensure that the grouping together of different types of tumour samples ob¬
tained in different ways (bulk preparations, microdissections etc) was not adversely
affecting our results, we analysed a subset of colon libraries. Only libraries that were
derived from bulk preparations of adenocarcinomas were compared to bulk prepara¬
tions of normal tissue. As would be expected fewer genes were detected as expressed
in the colon by this smaller set (4617), however only four out of eighty genes that
had a p value less than 0.00012 in this investigation did not also have a p value
less than this threshold in the larger analysis. Consequently, despite these p values
being uncorrected, it appears the grouping together of libraries may only lead to the
detection of more genes and a potential increased sensitivity in our analysis.
Of the 16814 genes seen expressed in normal or cancerous tissue from one of
2A p value cutoff of 0.0001 was used in these analyses as this corresponded to a q value of
approximately 0.05
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our ten tissues of interest, 191 were exclusively observed in the colon. Of these,
only four had a p value less than 0.0001 for differential expression in tumours and
could therefore be potential colon-specific drug targets (all had elevated expression
in normal tissue):
• ENSG00000186382
• ENSG00000174992 Zymogen granule protein 16.
• ENSG00000183026
• ENSG00000016490 Calcium activated chloride channel 1 precursor.
Literature analysis confirmed that CLCAl is only believed to be expressed in the
small intestine and colon mucosa [ 103]. However, in order to undergo a more com¬
prehensive analysis of colon specific expression all EST libraries would have to be
included. The two genes without annotation have since been retired from Ensembl,
likely due to the mistranslation of the corresponding transcript.
In order to try and validate our results we looked for congruence between our
EST expression data and that derived using SAGE. In order to do this we obtained
the data pertaining to four SAGE libraries derived from normal and cancerous colon
tissue. The mRNA content of these tissue samples was initially represented by
55209 different SAGE tags, however, having removed those tags that did not occur
more than once in either normal or cancerous tissue and those that either did not
map to an Ensembl gene or mapped to more than one, only 4128 remained. As
mentioned above these SAGE tags derived from the work of Zhang et al. [84] who
found that 86% of transcripts were represented by less than five tags across all
libraries examined, by taking only a subset of these libraries we had likely increased
this percentage. Likewise our use of Ensembl genes likely increased the percentage of
unmapped tags as Zhang et al. found that only approximately 10% of tags mapped
to known Genbank mRNA entries. As only 2839 of these genes were also represented
in our EST dataset we could only validate a fraction of our results. To identify any
agreement between these sets of data we examined the EST p values for those genes
that had scored a p value less than 0.0001 using the SAGE technique. Of the 39
genes whose expression was elevated in normal tissue via SAGE at this threshold, 12
(31%) were also deemed to have elevated expression in normal tissue using the EST
technique (using the same threshold). The remaining 27 genes had EST counts that
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were not significantly different (with none of the genes showing a significantly higher
cancer EST count). When only the direction of expression change was examined (i.e.
was the p value greater or less than 0.5) then there was 74% agreement. Examination
of 200 genes not deemed significant by SAGE (100 genes either side of the gene with a
p value closest to 0.5) found that in 99.5% of cases both techniques agreed that there
was no significant difference in expression (one gene was deemed to have significantly
greater expression in normal tissue by the EST technique). Although this data
argues for at least partial congruence between SAGE and EST data, examination of
those genes displaying elevated expression in cancer by SAGE provides confusion. In
this set of genes both techniques agreed that ten of them (33%) were differentially
expressed. However nine of these were believed to have elevated expression in normal
tissue by the EST technique (i.e. the opposite of the SAGE results). Listed below
are those genes deemed significantly differentially expressed in both the SAGE and
EST analysis. EEF-1B was the only gene to display elevated expression in cancer
(q < 0.05), the rest showed elevated expression in normal tissue in both datasets.
• ENSG00000186676 Elongation factor 1-gamma (EEF-1B GAMMA).
• ENSG00000090920 FC fragment of IGG binding protein.
• ENSG00000166165 Creatine kinase, B chain. (B-CK).
• ENSG00000130654 Alpha 2 globin. (two tags)
• ENSG00000092841 Myosin light chain 1 (MLC1SA).
• ENSG00000167996 Ferritin heavy chain.
• ENSG00000131981 Galectin-3.
• ENSG00000171747 Galectin-4.
• ENSG00000162896 Poly-IG receptor (PIGR) .
• ENSG00000143377 Calpactin I light chain.
• ENSG00000161280 Hemoglobin gamma-a and gamma-g chains.
• ENSG00000128016 Tristetraproline (TTP).
• ENSG00000125148 Metallothionein-II (MT-II).
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Since we were unable to find a suitable, publicly available colon microarray dataset,
out of interest, we also examined the results obtained for the prostate tissue and
the congruence observed between microarray and EST data. Initial investigation
of those genes identified as significantly differentially expressed in prostate tumours
through the analysis of EST libraries revealed that there was enrichment in this set
of genes for those with a previous strong association with cancer. For example, 1 in
9 (17/156) had previously been shown by the Annotation Consortium [104] to have
such an association as opposed to the value of 1 in 20 (1106/22184) for the genome
as a whole (x2, p<0.001). Further investigation of this set revealed that it contained
potential proto-oncogenes (e.g. rac-alpha serine/threonine kinase [105]) and tumour
suppressors (e.g. DAN [106]).
In order to try and validate these results we compared them to those derived
using microarrays. Analysis of those Ensembl genes that were deemed significantly
overexpressed in normal tissue (p<0.0001) showed that where there was correspond¬
ing microarray data available for that gene it agreed with the direction of potential
expression change (i.e. whether the normal intensity was greater than the tumour
intensity) around 72-80% (first 64 or 30 matches) of the time. However, as with the
SAGE comparison, when those genes that were believed to be significantly up in
cancer were examined there was little agreement (43% over 21 matches).
Therefore of the 81 genes deemed differentially expressed in colon tumours by the
EST technique, over a quarter (22) were also deemed differentially expressed in colon
tumours using the SAGE technique. This is substantially more than we would expect
by chance (hypergeometric cumulative p < 0.0001) and supports the hypothesis of
congruence between expression platforms. Consequently irrespective of the platform
used, a large number of the same candidates will be retrieved in expression studies.
However almost half (9) of the genes deemed differentially expressed across both
platforms differed in their direction of change. It may be that many genes involved
in oncogenesis need only be dysregulated to promote tumour development and there
are some known examples supporting this hypothesis. For example both increases
and decreases in expression of MIC-1 have been associated with tumourigenesis
[107], However despite the significantly high congruence between the SAGE and
EST analyses a large number of genes were also deemed differentially expressed on
only one platform. Whether these genes are less important candidates than those
shared across platforms will require further analysis.
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2.3.1 Further analysis
A number of genes, such as tp53, have been associated with a variety of cancers
and consequently we identified those genes that were differentially expressed across
tissues. Although 1376 genes were deemed to be differentially expressed in at least
one of the six tissues (colon, kidney, liver, lung, prostate and testis) listed in the
corresponding appendix table3, only 55 were deemed differentially expressed in at
least four. These did however include previously known general cancer drug targets
such as HSP90 [108].
Analysis of the genomic location of differentially expressed genes illustrated that
particular chromosomal locations were enriched for genes likely to be up in tumour
tissue (as well as vice versa). This data suggests that the likelihood of a gene being
called differentially expressed in cancer may partially be dependent on its chromo¬
somal location. More detailed examination of one of these regions (that mapped
to band ql3.2 of chromosome 19) highlighted the fact that it contained five genes
deemed significantly differentially expressed in colon tumours (Galectin-4, 40S ribo-
somal protein S16, 40S ribosomal protein S19, FC fragment of IGG binding protein
and tristetrapoline) and that three of these were in the list of 13 that were also
deemed differentially expressed by the SAGE technique. In total this region con¬
tained 89 genes, four of which had been associated with cancer by the annotation
consortium (fibrillarin, suppressor of ty 5 homologue, rac-beta serine/threonine ki¬
nase and carcinoembryonic antigen CGM2) as well as NF-KAPPAB inhibitor beta.
The probability of 5 of 89 randomly chosen genes being deemed significantly un-
derexpressed in tumours is less than 0.0001 (hypergeometric cumulative p). These
data could therefore potentially be used in conjunction with those derived by CGH
(comparative genomic hybridisation) to identify regions of potential chromosomal
aberrations in cancer. There is however a possible alternative explanation for at
least some of this non-random distribution, and it is discussed in the next section of
this report.
Further analysis of the data allowed us to identify several genes potentially coreg-
ulated with genes already associated with cancer (i.e. displaying similar expression
profiles across tissues). In an attempt to validate these results we looked for genes
whose best correlated partner was a known functionally associated gene (identified
by calculating the pearsons coefficient between the expression profiles across tissues
3http://www.hgu.mrc.ac.uk/users/james.prendergast/appendixtable.xls
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of all genes, and identfying for each gene its corresponding partner with the highest
r). A number were identified including several pairs from critical pathways in can¬
cer. These included FASL receptor and MAPKKK14; MAPKKK3 and MAPKK1;
and MAPKKKK4 and NFRkB which are all associated with the MAPK signaling
pathway and were all identified as being coexpressed.
The main aim of this project was to begin to identify candidate genes that may
be involved in colorectal cancer. Although this project is a start for such prioritisa-
tion it is unlikely to be sufficient by itself. This is because the fact that a gene is
differentially expressed in cancer is not by itself enough evidence to say that it is the
cause of cancer; nor unfortunately is the observation of a gene not being differentially
expressed evidence that it is not involved. The reasons behind this are numerous;
gene expression is not the same as protein expression; diseases can be caused by all
kinds of factors e.g. polymorphisms, inappropriate splicing etc and this technique is
not free from errors (like all gene expression techniques). These data however should,
when combined with information from other sources, be useful in characterising the
causes and progression of cancer [109].
One of the genes deemed differentially expressed in this study was the transcrip¬
tion factor EGR-1, whose expression was shown to be dramatically lower in colon and
lung tumours than in corresponding normal tissue (q values of 9x10~7 and 4xl0-7 re¬
spectively). EGR-1 has been shown to suppress transformed growth in fibrosarcoma
cell lines by directly controlling transforming growth factor-beta-1 ( TGFB1), and
its loss of expression can lead to uncontrolled growth in tumours [110]. Subsequent
tests in our lab by Dr Farrington have shown that polymorphisms within this gene
show an association with colon cancer. Although EGR-1 was the only gene tested,
the use of gene expression studies in this way is consequently likely to be a viable
technique for identifying candidates for gene association studies.
35
Chapter 3
Tumour Gene Expression and
Chromatin Structure
3.1 Introduction
In the previous chapter we illustrated that the genomic distribution of genes differen¬
tially expressed in cancer may not be random. In agreement with this, genes whose
expression increases in tumours have previously been found to be clustered into par¬
ticular chromosomal regions [111]. Likewise genomic domains have been identified
that contain genes co-expressed in cancer [112]. However, there has been little in¬
vestigation of how this differential gene expression in diseases correlates with global
chromatin structure. Recently, a genome-wide analysis of higher-order chromatin
structure showed that there are specific domains of the human genome that are en¬
riched in open chromatin fibres [113]. In this study we consequently investigated the
potential relationship between such chromatin fibre structures and changes in gene
expression in cancer.
3.1.1 Mammalian chromatin arrangement
The primary role of chromatin fibres is the packaging of the two metre long eu-
karyotic genomes into 10/im cell nuclei. This substantial compaction of DNA into
chromatin is achieved through its association with various key proteins, and the
first level of chromatin organisation in mammals is the nucleosome, that consists of
two tight superhelical turns of approximately 147 base pairs of DNA around a pro-
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tein octomer. Each protein octomer consists of two copies each of the four positively
charged histone proteins H2A, H2B, H3 and H4, and this combined DNA and protein
package is termed the nucleosome core particle. Each histone protein has been shown
to contain two distinct functional domains, a trihelical histone-fold motif required
for the histone-histone and histone-DNA interactions within the nucleosome, and
tail domains that are subjected to post-translational modification processes, such as
acetylation, methylation and ubiquitination. Further histone proteins, termed linker
histones ( e.g. HI), bind to these nucleosomes and are associated with a further 20
base pairs of DNA [114, 115].
Although the supercoiling of DNA into these nucleosomes reduces its total length
by approximately seven-fold, mammalian chromosomes in the interphase nucleus are
condensed in the order of 250-fold, with DNA at metaphase condensed even further
to around 10,000 times less than its uncompacted length. The nucleosome is therefore
only the first level of compaction in the mammalian nucleus. Electron microscopy
has shown that under certain conditions each nucleosome along a contiguous length
of DNA is separated by 10 to 100 base pairs, in an arrangement likened to that
of beads on a string. However these lOnm nucleosomal arrays have been shown
to be further condensed into 30nm fibres and finally into structures greater than
lOOnm in diameter in vivo. Although the precise mechanisms and conformation of
these higher order chromatin structures are still unknown, it has been shown that
if the linker histones or the core histone tails are removed, condensation beyond
nucleosomal arrays can not occur, and it has been proposed that linker histones
stabilise tail-mediated nucleosome-nucleosome interactions that are the core of higher
order chromatin structures [116, 117].
Despite a precise conformation still being unknown, the relatively rigid confor¬
mation of DNA around each nucleosome and the constraints imposed by the 30nm
size have allowed a number of models to be proposed for the structure of the 30nm
fibres of compacted DNA. These include the twisted-ribbon, solenoid and crossed-
linker models. However none have been conclusively shown to be the true structure
of 30nm chromatin. It may be the case that a number of different arrangements of
30nm fibres are found in vivo [60].
Beyond the 30nm fibre, a number of experiments have demonstrated the existence
of large loops of DNA within the mammalian nucleus that can bring together regions
of the genome that are initially several Mb apart [118]. It appears that each of these
loops is tethered at its base to the chromosome scaffold, a structure that provides
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the backbone and characteristic morphology of mammalian metaphase chromosomes
and that consists largely of two proteins; SC-1 and SC-2. The degree of looping
along chromosomes is however not constant and regions that stain dark upon treat¬
ment with the DNA-binding dye Giesma generally contain smaller, tighter loops.
These tightly looped "G-band" regions are comparatively gene poor and contain few
ubiquitously expressed housekeeping genes compared to the more diffuse structures
located in lightly stained "R-bands". There is some evidence that base composition
may play a role in determining these banding patterns as G-bands are, in general,
more AT rich than R-bands [60].
The final level of chromatin organisation are chromosome territories. A variety
of different chromatin types have been shown to occupy particular regions within the
nucleus, with gene-poor, mid-to-late replicating chromatin, for example, located at
the nuclear periphery [119|. Whole chromosomes have even been shown to occupy
distinct nuclear regions, with the relatively gene dense chromosome 19 adopting a
substantially more central position in human lymphocyte nuclei than the gene poor
chromosome 18 [120]. Likewise the transcriptional status of genes has been shown
to be associated with their position within chromosome territories, and it has been
proposed that gene repositioning in the nucleus can modulate expression levels [121].
Between chromosome territories themselves is the interchromatin compartment that
contains machinery involved in splicing, replication, transcription and repair, and
regions of DNA have been shown to loop into this region when active [117, 121],
3.1.2 Chromatin and gene expression
Although, as just discussed, chromatin provides the mechanism for substantial amounts
of DNA to be packaged into relatively small nuclei, chromatin also plays a vital
role in controlling DNA replication and gene expression. This is because the very
compaction of chromosomes that allows their packaging, inevitably makes the cor¬
responding DNA increasingly inaccessible. Transcription machinery must overcome
the obstacles of chromatin structure in order to induce gene expression. For example,
it has been shown through micrococcal nuclease digestion experiments, that the spac¬
ing of nucleosomes around a gene are radically altered upon its transcription (though
nucleosomes may still be associated with the corresponding section of DNA). This is
as would be expected as RNA polymerases are likely to require the displacement of
nucleosome proteins from DNA upon transcription. Likewise experiments in yeast in
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which the histone levels within cells were artificially lowered, led to the de-repression
of endogenous genes (though the expression of constitutive genes was unaffected).
There is therefore strong evidence of at least some form of passive role of chromatin
structure in gene expression; those regions of the genome that are transcriptionally
competent (rather than necessarily active) are relatively lacking in nucleosomes [60].
Some regions of the genome have even been shown to be completely lacking in
nucleosomes. These regions, that are identified through their extreme sensitivity to
digestion by DNasel (and are therefore termed DNasel hypersensitive sites or DHS),
are generally associated with transcription and replication regulatory motifs such
as promoters, enhancers and replication origins. It appears that some of these key
regions in the genome are protected from nucleosome packaging. For example, the
human /3-globin locus contains a cluster of DNasel hypersensitive sites collectively
known as the locus control region or LCR. Transgenic experiments in mice have
shown that irrespective of its position of insertion in the mouse genome, if the LCR
is intact, the chromatin structure of the human globin genes is opened and they are
expressed at the correct developmental stage. However mutations or deletions in the
LCR lead to random expression of the genes of the globin locus and no protection
from the surrounding chromatin structure [60].
The wrapping of DNA around nucleosomes leads to substantial bending of the
double helix, consequently some sequences of DNA can surround nucleosomes more
readily than others. For example AT base pairs have been shown to preferentially
occupy inside positions in nucleosome core particles and GC base pairs outside ones
[122], This is because the bending of DNA around the nucleosome involves the com¬
pression of the minor groove on the inside of the DNA double strand and expansion
of the major groove on the outside. As the minor groove of AT bases is compressed
more readily, they are generally found more centrally. Although no further simple
rules or motifs have been identified that determine nucleosome positioning, ran¬
domly generated synthetic sequences of DNA has allowed the identification of those
sequences that bend effectively around nucleosomes and those that appear unable to
form part of a nucleosome core particle. The sequence of DNA consequently plays
an important role in nucleosome positioning [60].
As discussed histones must however have some level of mobility to allow tran¬
scription, and it has been shown that nucleosomes bound with a strong positioning
sequence are still able to slide along the DNA strand. It appears nucleosomes are able
to move approximately 10 base pairs at a time so that those base pairs positioned
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on the inside and outside of the DNA sequence remain in these respective positions.
There appears to be a degree of flexibility in the precise location of a positioning
sequence around a nucleosome, that provides the various positions the nucleosome
may adopt. These small 10, 20, 30bp etc shifts in nucleosome positioning appear to
be enough to provide initial access to the underlying DNA [123, 124, 125].
Transcription is not however only controlled by the positioning of nucleosomes as
nucleosomes themselves are not always sufficient to inactivate the underlying DNA.
Likewise the cell requires mechanisms for displacing nucleosomes more than the few
base pairs possible through positioning sequences. Consequently a number of pro¬
tein complexes have evolved that are able to displace nucleosomes completely from
DNA. These include the SWI and SNF family of proteins, whose role in nucleo¬
some displacement were identified through their affect on DNasel cleavage patterns
of nucleosomal DNA; upon treatment with SWI and SNF proteins, cleavage patterns
more closely resemble those characteristic of free DNA [126]. Proteins that modify
nucleosomes, such as histone acetyltransferases that attach acetate groups to the
N-terminal tails of histones, have also been shown to reduce nucleosome binding.
The complement of histone acetyltransferases are histone deacetylases, and together
these proteins control the levels of histone acetylation, and consequently to some
extent gene expression, across the genome. Further histone post-translational modi¬
fications that have been shown to modulate gene expression, include ubiquitination,
that assists in maintaining transcription, and methylation, that appears to work in
conjunction with acetylation in activating regions of the genome [127, 128).
Beyond the level of the nucleosome the role of chromatin structure in modulat¬
ing gene expression becomes less clear. As the higher order structures of chromatin
are still poorly understood, their roles in gene expression are even less well charac¬
terised. For example, although modifications of the N-terminal domain of histones
are believed to impact higher-order chromatin structures, the precise alterations in
structure, and mechanisms by which they occur, are unknown. Perhaps the best
characterised link between higher order chromatin structure and gene expression is
that of heterochromatin. Regions of heterochromatin (i.e. those regions that stain
strongly), that are generally thought to be more condensed than the majority of the
genome, are also thought to generally be less transcriptionally active. However these
are both far from applicable to all regions of heterochromatin, and regions of both
relatively open and transcriptionally active heterochromatin have been observed.
Transgene experiments have shown however that, in general, heterochromatin is able
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to silence adjacent genes. It has been proposed that a repressive chromatin structure
may spread from blocks of heterochromatin, or alternatively, heterochromatin occu¬
pies areas in the nucleus rich in silencing factors to which nearby genes are drawn
(the role of nuclear positioning in gene silencing has already been discussed) [60].
3.1.3 Chromatin and cancer
As discussed in chapter 2 altered patterns of gene expression are a hallmark of can¬
cer, but the mechanisms that bring about such extensive changes in transcription are
unclear. There is however increasing awareness that chromatin structure plays an
important role in controlling the expression of genes, including those with relevance
to cancer. The widespread changes in DNA methylation seen in tumours, the efficacy
of inhibitors of chromatin modification as anti-cancer agents, and the involvement of
chromatin modifying enzymes in cancer, suggest that chromatin structure, at least
at the level of the nucleosome, plays a pivotal role in carcinogenesis [129, 130]. Al¬
though the molecular detail of higher-order chromatin structure is not known, it is
likely that this is also implicated in altered gene expression, both during normal
differentiation and in carcinogenesis. For example, the polycomb complex, which
compacts arrays of nucleosomes in vitro [131], is implicated in cancer and is involved
in regulating the expression of tumour suppressors such as pl6Ink4 [132]. Likewise
chromosome territories have been shown to be altered within some tumour cell lines
1133). In this study we have therefore investigated the potential role of chromatin
structure in tumour gene expression and attempted to determine whether an associ¬
ation between gene expression change in cancer and underlying chromatin structure
can be observed. If so, then this would lend support to the hypothesis that chromatin
structure and gene expression changes in cancer are inter-related.
3.2 Methods
3.2.1 Chromatin data
Data on chromatin fibre structure was obtained from the Bickmore lab. Their tech¬
nique for determining chromatin structure is as follows.
Nuclei from lymphoblastoid cells are first digested with micrococcal nuclease,
which specifically targets and cleaves DNA between nucleosomes. By using spe-
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cific digestive conditions DNA fragments of approximately 10-30kb in length are
then obtained. These fragments are then separated on an isokinetic sucrose gradi¬
ent according to their sedimentation rate. DNA fragments of the same length and
chromatin structure will be observed to sediment together, along with shorter frag¬
ments with an open chromatin structure as well as longer fragments with more closed
DNA. This is because a given length of DNA will sediment faster if it is packaged
into a more compact chromatin structure leading to a decrease in its frictional coef¬
ficient. To subsequently separate fragments by their size, and consequently also by
their chromatin conformation, each sedimentation fraction is run through agarose gel
electrophoresis. Fragments that run more slowly than the bulk of the fraction will
represent long fragments of relatively closed DNA with the faster moving fragments
on the other hand having a more open conformation. In order to analyse the distri¬
bution of open chromatin across the genome, differentially labeled open and input
chromatin fractions are cohybridised to a genomic DNA microarray. In this analysis
the array used was assembled from clones spaced at ~lMb intervals, from the 'golden
path' used in the sequencing of the human genome (16). The data used per clone
was the average of four hybridisations, performed with colour reversal. Regions of
the human genome enriched with open chromatin will display a log2 opeminput ratio
that is greater than 0 [113].
3.2.2 Expression data
81 adult, human EST Expressed Sequence Tag (EST) libraries were obtained from
dbEST (http://www.ncbi.nlm.nih.gov/dbEST) that were non-normalised, non-
subtracted and not obtained using the ORESTES [85] technique. They each con¬
tained a minimum of 250 sequences and were grouped according to tissue (colon,
kidney, liver, lung, prostate or testis) and disease state (normal or cancer). To iden¬
tify the gene of origin for each EST all 449,365 ESTs were RepeatMasked (A.F.A.
Smith and P. Green, unpublished results) and subsequently compared to the En-
sembl cDNA database (version 18) using BLAST [87]. Any EST that matched an
Ensembl cDNA sequence with 95% identity over at least 100 base pairs was assigned
to that cDNA. In this way approximately 66% of the ESTs were successfully assigned
to a known gene with the remaining unmapped ESTs a result of unknown transcripts
or poor sequencing (as mapping success varied dramatically between EST libraries,
even those of the same tissue, it is likely a large proportion of these ESTs are a result
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of poor library preparation).
13 adult human Serial Analysis of Gene Expression (SAGE) [82] libraries derived
from colon, lung or prostate tissue (normal or tumour) were obtained from CGAP
(http://cgap.nci.nih.gov/SAGE). Tag counts were grouped according to tissue
and disease state, and mapped to genes via data available at the NCBI website (ftp:
//ftp.ncbi.nlm.nih.gov/pub/sage). Two colon adenoma libraries (derived from
Familial Adenomatous Polyposis patients) were also obtained from SAGENET (www.
sagenet. org) and compared to the normal colon libraries using the same technique.
Three microarray datasets comparing normal and tumour tissue were used in this
analysis [134, 135, 136] (see table 3.1). The Affymetrix CEL data files of each mi¬
croarray dataset were analysed using the dChip software [137] (http://www.dchip.
org/). If appropriate information was available, tumour samples with less than 40%
tumour cells were removed before analysis. To exclude arrays with potential im¬
age contamination or sample hybridisation problems any chip with an array outlier
percentage greater than 5% was also discarded [138]. Using data available at the
Affymetrix website (http://www.dchip.org/) probes were subsequently assigned
to genes.
Author Array type Tumour type Normal arrays Tumour arrays
Bhattacharjee et al. 2001+ U95Av2 Lung adenocarcinoma 17 (16) 127 (72)
Lenburg et al. 2003* U133A Renal cell carcinoma 8 (8) 9 (9)
Singh et al. 2002 + U95Av2 Prostate tumour 50 (49) 52 (52)
Table 3.1: Microarray datasets used in this analysis.
Numbers in brackets indicate the number of arrays left after the quality con¬
trol stage and consequently used in the analysis. +Dataset available at:
http://www.broad.mit.edu/cgi-bin/cancer/datasets.cgi. *Dataset available at:
http://www.ncbi.nlm.nih.gov/geo/
Gene coexpression was measured through the use of the GNF Gene Atlas V2
Human U133A microarray collection [139]. The 158 raw CEL image hies for each
array of this dataset (79 tissues, 2 replicates of each) were analysed using the dChip
software [137]. Using dChip each array was first normalised at probe intensity level
to the array with median overall intensity and then expression values were calculated
using the PM/MM (perfect match/mismatch) [137] difference model (truncated val¬
ues to 1).
29 outlier arrays were removed in which the model-based standard error of greater
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than 5% of probes was greater than three times the median of all PM-MM probe pairs
(as implemented in dChip) and the remaining expression values were subsequently
log transformed. Redundant probes were masked (by only keeping the first occurring
probeset of those that mapped to the same LocusLink id, as in dChip) and all probes
that could not be mapped to a unique position in the genome (NCBI build 35) with
at least 90% identity were excluded (arguably a higher threshold could have been
set but we allowed for both mismatches as well as polymorphisms).
Expression values of replicate arrays were pooled so that each gene was repre¬
sented by 68 values, one for each tissue type remaining after the above filtering (often
only one of the two arrays for a tissue were lost after filtering and consequently only
12 tissues were completely unrepresented). Those genes that were potentially tissue
specific (i.e. those with a present call in less than 20% of the arrays, the default
cutoff in dChip) were also filtered out as we were not interested in those genes that
were purely expressed in the same single tissue but those that showed some level
of coregulation. As a match at a single tissue would lead to a large Pearson's r we
excluded these genes with restricted expression profiles.
To minimise the affect of large values the expression values across all tissues for
each gene were standardised to have a mean of 0 and a standard deviation of 1. Pear¬
son's correlation coefficients were subsequently calculated between these expression
values of all genes in the same chromatin category, and the proportion of comparisons
above a chosen threshold calculated.
3.3 Results and Discussion
During the investigation of tumour gene expression via the analysis of EST libraries
discussed in the previous chapter, we identified regions of the genome enriched with
differentially expressed genes. However further analysis illustrated that even whole
chromosomes differed in their average p values, and that some chromosomes con¬
tained a greater proportion of genes that were up-regulated in cancer than others.
As nuclear localisation is believed to play a role in gene expression, we investigated
whether an association between a chromosomes position in the nucleus and its av¬
erage gene expression change could be observed. As shown in figure 3.1 a simple
analysis seemed to suggest that this was indeed the case. However as nuclear locali¬
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Figure 3.1: Gene expression change and nuclear localisation
The relationship between gene differential expression in cancer and a chromosome's
(A) position in the nucleus and (B) average gene density
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structure we investigated whether a correlation between gene expression and chro¬
matin structure could be observed within chromosomes.
In 2003 Zhou et al. used EST sequences to investigate tumour gene expression.
The analysis of Zhou et al. [1111 identified chromosomal domains in which the genes
are generally up-regulated in tumours compared to normal tissues. They termed
these, regions of increased tumour expression (RITEs). We noted, in a compari¬
son to the Gilbert et al. dataset, that the distribution of RITEs both along, and
between, chromosomes was qualitatively similar to that of domains of structurally
open chromatin fibres 1113]. For example, on chromosomes 1 and 11 the largest
RITEs appear to align with the regions that are highly enriched in open chromatin
fibres at positions; 0-45Mb on lp34-36, 144-153Mb on lq21, 0-20Mb on llpl5, and
63-76Mb at llql3 (Figures 3.2+3.3 ). It was also noted that RITEs are very sparse
on chromosome 13, whereas a very large proportion of the genes on chromosome 19
are up regulated in tumours. Similarly, chromosome 13 is rather depleted of open
chromatin fibre domains whereas most of chromosome 19 is highly enriched for open
chromatin fibres (Figure 3.3).
We believe however that the analysis of Zhou et al. suffers from a number of
drawbacks. The first, is that Zhou et al. used normalised and subtracted EST li¬
braries. Normalisation and subtraction of EST libraries increases the sampling of
rare transcripts by preferentially forming duplexes of abundant sequences. Although
these techniques have proven useful in gene discovery, they degrade the quantita¬
tive relationship between transcripts. The extent of normalisation and subtraction
also differs across libraries and consequently expression levels based on these EST
collections are not representative of the true RNA abundance in a cell.
The technique of Zhou et al. also generally leads to gene dense regions of chromo¬
somes being scored higher than those regions with a more sparse coverage of genes.
This is due to the scanning index used by Zhou et al. To determine clusters of genes
up-regulated in tumours, they first calculated the TMZ (trimmed mean of Z-score)
for 500kb regions every lOOkb along the genome. Regions of the genome with consec¬
utive windows of high TMZ were then scored more highly depending on the number
of consecutive windows above a cutoff. Gene poor regions however are simply less
likely to contain consecutive windows, and as the presence of open chromatin fibres
across the human genome has been shown to correlate with gene density, this appar¬
ent correlation between chromatin and gene expression change may not actually be
the result of the upregulation of genes in open chromatin in cancer.
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Figure 3.2: Comparison between the gene expression analysis of Zhou et al. and
chromatin structure (I).
The log2 ratio of open:input chromatin fibres prepared from lymphoblastoid cells, is
shown for the BACs from the 1Mb array from human chromosome 1. Aligned to the
right, is the gene expression analysis of Zhou et al. [Ill] for the same chromosomes.
Regions of increased tumour expression in pancreas, lung, liver, kidney, colon, breast
and brain tumours are shown in red. Regions of decreased tumour expression are
shown in green.
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Figure 3.3: Comparison between the gene expression analysis of Zhou et al. and
chromatin structure (II).
The log2 ratio of opeminput chromatin fibres prepared from lymphoblastoid cells, is
shown for the BACs from the 1Mb array from human chromosomes 11, 13 and 19.
Aligned to the right is the gene expression analysis of Zhou et al. 1111] for the same
chromosomes.
To determine whether a relationship between chromatin structure and expression
change in cancer does in fact exist, as the data of Zhou et al. suggests, we adopted a
more simplified technique for analysing gene expression across chromosomes. Unlike
Zhou et al., we had no need to determine which regions of the genome were signif¬
icantly differentially expressed, and we therefore simply calculated the average log 2
gene expression change in sliding windows across the genome (using the EST expres¬
sion data from chapter 2). Each sliding window was 500kb in size and all windows
containing less than three genes of known gene expression were excluded (as an av¬
erage fold change based on only one or two genes may be dramatically skewed from
the true mean expression change of that region). As shown in figure 3.4 peaks of
gene expression change appear to coincide with areas enriched with open chromatin.
These initial results consequently led us to test for a relationship between chromatin
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Figure 3.4: The chromatin structure and gene expression change in cancer observed
across chromosome 11.
Clone log2(open:input) values are represented in red and window average gene ex¬
pression change in blue.
Adopting this sliding window approach had two major problems. First it suffered
from gene density effects and second it did not allow us to directly compare chromatin
structure and gene expression change, as at best the sliding windows only partially
overlapped regions of known chromatin structure (and therefore quantification of the
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relationship between chromatin and gene expression change was difficult). To more
precisely compare the changes in gene expression in cancer with the chromatin fibre
structure of the human genome, we collected EST data for six normal tissues (colon,
kidney, liver, lung, prostate or testis) and for cancers that involve these tissues. In
each case, the relative (log2) change in expression observed for each gene in cancer,
relative to the corresponding normal tissue, was calculated using algorithm 1.
Algorithm 1 Calculation of gene expression change
yo 771 • t ^ 7 / NumCancESTsAssigToGene/TotalNumCancESTs \GeneExpressionChange = log2{ jv^orm£SraAs4roGene/rotaWumAror7iT^)
Genes were excluded if corresponding ESTs could not be found in either normal
or tumour libraries, or if they were represented by less than 4 ESTs in total. The
average log2 expression change was then calculated across the six tissues. Finally
the average log2 fold change in expression of all the genes that fell entirely within a
BAC clone from the chromatin 1Mb genomic array was calculated. This was termed
the clone average log2 fold change (CALFC). All BAC clones with a CALFC value
> 0 were said to be up regulated in cancer. A significance cutoff was not applied
as we were looking for a trend across all clones rather than just in those deemed to
be significantly differentially expressed. BAC clones to which no genes mapped were
excluded from analysis. We grouped BAC clones according to their log2 opeminput
chromatin value. BACs with the most open chromatin fibre structure were grouped
as those clones with log2 opeminput < 2.5 and >1.5. Clones with log2 opeminput
of between 0.5 - 1.5 were the next group, followed by those between -0.5 and 0.5.
Regions with the most closed chromatin fibre structure were grouped together as
those BAC clones with log2 opeminput < -0.5 and > -1.5. Within each of these
groups, the proportion of BAC clones for which the CALFC value was > 0 was then
determined. As shown in figure 3.5 there is a clear correlation between CALFC
values and chromatin structure. A large proportion (70%) of BAC clones with a
very open chromatin structure (log2 opeminput >1.5) have a CALFC value > 0.
Conversely, only 40% of BAC clones from regions of the human genome depleted of
open chromatin (log2 opeminput -1.5 to -0.5) have CALFC values > 0.
We were however keen to ensure that a relationship between gene expression
change and chromatin structure could also be observed using other expression plat¬
forms. The correlation between chromatin fibre structure and gene up-regulation in
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Figure 3.5: The correlation between chromatin fibre structure and CALFC values
(A) Flistograms showing the percentage of BAC clones from the 1Mb array whose
average log2 fold change in expression in cancer (CALFC) was > 0. BAC clones
were grouped according to the log2 opeminput chromatin fibre structure hybridisa¬
tion ratio. Clones with the most open chromatin fibre structure are those where log 2
opeminput >1.5. Clones with the most closed/compact chromatin fibre structure are
those where log2 opeminput < -0.5. Data from three different expression platforms;
EST (open bars), SAGE (shaded bars) and microarray (filled bars) datasets, com¬
bined from six different tissues, is compared. (B) Analysis as in A, but comparing
microarray data from three different tissue/tumour types; kidney/RCC (open bars),
lung (shaded bars) and prostate (filled bars). (C) Histograms showing the percent¬
age of BAC clones from the 1Mb array whose average log2 fold change in expression
in cancer (CALFC) was > 0, for RCC tumours at Fuhrman stage 1. (Individual
ids are those from the original Lenburg et al. paper 1134], numbers in brackets fol¬
lowing each id indicate the individuals Fuhrman stage) (D) Histograms showing the
percentage of BAC clones from the 1Mb array whose average log2 fold change in
expression in cancer (CALFC) was > 0, for RCC tumours at Fuhrman stages 2 and
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forms. log2 fold gene expression changes of SAGE tags or microarray data were cal¬
culated as for ESTs (only the U95Av2 datasets were used in the combined microarray
plot). As with EST data, it was found that the regions of the human genome most
enriched in open chromatin fibres had the highest proportion of BAC clones with
CALFC values >0 (Fig. 3.5A) (combined EST: r2=0.78, p=0.004; SAGE: r2=0.476,
p=0.058; Microarray: r2=0.655; p=0.015). Therefore we conclude that genes are
most readily activated, or up-regulated, in cancer if they derive from regions of the
human genome that have an open chromatin fibre structure.
The graph in Figure 3.5A is the result of combining expression data derived from
six different normal/cancer tissue types. None of these tissues corresponds to that
used to investigate chromatin fibre structure - lymphocytes - however chromatin
structure is not believed to change dramatically between most cell types (personal
communication - Professor Wendy Bickmore). To examine whether the correlations
between CALFC and chromatin fibre structure are cell type dependent, data from
individual tissue types was examined (Fig. 3.5B). A significant correlation between
CALFC and chromatin fibre structure was found in each case (prostate: r2=0.862,
p=0.001; lung: r2=0.546, p=0.036; RCC: r2=0.689, p=0.011).
Tumour grading by pathological analysis of nuclear morphology and morphome¬
try indicates that very gross changes in chromatin/nuclear structure correlate with
later stages of tumourigenesis, and with generally poor prognosis and survival. For
example, Fuhrman nuclear grading for renal call carcinoma (RCC) is a good pre¬
dictor of disease survival [140]. Grade 1 tumours have small round, evenly stained
nuclei. Nuclei at grade 2 are more irregular in shape and staining, with mildly en¬
larged nucleoli, and this is more prominent in grade 3 tumours. At grade 4, cells are
very enlarged and pleiomorphic [141], We subdivided the RCC microarray dataset
according to Fuhrman grading of the analysed tumours (as defined in [134]), and
examined the correlation between chromatin fibre structure and average gene ex¬
pression change for tumour grades 1 to 3 (Fig. 3.5C+D). We observed no significant
correlation in grade 1 tumours (p=0.11) but a strong correlation in those defined as
grade 2 and 3 (p<0.001), with the grade 3 tumour displaying the greatest change
between open and closed categories (67 to 39%). A similar correlation to cancer
progression was seen for SAGE data in colon cancer. Differential gene expression
in colon adenomas (benign tumours) does not display the same relationship with




Figure 3.6: Chromatin structure, staging and coexpression
(A) Histogram showing the percentage of BAC clones from the 1Mb array (16) whose
average log2 fold change in expression in cancer (CALFC) was > 0, for SAGE data
obtained from two colon adenoma libraries and from two colon adenocarcinomas. (B)
Comparison of the levels of coexpression among genes in different chromatin cate¬
gories. The Pearson's correlation coefficient was calculated between the expression
profiles of all genes in the same chromatin category and the proportion of pairwise
comparisons with an r greater than 0.24 is shown (A cutoff of 0.24 was used as each
expression profile contained 67 values, one for each tissue examined, and with 66
degrees of freedom, the significance threshold of r at an a of 0.05 is 0.24). r2of
proportions versus chromatin as shown in panel B =0.90, p=0.05.
53
We had one major concern about this analysis however. Traditional methods
of analysing microarray data are dependent on the assumption of constant variance
across all levels of gene expression and often that the data are normally distributed.
However in 2001, Rocke and Durbin showed that microarray data are more accu¬
rately modelled by the equation shown in algorithm 2. From this equation it can be
observed that when expression levels are large the middle error term dominates and
the raw (measured) expression value is approximately equal to ye*1. However when
expression levels are near background, i.e. y is close to 0, then the middle error term
is almost insignificant and the measured expression level is approximately equal to
simply a+s. Consequently, as log(y) = log(y) + r), simple log transformations should
sufficiently stabilise the variance of expression data at high levels. However the closer
expression levels get to background levels the less applicable a log transformation
will be, and the more inflated the variance of observations. As variance will also not
be symmetrically distributed around the true expression level, measured expression
levels of genes of low expression will be artificially skewed.
Algorithm 2 Rocke and Durbin's two-component model of microarray error.
y the measured raw intensity, a is the mean background noise, y the true
expression level and r) and e are normally-distributed error terms with mean 0 and
variance o^ and respectively.
y = a + yev + e
Gilbert et al. [113] had observed no correlation between gene expression and
chromatin structure, and therefore this poor performance of traditional log transfor¬
mation was initially of little concern. However if certain chromatin categories were
enriched with genes of low expression, and the skewed variance was not identical in
both normal and tumour samples, this could lead to artificial correlations between
gene expression and chromatin structure. We therefore retested the hypothesis that
chromatin structure and gene expression were independent. To do this we obtained
the gene expression profiles of normal human B cells from the study of Klein et
al. [142] (as chromatin structure was determined in lymphoblastoid cells). Com¬
parisons of clone average gene expression values to the log2(open:input) scores of
the corresponding clones, suggested, that there was in fact a relationship between
gene expression and chromatin structure. As can be seen in figure 3.8A the average
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Figure 3.7: Combined RCC stage II and III results shown in Figure 3.5, split into
smaller categories (-1.5 to -1, -1 to -0.5 etc) with corresponding boxplot.
The blue diamonds of the boxplot mark the means and corresponding confidence
intervals of the CALFC values in each category. The notched boxes show the medi¬
ans, their confidence intervals and the lower and upper quartiles. The dotted lines
connect the nearest observations within 1.5 inter-quartile ranges of the lower and
upper quartiles. Red crosses and circles mark near (greater than 1.5 inter-quartile
ranges away) and far (greater than 3 IQRs) clone outliers respectively. This figure
illustrates that although there are relatively large changes in the proportion of BAC
clones with a CALFC value > 0 for each chromatin fibre structure category, the
actual difference in the mean CALFC between clones in each category are relatively
small. The linear relationship between the chromatin structure and CALFC values
of clones was also confirmed by linear regression and it was shown to be weakly but
significantly correlated (r2=0.011, p=0.001)
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expression of clones with a more open chromatin structure is generally higher than
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Figure 3.8: Hawkin's transformation
(A) Clone chromatin structure versus log transformed average gene expression (r2
- 0.066, p = 5xl0_u). (B) The rank of the measured intensity versus the IQR for
raw probe intensities. (C) The rank of the measured intensity versus the IQR for
log transformed probe intensities. (D) The rank of the measured intensity versus
the IQR for Hawkins transformed probe intensities.
To test therefore whether variance between replicates was indeed affected by a
probes expression level we ranked the probes of the same Klein B cell dataset accord¬
ing to their median intensities. As shown in figure 3.8B the probes with medians
near 0 displayed relatively similar variances in intensities. However, those probes
with large median intensities showed large variations between repeats. Although, as
shown in figure 3.8C, log transformation of the data can lead to a stabilisation of the
variance of probes with large expression intensities, a large number of probes with
low medians are outliers and display a high variance.
These results therefore agree with the two-component model of microarray data
predicted by Durbin and Rocke, and in conjunction with the apparent correlation
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between gene expression and chromatin structure, highlight a potential issue with
our analysis. This is because the variance observed in these microarray datasets can
lead to skewed values of genes with low expression profiles. Randomisations carried
out by Durbin et al. have shown that lowly expressed genes can show relatively
large negative skews in their values upon simple log transformation. If therefore
this underestimation of the expression of probes near background is not identical
in both the normal and cancer array sets, an artificial correlation between gene
differential expression and chromatin structure may result. We consequently applied
the variance-stabilising transformation of Hawkins to try and negate the relationship
between expression level and inter-replicate variance. This stabilisation is a solution
of the algorithm shown in algorithm 2 and is itself shown in algorithm 3. Application
of this transformation, as illustrated in figure 3.8D, does lead to stabilisation of
the variance observed across expression levels and reanalysis of our data using this
transformation does not lead to the loss of the correlations observed between gene
expression change in cancer and chromatin structure (Figure 3.9). We therefore
hypothesise that the correlations observed above are not the indirect result of a
correlation between gene expression and chromatin structure. This is however based
on the assumption that the transformation of the normal and cancer datasets are
perfectly matched (even Durbin et al. have illustrated that this transformation does
not completely negate the skewing of genes of low expression). As this transformation
is also designed to stabilise the variance between experimental repeats, and not as
in our datasets inter-person replicates, further analysis will be required to confirm
without question that gene expression levels are not playing a role in creating the
observed correlations. This will require the creation of a novel gene expression study
that can be designed from the start to be controlled for the affects of gene expression
levels across chromatin structure.
Algorithm 3 Hawkins microarray data transformation [143].
c, a constant determined from the data, equals crl/a^.
z = ln[(y - a) + y/(y - a)2 + c]
We are confident however that the correlations we have observed are real as there
are other levels of evidence that suggest that the relationship between gene expression
and chromatin structure is unlikely to be leading to the correlation between gene

































Figure 3.9: RCC stage II and III results with and without variance stabilising trans¬
formation having been applied.
With the transformation the results marginally improve (With transformation r2
0.96. without transformation r2 = 0.95).
positive correlations. There is no reason to believe that normal microarrays will
be consistently more (or less) skewed than cancer arrays. Likewise the observation
of changes in the strength of the relationship between gene expression change and
chromatin structure with tumour stage does not seem to be consistent with what we
would expect if skewed data was the cause of the correlations. Only if the relationship
between gene expression and chromatin structure was affected by disease state or
stage could skewing lead to these correlations, and although this may be expected,
we could find no evidence that this is the case.
So why do the majority of regions of open chromatin display a mean increase in
gene expression in later stages of certain cancers (Figure 3.5)? Does the expression
of genes in open chromatin generally change in the same direction across tissues?
In an attempt to answer this question we used the Novartis Gene Atlas V2 human
expression dataset [ 139) to determine whether there was a higher level of coexpression
between genes in open chromatin than those in closed, i.e. do genes from open
chromatin regions generally show more similar expression profiles to one other than
those in closed chromatin? This was indeed found to be the case. As shown in
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figure 3.6 when the expression profiles of all genes in open chromatin were compared
to one another, 43% of the pairwise comparisons were above the significance cutoff
of an r of 0.24. This is compared to only 19% in closed chromatin. Although the
tissues used iu this analysis were not independent and consequently the significance
cutoff used in this analysis may be too lenient, the same results were also observed
with higher r2 values (a weighted Pearson's would have been more appropriate).
Likewise we observed a correlation between chromatin structure and the average r2
value between genes, i.e. the more open the chromatin category the higher the mean
r2 was when the expression profiles of all the genes within that chromatin category
were compared.
Figures 3.10 and 3.11 illustrates that there are at least two distinct expression
patterns in open chromatin; those genes highly expressed in tissue from the brain
and those genes highly expressed in tumours and various other tissues. A potential
cluster of genes highly expressed in the brain is also seen in closed chromatin but
further clearly defined clusters are less easily observed. Only four genes in closed
chromatin are strongly expressed in tumours, and of these the two that show strong
expression in more than one cancer type (MAD2L1 and EIFJ^E) have already been
strongly associated with cancer 1144, 145]. It appears therefore that chromatin may
have a key role to play in controlling the expression of genes, particularly those in
open chromatin, and that this role may be dysregulated in cancer.
We have therefore found a correlation between gene expression changes in can¬
cer and the recently described chromatin fibre architecture of the human genome.
Our analysis provides a potential mechanistic basis for the observed genomic clus¬
tering of genes over-expressed in cancer that had previously been reported [111].
The regions of the human genome where genes are generally upregulated in cancer
correspond to those regions that have been shown to have a biophysically open chro¬
matin fibre structure 1113]. This correlation was found for three different expression
platforms; ESTs, SAGE tags and microarray datasets. This is particularly notable
given the rather modest congruence that we, and others, had previously observed
between these platforms [146]. The presence of open chromatin fibres across the
human genome has been shown to correlate with gene density, but not with gene
activation or silencing per se [113]. It has been suggested that these domains of open
chromatin fibre structure provide a constitutively open environment that facilitates
transcription. Indeed, genes that are widely expressed in normal tissues tend to
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Figure 3.10: Cluster analysis of genes located on the most open clones.
Genes were clustered according to their standardised expression in 68 tissue types,
with the distance between genes calculated as 1 - r (where r is the pearsons coeffi¬
cient). Expression values were clustered by both gene and tissue. For more details see
www.dchip.org A: Cluster of arrays derived from tumour tissue, B: Arrays derived
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Figure 3.11: Cluster analysis of genes located on the most closed clones.
Genes were clustered according to their standardised expression in 68 tissue types.
A: Cluster of arrays derived from tumour tissue. Note that cluster A is interspersed
with arrays derived from thymus, bone marrow, and tonsil.
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lation between transcriptional up-regulation and these same domains in a variety of
tumours that are derived from different tissue-types. We also observed higher levels
of gene coexpression between genes in open chromatin than those in closed regions of
the genome. However, the magnitude of changes in gene expression in cancer is quite
modest, clones within the most open chromatin fibre domains show on average only
a 16% increase in expression in stage II and III renal cell carcinomas. This could
be because the basal level of gene expression of genes within these regions is already
quite high in normal tissues [148]. In contrast, expression of genes within domains
that have a generally closed/compact chromatin structure may require remodeling
of the higher-order chromatin structure before they can be activated during disease.
The correlation of gene-expression changes and chromatin fibre structure appears to
be most prominent for the later stages of cancer progression. This suggests that the
structure of chromatin itself may be altered during cancer progression. Understand¬
ing how and why this occurs may provide new insight into the mechanistic basis of
gene-expression changes and cancer progression.
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Chapter 4
Chromatin Structure, Mutation and
Selection
4.1 Introduction
As discussed, regions of open and closed chromatin structure have recently been
defined across the human genome [113]. In chapter 3 we highlighted the relationship
between this chromatin structure and gene expression change in cancer. However
the mechanism behind this observed relationship remains unclear. Why do genes
in open chromatin generally show an increase in gene expression in later stages of
tumourigenesis? Although we illustrated that genes in open chromatin generally
show high levels of coexpression, this does not provide an explanation for the initial
driving force behind this correlated change in gene expression. However one potential
mechanism behind this phenomenon is mutation. DNA mutation is one of the key
factors underlying oncogenesis and loss of efficient DNA repair is a hallmark of most
if not all cancers. Although many mutations associated with tumourigenesis have
been shown to affect a protein's structure, many have also been shown to modulate
a gene's expression levels, for example through changes at a gene's regulatory region.
It is plausible that any given mutation at a regulatory motif in open chromatin is
more likely to lead to an increase in gene expression than a reduction. This is because
an open chromatin structure provides the most conducive possible environment for
transcription, consequently regulatory motifs in open chromatin are more likely to
be limiting a gene's expression than those in closed regions. Single base mutations
may also explain the relatively small changes in expression observed in our analysis,
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copy number changes or large scale insertions or deletions would likely lead to larger
differences in expression levels between normal and tumour tissue.
Mutation rates may also underlie the paradox surrounding chromatin structure
and gene expression. If open chromatin fibre domains provide a chromatin envi¬
ronment more conducive to transcriptional activation, why are genes also found in
regions of closed chromatin structure if this simply means they are less accessible for
transcription This question can not simply be answered by the compaction require¬
ments of DNA as the vast majority of the genome is non-coding. One possibility
is that some genes need to be subject to especially tight transcriptional regulation,
and that their aberrant or leaky expression in inappropriate cells cannot be toler¬
ated. However, it has also been proposed that open chromatin structure may make
the underlying DNA sequence more susceptible to DNA damage [149]. Consequently
certain genes are located in closed regions of the genome due to the low mutation
rates they confer.
Although some studies have predicted that rates of mutation are relatively con¬
stant across mammalian genomes, analysis of human-mouse alignments has suggested
that there may be as much as a 3-fold difference in substitution rates across chromo¬
somes [150], with regions containing genes involved in extracellular communication
displaying unusually high levels of synonymous substitutions [151]. Previous studies
have also shown that, in mammals, genes within close genomic proximity undergo
similar rates of mutation and evolution [152, 153, 151]. For example, Williams and
Hurst showed that the mean difference between the Ka values (substitution rate at
non-synonymous sites) of 176 pairs of linked genes was significantly lower than would
be expected by chance [152]. Similar results were also observed with Ks (substitu¬
tion rate at synonymous sites) and Ka/Ks (that is often used to infer the mode and
strength of selection). Consequently they proposed that the murid genome was split
into domains of evolution. Why this was the case was unknown, but it is possible
that some aspect of chromatin structure over different genomic regions influences
the rate of DNA damage or its repair. Similar analyses in to the clustering of genes
with similar expression profiles has shown that a much smaller proportion of human
and mouse genes (3-5%) show evidence of restricted gene order [154]. This analy¬
sis consequently argues for only limited constraint on the clustering of coexpressed
genes.
The availability of a map of long-range chromatin structure across the human
genome [113] allows us to assess this idea. In this study we have investigated the
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rates of selection and mutation across chromatin categories. By excluding CpG
sites we have exclusively looked at mutation rates not attributable to the inherent
mutability of methylated cytosines. This is obviously important as open chromatin
is enriched with CpG islands. To fully investigate the potential relationship between
mutation rates and chromatin structure we looked at various measures of neutral
mutation; including intronic, intergenic and ancient repeat divergence as well as
SNP density. We also looked for any link between chromatin structure and selection
in the human genome.
4.2 Methods
The abundance of open chromatin fibre structure in lymphoblastoid cells, at clones
spaced approximately 1Mb apart along the human genome was determined as pre¬
viously described. Relative chromatin structure is represented in this analysis by
log2(open chromatiminput chromatin) values; determined by cohybridising differ¬
entially labeled "open" and input chromatin fragments to a human genomic DNA
microarray. A large log2(open:input) value in this analysis indicates a region en¬
riched with open chromatin. See above or Gilbert et al. [113] for further details.
The 2,787 human genes that mapped to each of these clones and their corresponding
mouse orthologues were obtained from Ensembl. Coding sequence alignments of each
of these orthologous pairs were derived via protein alignments (using the MUSCLE
[155, 156] and tranalign [157] programs) and the PAML [158] package was used to
calculate dN (rate of divergence at nonsynonymous sites), dS (rate of divergence at
synonymous sites) and dN/dS. Gene pairs with anomalously high dS values (>1.270
i.e. twice the median dS of all Ensembl human vs mouse pairs) were excluded.
Rates of transitions in alignments were estimated by observing the positions in
each alignment where a transition appeared to have occurred i.e. an A was aligned
with a G or a T was aligned with a C. At all other positions in the alignment
where bases differed between mouse and human, the mouse base was made the
same as the human base and values of dN and dS were recalculated. An analogous
process was used to estimate the rate of transversions. It should be noted that this
technique will miss those transitions that have been masked by a second change at
the same site, so that it appears only a transversion has occurred (and vice versa).
However as this analysis was carried out in human-chimpanzee comparisons multiple
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substitutions at the same site should be extremely rare. Human vs chimp orthologues
were also obtained from Ensembl and again they were filtered according to their dS
values. However alignments with very low identity (< 85%) were also excluded.
Due to the limited number of differences between human and chimp orthologues,
all alignments of genes in the same chromatin categories (i.e. in regions of similar
chromatin structure) were concatenated and rates of dS, dStransi and dStransv were
calculated for these combined alignments.
The posterior probability that a gene harbours excess amino acid variation (P-) as
calculated by Bustamante et al. was obtained from 1 . These data are based on the as¬
sumption that purifying selection will lead to a greater proportion of non-synonymous
polymorphisms in a gene, relative to synonymous polymorphisms, when compared
to the proportion of fixed non-synonymous differences (relative to synonymous dif¬
ferences) found between human and chimpanzee. The hypothesis being tested is
that the product of the selection coefficient and population size, 7 (7 = 2Nes), is
not different from 0. Genes are annotated as under positive or negative selection
via quantifying the posterior probability that its selection coefficient is less than or
greater than 0 given the respective observed data for that gene. If the equal tail
credibility intervals of a gene's selection coefficient fall entirely below 0 the gene is
deemed to be under purifying selection. See Bustamante et al. for more details [159].
In our analysis we used those genes with at least two variable non-synonymous sites,
i.e. Bustamante et al.'s INS (Informative only about Negative Selection) dataset. Of
these 6,033 genes, 690 mapped to one of our clones of known chromatin structure.
For each chromatin category we calculated the proportion of these genes with a high
P-, i.e. greater than 0.95.
Human chimpanzee divergence was determined through the use of the chained
and netted human-chimpanzee alignments available at the UCSC website ( hgl7-
panTrol) [160]. Ensembl gene predictions were used to identify intronic, intergenic
and protein coding regions. All exclusively intergenic and intronic regions found
within clones were identified, and divergence measured in the corresponding sections
of the human-chimpanzee alignment using PAML's baseml with the REV model.
Before calculating divergence all sequence from the same chromatin category was
concatenated and all bases that overlapped a CG dinucleotide in either species were
removed from the alignments to conservatively calculate non-CpG rates of divergence
1 http: / /www.nature.com/nature/journal/v437/n7062/extref/nature04240-s2 .txt
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[1611 •
To identify potential genes with CpG islands, the positions of predicted CpG
clusters were obtained from the UCSC genome browser [162], Of these islands, any
that were less than 500bp long, had a G+C content less than 55% or had a CpG to
expected CpG ratio of less than 0.65 were excluded [163]. Those genes whose 5' end
was within 2kb of one of these islands were determined to be potential CpG island
genes. Genes annotated as housekeeping by Hsiao et al. [164], i.e. called as present
by Affymetrix software in all 19 tissues examined, were obtained from hugeindex.org.
Intergenic repeats were identified through UCSC's RepeatMasker annotation.
Ancient repeats were defined as in Gibbs et al. [165] and Taylor et al. 1166] as repeats
from the same RepeatMasker subfamily conserved between mouse and human in the
same orientation. Simple repeats and regions of low complexity were excluded.
The SNP Consortium data (TSC) were used to calculate SNP density across
chromatin categories [167]. To ensure these densities were not biased as a result of the
variety of protocols used to detect SNPs (some of which were chromosome specific),
SNP densities across chromatin categories were also calculated using only SNPs
randomly identified via the TSCM0019 protocol (a panel of 24 DNAs sequenced by
the Sanger Centre, for more details see http://www.ncbi.nlm.nih.gov/projects/
SNP/snp_viewTable . cgi?method_id=58l). By using this one protocol, that covered
the whole genome and not just certain chromosomes, any bias resulting from the
variety of different protocols used should have been removed. The location of TSC
SNPs was determined by mapping their sslds to current rslds via data available at
dbSNP.
Predicted Exonic Splice Enhancers (ESE) hexamers were obtained from Fair-
brother et al. 1168]. The occurrence of each of these hexamers in the coding regions
of each of the genes that mapped to a 1Mb clone was determined. In order to iden¬
tify the number of hexamers we would expect to detect by chance given the base
composition of the genes and hexamers, we randomly shuffled the bases in each of
the coding regions 100 times and recalculated the occurrence of each of the hexam¬
ers. The distribution of non-protein coding genes across chromatin categories was
determined through Ensembl annotations.
The proportion of SNP pairs on each clone that displayed strong evidence for re¬
combination or strong LD (linkage disequilibrium) were calculated using the method
of Gabriel et al. [169] (using the Haploview program [57]). Clones less than lOOkb in
length or with an average SNP density less than one every 5kb were excluded. Clones
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were subsequently split into categories of similar chromatin structure (log2(open:input)
of-2 to -1.5, -1.5 to -1 etc) and the average proportion of pairwise comparisons dis¬
playing evidence for recombination or LD was calculated for each group. This was
done for all four HapMap populations 1170]. To determine whether regions of rela¬
tively closed chromatin display significantly low levels of recombination, the propor¬
tion of markers that display strong evidence for recombination and that are less than
various distances apart was calculated in the 60 clones with the lowest log2 open:
input values (again clones less than lOOkb in length were excluded). This process was
repeated with all clones and results compared. Randomisations were also carried out
by selecting and analysing in the same way 60 random clones from the 1Mb cloneset,
1,000 times for each population. In all populations the proportion of pairs that were
less than 150kb apart and that showed strong evidence for recombination in the 60
open clones was less than the corresponding value in 95% of the randomisations.
4.3 Results and Discussion
4.3.1 Non-dS measures ofmutation are highest in closed chro¬
matin
In order to determine whether mutation rates are associated with chromatin struc¬
ture we first determined intergenic divergence rates, using human versus chimpanzee
whole genome alignments, in regions whose chromatin environment in human lym-
phoblastoid cells had been determined. The majority of intergenic bases should
be under little or no selection and therefore intergenic divergence should be ap¬
proximately analogous to mutation rate. As shown in Figure 4.1, we see a negative
correlation between intergenic divergence and chromatin structure. However as open
chromatin is generally more gene rich than closed, and may therefore contain more
regulatory elements than intergenic regions, we also examined divergence rates in
ancient repeats only, but these also displayed the lowest divergence rates when in
open chromatin.
It has been proposed that DNA sequences nearer the centre of the nucleus may
be protected from DNA damage by those on the periphery (the "bodyguard hypoth¬
esis"). Likewise the chromosomes most enriched with open chromatin are generally
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Figure 4.1: Increased mutation rates in closed chromatin.
(A+B) Mean intergenic and ancient repeat divergence observed across chromatin
categories(Intergenic: r2= 0.87, p = 9xl0~5; Intergenic repeats only: r2= 0.93, p =
7xl0~"6; Ancient repeats only: r2= 0.93, p = 6xl0~6). (C) Intergenic divergence of
each 1Mb clone from chromosome 1 against their corresponding chromatin score
(10 clones containing less than 10,000 intergenic bases were excluded). (D) Mean
human SNP densities (SNPs/bp) observed across chromatin categories (All SNPs:
r2= 0.89, p = 0.016; Single random detection protocol (TSCM0019) SNPs only:
r2= 0.93, p = 0.008).
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vergence rates and chromatin structure may therefore be an indirect result of these
phenomena. We therefore investigated whether a correlation between intergenic di¬
vergence and chromatin structure could be observed within chromosomes. Although
chromosomes themselves have been shown to display some level of polar organiza¬
tion such that their most gene-poor regions are those closest to the nuclear periphery
[171], adjacent intergenic regions within chromosomes often have very different chro¬
matin structures despite displaying approximately the same nuclear localisation. If
the observed correlation between intergenic divergence and chromatin structure re¬
flects the predictions of the bodyguard hypothesis, we would expect to see no such
correlation within chromosomes. This however is not the case, for example, as shown
in Figure 4.1 there is a negative correlation between intergenic divergence and chro¬
matin structure within chromosome 1 (r2= 0.053; p = 0.0043). The two outlier
clones observed in this figure, with a divergence greater than 0.025, could represent
mutational hotspots in the genome. However the degree of difference between the
divergence observed in these clones compared with the rest of the chromosome sug¬
gests to us that the alignment in these regions are more likely be of poor quality.
Removal of these clones increases the significance of the correlation observed between
divergence and chromatin structure (r2= 0.113; p = 3xl0~5). In total 7 out of 22
chromosomes display a significant negative correlation (p<0.05) between clone in¬
tergenic divergence and chromatin structure (Chromosomes 1 p=0.012, 2 p=0.033,
5 p=0.014, 8 p=0.016, 12 p=0.046, 17 p=0.025 and 20 p=0.038; false discovery rate,
or FDR, analysis using the q value package suggests at most one of these is expected
to be a false positive). These data therefore argue against the bodyguard hypothesis
being solely responsible for these observed correlation between chromatin structure
and mutation rate.
Another measure often used to predict mutation rate is SNP density [172, 173].
It is predicted that as the majority of intergenic sequence is non-functional and that
there has been little time for selection to act on SNPs, their density along the genome
should generally reflect underlying mutation rates. A further benefit of the use of
SNPs in this way is that mutation rates can be predicted without relying on sequence
comparisons with other species. We consequently determined the mean intergenic
SNP densities observed across chromatin categories. As shown in Figure 4.1 the
mean SNP density was lowest in the most open regions of the genome.
There is therefore strong evidence that mutation rates are associated with chro¬
matin structure. Not only are intergenic, intronic (Figure 4.4) and ancient repeat
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divergence rates highest in closed chromatin but the density of SNPs is also elevated
in the most closed regions of the human genome and we hypothesise that closed
regions of the genome are simply less accessible to DNA repair mechanisms.
Through the use of the DAVID program [174] we identified the classes of genes
most over-represented in closed chromatin, and therefore likely to be experiencing
the highest mutation rates. Of the 148 genes in the most closed regions of the
genome 40 encode glycoproteins (p for enrichment: 0.000074, modified Fishers Exact
test) and 22 were associated with the G-protein coupled protein signaling pathway
(p = 0.00011). As this group of genes contained less than 500 distinct GO terms
both these results remained significant after Bonferroni multiple testing correction.
Glycoproteins and G-protein coupled receptors are involved in immune response and
cell signaling and it has previously been proposed that such genes are likely to evolve
quickly in response to changing stimuli [1511. Being located in closed regions of the
genome, where we have observed mutation rates are particularly high, will allow this
more rapid evolution. Genes that have previously been shown to evolve relatively
slowly, i.e. genes such as housekeeping genes, are also preferentially located in open
regions of the genome where mutation rates are relatively low (Figure 4.2). The
location of a gene in the genome and its subsequent local chromatin structure may
therefore at least partly be governed by the suitability of the local mutation rate it
confers.
4.3.2 dS is highest in regions of open chromatin
-2 to -1 -1 to 0 0 to 1 1 to 2 2 to 3 P
dN 0.11 0.12 0.094 0.089 0.075 2.2xl0"6
dS 0.62 0.64 0.65 0.66 0.68 0.13
dN/dS 0.18 0.18 0.14 0.13 0.11 5.8xl0~9
dN (without CpG island) 0.14 0.14 0.12 0.11 0.082 3.4xl0-4
dS (without CpG island) 0.65 0.64 0.68 0.7 0.7 0.045
dN/dS (without CpG island) 0.21 0.22 0.17 0.15 0.12 4.16xl0~6
dN (with CpG island) 0.073 0.095 0.071 0.075 0.07 0.043
dS (with CpG island) 0.58 0.64 0.62 0.64 0.66 0.53
dN/dS (with CpG island) 0.13 0.14 0.11 0.11 0.1 0.012
Table 4.1: The raw numbers of the data shown in Figure 4.3 as well as the corre¬
sponding p values for the correlation between each data type and chromatin structure
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Figure 4.2: The distribution of housekeeping and CpG island genes across chromatin
categories.
(A) The mean chromatin structure of genes by expreesion breadth (B) The
percentage of genes in each chromatin category that are associated with a CpG
island.
dS has historically been used as a further surrogate measure of basal mutation
rates, as synonymous sites were believed to be under little or no selection. Changes
at synonymous sites, unlike at non-synonymous sites, do not affect the encoded
amino acid, and due to the relatively small effective population sizes of mammals,
a synonymous site would have to experience relatively strong selection to evolve
in a non-neutral manner 1175]. As shown in Figure 4.3 the average rate of non-
synonymous changes (dN) observed in human mouse alignments is 51% higher in
the most closed chromatin regions of the genome than in the most open. Similarly
the ratio of non-synonymous to synonymous substitution rates (dN/dS), frequently
used as a measure of selection, is 61% higher. However, the average synonymous
rate (dS) for genes in relatively open chromatin is higher than that for genes in
a more closed chromatin structure. This is consistent with the reported high Ks
for human chromosome 19, the human chromosomes with one of the most open
chromatin structures of all (176]. The observation by Hurst et al. of similar levels of
human-mouse dS, dN and dN/dS in linked genes is likely therefore to be the result
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Figure 4.3: Human-mouse divergence observed across chromatin categories.
The correlations observed between chromatin structure and mean dS (A), dN (B)
and dN/dS (C) in human/mouse coding sequence alignments. (All protein coding
genes dS: r2= 0.99, p = 0.001; dN: r2= 0.92, p = 0.01; dN/dS: r2— 0.92, p = 0.009.
Genes associated with a CpG island dS: r2= 0.72, p = 0.07; dN: r2= 0.17, p = 0.5;
dN/dS: r2— 0.64, p = 0.1. Genes not associated with a CpG island only dS: r2=
0.84, p = 0.03; dN: r2= 0.95, p = 0.005; dN/dS: r2= 0.92, p = 0.01.). If values are
not binned then chromatin structure and both dN and dN/dS remain significantly
correlated across all genes (p = 2.2xl0~6 and 5.8xl0-9 respectively) however the p
of the correlation between dS and chromatin structure rises to 0.13.
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converse is not true, and that the results observed in this study are not the result
of linked genes, we randomly selected only one gene from each clone (so that all
genes analysed were approximately 1Mb apart and therefore unlinked) however we
still observed the same correlations shown in Figure 4.3.
As previously discussed, housekeeping genes have been shown to be under stronger
levels of purifying selection than other classes of genes [177], and it has been hypoth¬
esised that this is a result of their broad expression, intracellular location and key
role in cellular processes. As shown in Figure 4.2 open chromatin is enriched with
broadly expressed genes. We would expect this enrichment of housekeeping genes
in relatively open regions of the genome, as open chromatin is likely to provide a
more conducive environment for transcription. However the lower average dN/dS
observed in open chromatin may simply be a consequence of this higher number of
housekeeping genes in these regions. The exclusion of housekeeping genes from the
analysis however has little affect on the correlations in Figure 4.3. Even the exclusion
of all genes from the analysis whose 5' end is associated with a CpG island (which
includes almost all housekeeping genes [178]) does not lead to the loss of the correla¬
tions between chromatin structure and dN, dS and dN/dS. In fact the rate of dN in
CpG island genes, unlike that in genes not associated with a CpG island, is relatively
constant across chromatin categories and does not show a significant correlation with
chromatin. Consequently selection appears to maintain similar levels of dN in genes
associated with a CpG island irrespective of their local chromatin structure.
To ensure these results were not confounded by CpG associated or sex chromo¬
some specific factors (sex chromosomes have been shown to display abnormal rates of
divergence when compared to the autosomes [161]), we calculated divergence rates at
non-CpG, fourfold degenerate sites in genes on autosomes only. We also used human-
chimp alignments instead of human-mouse alignments as the chromatin structure of
the chimp genome should be more similar to that in humans, due to the dramatically
closer evolutionary distance between human and chimp than human and mouse, and
consequently the species of origin for each change should be less important (it should
be noted however that even comparisons of human and mouse chromatin structures
have shown striking levels of conservation even when the underlying DNA sequence
has diverged [179]). However, as shown in Figure 4.4, the highest rates of divergence
are still observed in genes from the most open regions of the genome.
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4.3.3 Genes in closed chromatin display the highest levels of
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Figure 4.4: Intronic and exonic human-chimp divergence across chromatin categories.
The divergence at non-CpG fourfold degenerate and intronic sites on autosomes
only, with the divergence observed across the splice sites of the most open and
most closed genes shown below, (closed exonic vs closed intronic Mann-Whitney U
test: p = 4.4e-16; open exonic vs open intronic Mann-Whitney U-test: p = 0.053)
Although, historically the synonymous substitution rate (dS or Ks) has been
used as a measure of the rate of mutation, there is increasing evidence that at least
weak selection may be occurring at synonymous sites 1175]. For example, it was
shown in the chimpanzee genome paper that the rate of human-chimp divergence
in exons was 25% lower than at neighbouring introns, and it is hypothesised in this
paper that this is a result of direct purifying selection at synonymous sites 1161 ]. To
investigate the potential role of any selection on synonymous sites in the disparity
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between dS and other measures of mutation, we analysed the rates of divergence
observed across intron-exon boundaries, as in [161 ]. As shown in Figure 4.4 the rates
of intronic divergence in open regions of the genome are comparable to those observed
at corresponding exonic, fourfold degenerate sites. This would suggest that genes in
open chromatin display little if any evidence for selection at their synonymous bases.
However genes in closed chromatin display markedly higher rates of divergence at
their intronic sites than at corresponding fourfold degenerate sites. Genes in closed
chromatin therefore, unlike those in open, display strong evidence for synonymous
site selection.
Although the rate of selection against both synonymous transitions and transver-
sions is highest in closed chromatin, only the rate of synonymous transversions is
strongly positively correlated with chromatin structure. The rate of transversions
at fourfold degenerate sites shows no obvious trend across chromatin categories and
consequently selection against transversions, unlike transitions, appears to be inde¬
pendent of any factors associated with chromatin structure (Figure 4.6). We are
not aware of any reason for the observed association between rates of transitions
at non-CpG fourfold degenerate sites and chromatin structure, but it could reflect
constraint in motifs whose distribution is not uniform across the genome.
As previously shown open regions of the genome are particularly gene dense
whereas closed regions are relatively gene poor [113]. Consequently, the use of dS
as a measure of mutation rate may be appropriate for a large proportion of genes.
However the use of dS as a surrogate measure of mutation rate for genes in closed
chromatin will lead to the under-estimation of the true mutation rate in these regions
and also the miscalculation of the levels of selection when used to measure dN/dS.
Although dN/dS is a general indication of selective constraint measured by compar¬
ing substitutions between species other measures of selection are likely to be affected
in a similar fashion. For example an alternative test for selection is to compare the
synonymous and nonsynonymous differences between species with the synonymous
and nonsynonymous changes observed within a species [180]. Measuring selection us¬
ing data generated by Bustamante et al. [159] we compared the numbers of genes in
each chromatin category displaying evidence for purifying selection. As can be seen
in Figure 4.5 the proportion of genes with high P- (the posterior probability that a
gene harbours excess amino acid variation) is substantially higher in open chromatin
than it is in closed. However as the McDonald-Kreitman test uses synonymous sites
as a measure of neutral mutation in the same way as dN/dS these results are likely
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to also result from the selection at synonymous sites observed in this analysis.
Log2(open:input)
Figure 4.5: The proportion of genes across chromatin categories displaying strong
evidence of purifying selection (i.e. whose P- was greater than 0.95)
4.3.4 Exonic Splice Enhancers and RNA secondary structure
It has been proposed that synonymous sites may experience constraint because they
play a role in controlling splicing or RNA stability [175]. For example synonymous
sites may be part of an exonic splice enhancer (ESE) motif or lead to a more stable
base-paired RNA that is less susceptible to degradation. Although codon usage bias
resulting from unequal abundances of tRNAs and subsequent selection at synony¬
mous sites in favour of codons corresponding to the most abundant tRNAs has also
been proposed as an explanation of synonymous site selection, the evidence for this
in mammals is weak 1181]. We therefore looked at the distribution of each predicted
ESE motif across chromatin categories to see if their relative densities could explain
the high levels of synonymous selection in closed chromatin. Although the density
of a large proportion of ESE hexamers (44%) did display a significant negative cor¬
relation with chromatin structure (i.e. p < 0.05); given the base composition of ESE
hexamers and coding regions across chromatin categories, we actually observed far
fewer hexamers displaying a negative correlation than we would expect by chance
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(66%). This is because coding sequence base composition is itself correlated with
chromatin structure and ESEs also show biases in their base composition. As shown
in Figure 4.6 excluding all sites from coding regions that overlap a predicted ESE
hexamer leads to only a small increase in the rate of transitions observed at fourfold
degenerate sites. Consequently, either there are many ESE motifs that are yet to
be determined, or selection at synonymous sites is at most only partly the result of
exonic splice enhancers.
We also looked at the distribution of gene types across chromatin categories; if
genes whose RNA structure are important were preferentially located in closed chro¬
matin we may expect an over-representation of non-protein coding genes in closed
regions. As shown in figure 4.6 certain classes of non-protein coding genes are indeed
over-represented in closed chromatin (rRNAs and snRNAs), while the distribution
of other types of genes such as rniRNAs and snoRNAs show no relationship with
chromatin structure.
Further analysis is therefore required to determine why protein coding genes in
closed regions of the genome display such comparatively high levels of selection at
their synonymous sites. If it is indeed because of a requirement for a more stable
secondary structure, then we may expect that the predicted stability of mRNAs from
closed regions would be greater than those in open [182]. Future tests of this kind
may help determine the reasons behind the enrichment of selection at synonymous
sites in closed chromatin observed in this study.
4.3.5 Levels of linkage disequilibrium are also correlated with
chromatin structure
It has been shown that mutation and recombination rates covary in the human
genome [173|. We therefore used HapMap 1183] genotype data to investigate whether
fewer SNPs in regions of a more closed chromatin structure displayed evidence for
linkage disequilibrium. By using Gabriel et al.'s [169] definitions of which SNPs
show "strong evidence for historical recombination" (one sided upper 95% confidence
bound of D' less than 0.9) and which are in "strong LD" (upper 95% confidence
bound of D' greater than 0.98 and lower bound greater than 0.7) we determined that
the proportion of pairwise comparisons displaying strong LD was consistently lower
in closed chromatin (Figure 4.7). Likewise the proportion of pairs displaying strong
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Figure 4.6: The effect of ESEs on fourfold degenerate site divergence and the ncRNA
gene distributions observed across chromatin categories.
(A+B) The observed rate of transversions and transitions respectively, at fourfold
degenerate site with and without ESE sites excluded (Fourfold degenerate site
transversions: r2= 0.02, p = 0.69; fourfold degenerate site transversions at
non-ESE sites: r2~ 0.13, p = 0.30; intergenic transversions: r2= 0.92, p = lxlO-5.
Fourfold degenerate site transitions: r2= 0.78, p = 0.001; fourfold degenerate site
transitions at non-ESE sites: r2= 0.67, p = 0.004; intergenic transitions: r2= 0.81,
p = 4xl0~~4). (C+D) The percentage of genes in each chromatin category that are
of each Ensembl ncRNA class. Only the distributions of rRNAs and snRNAs show
a significant negative correlation with chromatin structure (rRNA: r2=0.96,
p=0.004; snRNA: r2=0.92, p=0.01)
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all four HapMap populations. Recombination rate is not however the only biological
determinant of LD. Rates of mutation and gene conversion also contribute to its
disruption [169]. To investigate the potential contribution of recombination 011 this
correlation we assumed that, if many SNP pairs are examined, the contribution of
mutation rate and gene conversion should be approximately the same irrespective of
the distance between markers (this may not be strictly the case when the markers
are very close together but should hold across most distances). Therefore, a higher
rate of LD disruption with increasing distance between SNPs should primarily be the
result of increased levels of recombination (the greater the distance between markers
the greater the chance of a recombination event). By comparing clones with a rela¬
tively closed chromatin structure to all clones in the 1Mb clone set we showed that
the rate of increase of LD disruption was significantly lower in these closed regions
than in the genome in general. This was observed in all four HapMap populations.
Open chromatin did not however show a significant difference from the genome in
general, suggesting that a closed chromatin structure may inhibit recombination but
an open structure does not promote it. We therefore used the more statistically
rigorous technique of McVean et al. [184] to estimate recombination rates and con¬
firmed that recombination rates are significantly lower in closed chromatin than in
the genome in general (Mann-Whitney test rate in closed clones versus all: p =
0.031) Extrapolation of the lines in Figure 4.7 to a distance of 0 between markers
(i.e. no recombination) suggest that at most 5% of SNP pairs show "strong evidence
of historical recombination" for reasons other than recombination (recurrent muta¬
tion, gene conversion, genotyping errors etc). There is also no significant difference
between closed chromatin and the genome in general at this point, suggesting the
observed correlation between chromatin and LD is not the result of the correlation
between mutation rate and chromatin.
4.4 Conclusions
We have shown that rates of mutation and synonymous selection are correlated with
chromatin structure. Regions of open chromatin display the lowest mutation rates
and the least constraint at the synonymous sites of genes. Consequently previous ob¬
servations of mutational hotspots in the human genome, high mutation rates around































































Figure 4.7: The proportion of SNPs, at various distances apart, that show strong
evidence for recombination in the four HapMap populations. (A) CHB, (B) CEU,
(C) JPT, (D) YRI.
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housekeeping genes and the clustering of genes with similar divergence levels can all
also be associated with chromatin structure. These correlations are observed despite
the relatively low resolution of the chromatin dataset. The average length of the
clones used in this analysis was 146kb, however the average human exon for exam¬
ple is approximately a thousand times smaller. There is consequently a disparity
between the DNA regions whose rate of change we are measuring and the region of
which we know the chromatin structure. The ability to measure chromatin structure
at a higher resolution in the future may help increase the strength of these observed
correlations.
We believe the lower mutation rate observed in open regions of the genome in this
study is likely to be a result of these regions being more accessible to repair mecha¬
nisms, and not a result of selection. Indeed it is known that sites of transcription-
coupled repair are clustered in the gene dense (and therefore) open chromatin regions
of the genome [185]. Despite it now appearing that the majority of the genome is
transcribed, Surralles et al. showed that transcription-coupled repair was prefer¬
entially located at these GC rich and gene dense regions (probably as a result of
the higher levels of transcription in these areas). Likewise chromatin remodeling
is known to be a precursor to DNA repair, and efficient DNA lesion detection is
associated with relaxed chromatin structures [186, 187, 188]. However, contrary to
mutation rate, we believe it unlikely that chromatin structure mediates selection on
synonymous sites directly. Rather, it is more likely that genes that display a high
level of selection at their synonymous sites are preferentially located in closed re¬
gions of the genome. It may be that these genes in general require especially tight
transcriptional regulation, with a consequence being they are less accessible for DNA
repair.
Chromatin structure is likely, however, to be only one of a number of factors
that are associated with the variance in divergence rates observed across the human
genome. This is supported by the fact that the levels of intergenic divergence of chro¬
mosome 19 are substantially higher than other autosomes, despite being gene dense
and relatively open in structure. Most notably, both the chromatin dataset used in
this analysis, as well as nucleosome formation potential [189], have previously been
associated with GC content. Although this agreement between the lymphoblastoid
chromatin dataset used in this analysis and other more general datasets is reassur¬
ing, GC content has previously been associated with rates of mutation and selection.
However, although the mechanisms underlying the appearance of GC variability and
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isochores along the human genome remain controversial, it has been proposed that
they may be a result of selection for the structural requirements of DNA. For exam¬
ple, an increase in GC content has been associated with an increase in bendability of
DNA and a decrease in curvature, properties associated with more open chromatin
|189j. Further analysis is consequently required to determine the complex interplay
between the various factors involved in rates of mutation and selection across the
human genome.
These results have important implications for cancer. Approximately 75% of
colorectal cancer cases are sporadic in nature, i.e. there is no indication that the
disorder was inherited, instead it likely arose as a result of novel mutations and/or
environmental factors [190]. Our analysis indicates that genes located in closed
regions of the genome are particularly susceptible to such uncorrected mutations
(although the rate of mutations was determined from fixed germline changes various
lines of evidence, not least the incredibly strong relationship between chromatin
structure and GC content that is fixed across tissues 1113], suggest higher order
chromatin structure does not change dramatically between cell types). Consequently
not all cancer associated genes are equally likely to accumulate a novel mutation over
equal periods of time. One of the most important genes in colorectal cancer, the
"gatekeeper" APC, has been shown to be mutated in approximately 80% of sporadic
colorectal tumours [4], This gene is also located in a particularly closed region of the
human genome. The local chromatin structure of APC may therefore be indirectly
affecting the incidence of colorectal cancer. Work carried out in our lab involving the
sequencing of APC in cell lines, has already shown that the background mutation rate
of APC is higher than that at other randomly chosen genes, tentatively supporting
this hypothesis [191].
4.4.1 High resolution chromatin dataset
The microarray used in the analysis above was the Sanger 1Mb array. However
towards the end of my PhD the Bickmore lab produced a higher resolution 30k
chromatin dataset and we were keen to see how results compared with this new data.
After filtering out overlapping clones, the 30k dataset contained 4,988 remaining
clones. However, although this dataset contained twice as many clones as the original
1Mb dataset, the correlations observed above were generally weaker with this new
data. In all comparisons the largest discrepancies between the two datasets were at
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the most open clones.
There were therefore two potential explanations; the first was that the new
dataset was simply more accurate and the strong correlations we observed with
the 1Mb dataset were an artifact of the relatively low resolution. However stronger
correlations as a result of lower resolution seemed unlikely. Alternatively there may
have been some error present in one of these datasets.
In order to further investigate these differences we compared the overlap between
the 30k and 1Mb datasets. Although there is little direct overlap between the clones
used in these studies (only 1 filtered clone was represented on both arrays), 858
clones of the new dataset showed greater than 99% overlap in its genomic position
with a clone represented on the 1Mb array (by taking only those clones with a greater
than 99% overlap it is unlikely that any differences observed between the platforms
would be a result of differing G+C content of the clones). We therefore compared the
log2(open:input) values of these clones, and as would be expected, there is a positive
correlation between the platforms (r2 = 0.09, p < 2.2xl0~16). The Bickmore lab
had however also produced log2(closed:input) values for the 30k array, i.e. they
had looked for enrichment for closed, as well as open, chromatin across the genome.
We expected that in general there would be an inverse correlation between a clones
log2(open:input) and log2(closed:input) values, and comparisons between this closed
analysis and the 1Mb open dataset did indeed show such a negative correlation
(r2 = 0.03, p = 2.0xl0~7). However comparisons between the new 30k open and
closed values showed a weak positive correlation (r2= 0.012, p = 0.0012). This is
contrary to what we would expect and suggests that the clones most enriched with
open chromatin are also the most enriched with closed chromatin. Although this
is possible we believe the weaker correlations observed between mutation, selection
etc and chromatin structure with the new 30k open dataset is a result of some
incorrectly annotated clones, and mainly those clones are annotated as particularly
open. We can see some evidence supporting this hypothesis in fig 4.8. Clones with
a log2(open:input) value greater than 2 in the new dataset show a range of values in
the 1Mb analysis, including as low as -1.5. However, conversely, the few clones with
a log2(open:input) value greater than 2 in the 1Mb analysis all have positive values
in the new dataset.
To determine those clones which showed agreement across platforms we deter¬
mined the distribution of clone log2 values both within and across platforms. The
distributions seen within each platform showed a high level of agreement with one
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Figure 4.8: Chromatin dataset comparisons.
(A) Comparison of open datasets. (B) Comparison of old 1Mb open dataset to new
30k closed dataset. (C) Comparison of new open and closed datasets.
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another and consequently we were able to assume all values, from all platforms were
from the same distribution. We were therefore able to calculate the probability of
obtaining two values as similar as observed for each clone. To compare the closed
platform to the open datasets we reversed the closed distribution under the assump¬
tion that generally clones enriched with open chromatin will be depleted with closed
chromatin. Although we observed differences in the distribution and clustering of
clones showing strong agreements between platforms, for example almost a quarter
of clones on chromosome 2 and 16 show strong agreement (p<0.05) between the open
platforms compared to only 3% of clones on chromosomes 7 and 17, no biologically
plausible explanation for differences between the platforms could be found.
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Chapter 5
Candidate Gene Association Study
5.1 Introduction
5.1.1 Association Studies
Although various genes and pathways that participate in the development and pro¬
gression of colorectal tumours have been identified, as mentioned previously there
still appears to be a large number of genetic factors involved in colorectal carcino¬
genesis that have yet to be determined. There is therefore a requirement to try and
identify further genes that may be involved in the development of colorectal cancer.
To date, the successful identification of genes involved in a particular disease has
largely relied upon traditional positional cloning techniques, for example the use of
linkage studies to look for co-inheritance of chromosomal regions with disease [192],
However, despite the success of these techniques with rare, monogenic conditions the
complex genetic nature of cancers means this approach is unlikely to be sufficient.
To fully investigate the genetic influence of colorectal cancer would require iden¬
tifying all differences observed between the genomes of affected individuals and those
of controls. In this way polymorphisms, epigenetic states, gene copy numbers etc
that contribute to the disease would be expected to be observed at different frequen¬
cies in the two groups of individuals; the basis of association studies. Although such
a comparison on a sufficiently large number of individuals is currently unfeasible,
much of the difference between individuals can be identified by determining only a
subset of the variation among people. This is due to the fact that when genetic
factors such as polymorphisms or gene copy number changes first arise in a popula-
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tion they do so on a specific background. For example, when a single base mutation
arises in an individual, the single nucleotide polymorphisms around it will each be of
a certain allele. As this mutation is passed from one generation to the next it will be
inherited with the same alleles around it, and consequently if an individual contains
this mutation you will know the alleles of each of the surrounding polymorphisms
(without having to type them). Over time the mutation may spread through the
population to become detectable as a SNP itself and recombination and mutation
will change the alleles around it and break up this relationship between the mutation
and polymorphisms surrounding it. However, recombination between the mutation
and the polymorphisms close to it will be rare so that the mutation will most often
be seen with the same specific alleles of the surrounding SNPs. The original muta¬
tion and these SNPs are therefore in linkage disequilibrium and the combination of
alleles observed with the mutation a haplotype. Linkage disequilibrium is therefore
a strong tool in disease mapping and association studies as it allows only a subset of
markers to be typed to capture the majority of the variation between individuals in
a region.
So what is the advantage of association studies over traditional linkage analysis
The answer is power. Detection of an allele with a relatively low relative risk using
linkage analysis requires significantly more individuals to be tested than through the
use of an association study. For example, computer models predict that to detect a
disease allele with a genotypic risk ratio of 2 and a frequency of 0.1 would require
5382 families. Detecting this allele through an association study of affected siblings
would require only 264 sib pairs 1193].
Although the most powerful association studies are performed on families (i.e.
with sib pairs or affected individuals and their parents), there are a number of ad¬
vantages of using population-based cases and controls in association studies. Firstly,
the role of a gene in cancer is often only apparent upon exposure to certain environ¬
mental factors. For example variations in the activity of glutathione s-transferases,
enzymes involved in the detoxification of environmental carcinogens, are believed
to affect susceptibility to tumours with large environmental contributions [194].
Family-based studies however are generally poor at assessing gene-environment in¬
teractions. Likewise, as analyses of family based studies such as TDT (the trans¬
mission/disequilibrium test) are based on comparing observed allele frequencies to
those expected from parental genotypes, they can often be confounded by alleles
which affect fertilisation success [195]. Association studies based on cases and con-
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trols drawn from the population are also generally easier, quicker and cheaper to
construct, especially in late onset diseases such as cancer where relatives of affected
individuals are often deceased. On the other hand population based case/control
studies are strongly affected by ethnic admixture [193]. For example subpopulations
that differ in disease prevalence and allele frequencies can lead to artefactual associ¬
ations. Properly matched cases and controls are therefore vital in non-family based
association studies.
There has already been a number of notable successes in using association studies
to map disease genes/variants. For example in 2004, Begovich et al. typed 87 puta¬
tive functional SNPs in 475 individuals with rheumatoid arthritis and 475 matched
controls [196|. A variant in PTPN22, a gene responsible for negative regulation of
T-cell activation, was shown to have an odds ratio of 1.65 (95% confidence interval
1.23-2.20). This association was subsequently confirmed in a replication study of 463
affected individuals. Recently there has even been successes in relatively complex
diseases. Three independent studies investigating age-related macular degeneration
identified the same gene as associated with the disease [197, 198, 199]. Similar success
in cancer has however never been certain.
The primary concern of using association studies to determine genetic factors
influencing cancer is that unknown common cancer susceptibility genes that confer
substantial risk may not exist. The ultimate aim of any cancer association study is
to identify genetic variants that will lead to a clinical benefit. Rare variants that only
affect a small subset of the population, though biologically informative, will never
be feasibly tested in a population screen. For screening to be viable the variant
must be relatively common and confer a reasonable relative risk. However recent
studies suggest that such variants may not even exist in cancer. The environment is
believed to make a substantial contribution to colorectal cancer risk with Lichtenstein
et al. [42] estimating a 70% contribution of non-heritable factors. Likewise migration
studies show that the incidence of cancer can change dramatically within one or two
generations; too quick to be the result of the introduction of new susceptibility genes
[200]. This combined with the numbers required to confidently detect variants of
a realistic relative risk of 1.25 (>2000 cases) suggests that the search for cancer
susceptibility variants is far from guaranteed to succeed.
Without testing cancer however it is impossible to know whether common cancer
susceptibility variants of reasonable risk do or do not exist. The aim of any LD-
based association study should simply be to be rigorous enough to detect them
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if they do. Although various genetic markers can be used in LD-based methods
of disease mapping, single nucleotide polymorphisms are relatively common in the
genome (there are currently around 5 million validated Ref-SNP clusters in dbSNP)
and therefore, despite generally only having two or three alleles at each SNP, have
become the predominant marker used in association studies.
However, to take advantage of linkage disequilibrium in designing association
studies it is first necessary to know which SNPs are in LD. To this end the SNP
Consortium [167] and subsequently the International HapMap project [170, 183]
were launched to not only discover SNPs but to also determine their genotypes in
people from four different populations. The four populations chosen by the HapMap
consortium were 45 Han Chinese from Beijing, 44 Japanese individuals from Tokyo,
90 individual (30 parent-offspring trios) from Ibadan, Nigeria and 90 individuals
(again parent-offspring trios) from Utah. From these genotypes researchers are able
to determine which SNPs are in LD and which capture most of the variation in a
genomic region. The northern European descent of the individuals from Utah means
the LD structure in this group is most likely to closely represent that of the Scottish
population.
In 2005 HapMap released their phase I data with one SNP genotyped approxi¬
mately every 5kb [183]. Examination of 10 500kb fully sequenced regions scattered
across the genome illustrated that 80% of common SNPs are in perfect LD with
another polymorphism (i.e. are completely redundant). It is not necessary however
for tagging SNPs in association studies to be in perfect LD with the SNPs they are
to capture (given enough cases and controls) and greater than 90% of variants were
correlated with an r2 of at least 0.8 with another SNP. Likewise comparison of these
ENCODE regions to the phase I HapMap data suggests that approximately 75% of
all common SNPs in the genome will be correlated with an r2 of at least 0.8 with
a polymorphism in the phase I release. Therefore picking HapMap tagging SNPs
for an association study using an r2 cutoff of 0.8 should capture 75% of all common
variants in the genome.
The aim of this project was, as part of the SOCCS (Study Of Colorectal Cancer
in Scotland)/COGS (Colorectal cancer Genetic Susceptibility Study) project, to pri¬
oritise, select and analyse SNPs that could be used to investigate any link between
cancer and various candidate genes. These candidate genes included all known re¬
pair genes (as the majority of genes associated with colorectal cancer are involved in
DNA repair) as well as several other genes that have been associated with tumours
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of the colon (expression analysis, known interactor etc).
5.2 Methods
5.2.1 Gene selection
Repair genes were identified from two sources. The first, a list published by Wood
et al. in 2005 [201], contained 145 manually annotated repair enzymes and genes
associated with cellular response to DNA damage. This list, though subsequently up¬
dated, is available at http://www.cgal.icnet.uk/DNA_Repair_Genes.html. Each
gene was mapped to an Ensembl gene id via its HGNC code [202], The second
source of repair genes was Gene Ontology terms [203|. The aim of the Gene Ontol¬
ogy project is to use controlled vocabularies to describe genes and gene products. GO
terms are associated with genes by both manual curation and automatic annotation,
for example by homology to known repair genes or domains. As the ontologies are
arranged in a hierarchical fashion, the GO id for DNA repair as well as the id for all
child nodes (such as mismatch repair) were determined. 107 Molecular function GO
terms associated with DNA repair were identified and are listed in the appendix in
chapter 9. All Ensembl genes associated with one of these GO terms (as of February
2006) or listed by Wood et al. are also shown in the appendix in chapter 9.
SNPs with a previous association with colorectal cancer were also identified from
two sources. The first was a list published by Kemp et al. listing polymorphisms
published as having been tested for an association with colorectal cancer [41]. SNPs
annotated by Kemp et al. as having some or good evidence of an association with
colorectal cancer were identified (i.e. all SNPs with reported but perhaps uncon¬
firmed associations with colorectal cancer). The second source was a list of papers
compiled by Dr Barnetson, each reporting an association between a variant and col¬
orectal cancer. Insertions, deletions etc were ignored due to their difficulty of being
typed using Illumina bead arrays. Each SNP, where possible, was mapped to a cur¬
rent dbSNP rs number. In total a list of 59 variants with a previous association to
colon cancer was compiled (see appendix in chapter 9).
A further list of candidate genes was compiled containing genes with further
associations with colorectal cancer. Each was mapped to an Ensembl gene id where
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possible and these can be seen in the appendix in chapter 9.
5.2.2 SNP selection
All non-synonymous Single Nucleotide Polymorphisms located in our list of DNA re¬
pair genes were identified through dbSNP. Only SNPs annotated as validated through
non-computational methods were selected. HapMap tagging SNPs were identified
through the use of the Haploview program [57] that contains an implementation of
Paul de Bakker's Tagger tag SNP selection algorithm [204], As many SNPs can not
be typed on the Illumina bead array many potential tagging SNPs had to be ex¬
cluded. Likewise, as we were keen to compare our repair analysis to a similar study
by Professor Gallinger at the University of Toronto, we preferentially selected 433
tagging SNPs typed in his study. We also forced non-synonymous HapMap SNPs to
be used as tags where possible to minimise redundancy.
Only HapMap Phase I SNPs in our repair and candidate genes with a minor
allele frequency of at least 5% were tagged in this study. The r2 cutoff we used for
selecting tagging SNPs was 0.8, i.e. every HapMap SNP within lOkb of one of our
genes with a MAF greater than 0.05 had an r2 of at least 0.8 with a tagging SNP.
Due to the number of genes involved, the tag selection process was automated. This
was achieved through a MySQL database and Perl scripting.
We compared the numbers of SNPs required to tag our genes using both pairwise
and aggressive tagging (where aggressive tagging is where multi-marker tags are
allowed). Although aggressive tagging required approximately 8% fewer tags, we did
not feel this was sufficient to outweigh the more complex analysis required and the
potential for missing disease haplotypes. Cases and controls were selected matched
according to age, sex and postcode by Dr Tenesa.
5.3 Results and Discussion
5.3.1 Gene and SNP selection
The aim of this project was to design an association study, as part of the COGS/SOCCS
project, with the aim of testing the association between colorectal cancer and various
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candidate genes and SNPs. As discussed the main group of candidate genes being
tested were the DNA repair genes, a list of which were compiled from two sources;
GO term annotation and a paper published by Wood et al. in 2004. As can be seen in
figure 5.1 the majority of repair genes were identified by both methods, with 116/220
genes being both associated with a repair GO term and listed by Wood et al. Far
fewer genes were identified exclusively by Wood et al. only than solely through GO
term annotations. However many genes are assigned a GO term through automated
annotation and are therefore only predicted to be involved in DNA repair. This does





Figure 5.1: Overlap between repair genes listed by Wood et al. and those identified
by GO term analysis
The second group of candidates contained various genes thought to be involved in
cancer. These included the galectins shown to be differentially expressed in colorectal
cancer (see chapter 1) as well as genes involved in folate metabolism and alcohol
intake such as thymidilate synthase.
The tagging SNPs in both groups of genes were selected using Haploview. On
average each gene contained 6 tag SNPs. However, as can be seen in figure 5.2 the
distribution of tag counts per gene was skewed, a result of a few genes requiring many
tag SNPs. The median tag count was 5. The average distance between tagging SNPs
ranged from one tag every 691 base pairs in GADD45G to one tag every 81kb in
HMGB1.
As can be seen in figure 5.3 the majority of the tag SNPs picked (54%) had no
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Figure 5.2: Number of tags per gene
they tagged themselves. However, although tag SNPs were selected because of their
ability to tag the HapMap SNPs in repair genes, many of the tag SNPs picked also
had proxies outside the immediate region of its gene. As shown in figure 5.3 only
40% of tag SNPs picked had no HapMap proxy within 500kb. This is compared to
26% of all HapMap SNPs in the genome having no proxy. However, this is as would
be expected as tag SNPs will be enriched for SNPs that can only tag themselves (as
all SNPs with no proxy have to be selected compared to, for example, only half the
SNPs that have 1 proxy). The total number of SNPs tagged were ~2500 in repair
genes, and ~6000 in the genome as a whole.
All validated, nonsynonymous SNPs located in one of our repair genes were also
typed, along with a further 59 SNPs that had a previous association with colorectal
cancer. Although this gave a total of 1920 polymorphisms, 149 SNPs failed geno-
typing and 148 were fixed in our population (table 5.1) (the majority of which were
nonsynonymous SNPs from dbSNP that either did not in fact exist or were not
present in this population). Two SNPs departed from Hardy-Weinberg equilibrium
with a p <= 0.001, however this was no more than what would be expected given the
number of SNPs tested in this study, and no SNPs departed with a p <= 0.0001. We



















Our tags, just our :
genes
>20 7.67 4.01 0.80
11-20 10.65 6.49 2.41
*6-10 14.37 11.30 5.82
■ 3-5 18.34 15.18 11.24
■ 2 9.80 8.36 9.03
■ 1 13.22 14.98 16.92
■ 0 25.94 39.67 53.78
Figure 5.3: Proxies per tag.
The percentage of HapMap SNPs that are within an r2 of 1 with 1, 2, 3-5, 6-10,
11-20 or greater than 20 other HapMap SNPs; the percentage of our chosen tag
SNPs that are within an r2 of 1 with 1, 2, 3-5, 6-10, 11-20 or greater than 20
HapMap SNPs and the percentage of our chosen tag SNPs that are within an r2 of
1 with 1, 2, 3-5, 6-10, 11-20 or greater than 20 HapMap SNPs located within a
repair gene.
Study SNPs selected Non-synonymous Genotyped successfully Fixed in population
Repair genes 1650 414 (25%) 1530 (93%) 138 (9%)
Candidate genes 211 26 (12%) 187 (89%) 7 (4%)
SNPs with prev. assoc. 59 30 (51%) 54 (92%) 3 (6%)
Table 5.1: SNP counts
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As we used the CEU HapMap data to select our tagging SNPs we were keen to see
how this population compared to our Scottish controls (for validation purposes). We
therefore compared minor allele and heterozygote frequencies across populations.
Figure 5.4 clearly shows that the frequencies observed in our Scottish controls is
highly similar to that in the HapMap CEU population. Frequencies observed in the
other HapMap populations are however markedly different. The only SNP whose
allele and heterozygote frequencies were considerably different between our Scottish
controls and the CEU data was rs2061783. This SNP had an observed minor allele
frequency of 0.5 in the HapMap data but of only 0.023 in our Scottish controls. It
is possible that this SNP does in fact show such differences between its frequencies
and is to some extent a marker of the Scottish or Utah populations. However it
seems more likely that it was simply mistyped in one of the two studies. Although it
would have been possible to also compare LD structures across populations to ensure
the validity of our tagging SNPs, previous work in our lab has shown that power in
association studies is only marginally affected by the choice of HapMap population
[205].
5.3.2 Comparison to Whole Genome Data
A number of the polymorphisms genotyped in this study were also typed as part of a
whole genome association study carried out by our lab. As this study had been car¬
ried out on a second Illumina platform we were able to determine the reproducibility
of our results. In total 1978 people and 765 SNPs had been typed in both studies1.
As can be seen in figure 5.5 the reproducibility between people and SNPs was high,
and of 1,055,434 genotypes, 99.95% were identical in both studies. The polymor¬
phism rs2061783 that had shown such a marked difference in allele and heterozygote
frequencies between the HapMap CEU and our Scottish population had a repro¬
ducibility of 100%, which suggests that the frequencies observed in our population
for this polymorphism were real and not the result of incorrect genotyping. Some
polymorphisms however were clearly mistyped in one of the studies. For example,
rsl799949 had 236 individuals whose genotypes were different between studies and
in all these cases the individual was typed as a GG in the whole genome study and as
an AG on the custom array. Heterozygote and minor allele frequencies observed by
1More SNPs than we would have liked were typed in both studies as the Illumina 550k content
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Figure 5.4: Control versus HapMap heterozygote and minor allele frequencies
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Perlegen and HapMap in Europeans at this SNP are however more consistent with
those observed in the whole genome than the custom study; allowing us to hypoth¬
esise this SNP was mistyped on the custom array. Some of the discrepancy between
platforms was also likely the result of mislabeled individuals. For example, MD2246,
showed a reproducibility of only 54%, it is however difficult to determine on which
platform this individual was incorrectly genotyped. SNPs and individuals with low
reproducibility percentages were removed from further analysis (People to exclude
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Figure 5.5: Genotvping reproducibility
Reproducibility between Illumina platforms for (A) the 765 SNPs and (B) the 1978
individuals successfully typed in both studies
5.3.3 Testing for association
To test for association between colorectal cancer and each SNP on the custom array
a Chi-Squared test of allelic counts was used (i.e. a chi-squared test was performed
on the counts of each allele at each SNP in cases versus controls, calculated using the
PLINK program |206]). The top 20 polymorphisms with their corresponding p values
are shown in table 5.2. Due to the number of tests performed it was necessary to
correct these values for multiple testing array wide, and a number of strategies were
used. These included the calculation of False Discovery Rates (q values, Benjamini &
Hochberg and Benjamini k Yekutieli) and the application of Bonferroni, Holm and










































































































































































































no SNPs approached significance. Under the null hypothesis p values should be
distributed uniformly between 0 and 1 with any enrichment of low values due to true
positives, and as can be seen from figure 5.6A there was no apparent enrichment of
SNPs with low p values within our study.
As the unit of interest in this study was generally genes rather than SNPs,
and therefore each gene rather than each SNP is really the unit of independence,
we also corrected for gene wise type I error rates while also correcting for experi¬
ment wide testing by running 1000 (phenotype) permutations and only examining
the top hit from each gene (we are only interested in whether any SNP in each
gene shows an association with colorectal cancer and not all SNPs, for more de¬
tails see PLINK set-based tests http://pngu.mgh.harvard.edu/~purcell/plink/
anal. shtml#set). Although this technique is biased towards genes with relatively
few SNPs, no genes were significant at greater than the 20% level.
Consequently having corrected for multiple testing no SNPs approached signif¬
icance irrespective of the correction used. However one question we were keen to
answer in this analysis was whether currently available SNP prioritisation programs
such as SIFT [66] and SNPs3d [207] can be applied to cancer association studies to
predict functionally important polymorphisms. It is thought that SNPs involved in
cancer are less well conserved than their monogenic counterparts due to the complex
gene-environment and late onset nature of the disease. Consequently, the power of
programs that predict the impact of a polymorphism on disease through analysing
conservation profiles is likely to be diminished, and SNP prioritisation programs
may not therefore be applicable to cancer. However if polymorphisms associated
with carcinogenesis are indeed generally more conserved than SNPs in general, then
conservation may prove an alternative method for determining true positives from
false positives.
To test this hypothesis we compared the uncorrected chi-square values from above
to the output of various SNP prioritisation programs. Figure 5.7 shows the results
of plotting the SNPs3d score of a non-synonymous SNP versus its corresponding
chi-square value. As can be seen, there is no apparent relationship between these
values, which suggests that Prioritisation of SNPs according to their SNPs3d score
is unlikely to enrich for polymorphisms displaying an association with cancer.
However as shown in figure 5.7 those SNPs with high chi-square values generally
showed low SIFT scores. Conversely, as expected, polymorphisms with low chi-square
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Figure 5.6: (A) The distribution of the p values of all the SNPs on the custom array.
(B) The distribution of the p values of the Gallinger proxies of the custom array
SNPs. (C) The distribution of the p values of the Gallinger proxies corresponding
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Figure 5.7: SIFT and SNPs3d scores against allelic case versus control chi-square
values for our non-synonymous SNPs (SIFT versus chi-sq: r=0.18, p=0.026)
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for reasons other than an involvement in cancer). This is in agreement with a more
limited analysis by Zhu et al. that also observed a weak correlation between the odds
ratios of 46 non-synonymous SNPs and their corresponding SIFT scores [208]. It is
likely that the poor performance of SNPs3d relative to SIFT is at least partly a result
of the fact that it is trained on monogenic diseases. SIFT on the other hand makes
ab initio prediction with only the thresholds being determined from monogenic data.
The threshold of 0.05, recommended by the authors of SIFT for annotating SNPs
as deleterious, is likely to be too strict for use in cancer for the reasons discussed
previously.
Despite this correlation between SIFT and chi square scores, the application of
SIFT in designing association studies is likely to be limited. The modest enrichment
in the proportion of detected true positives obtained is unlikely to outweigh the cost
of missing further true positives considering the ever decreasing cost of SNP geno-
typing and the relatively small number of polymorphisms actually associated with
cancer. However programs like SIFT may prove useful in separating true positives
from false positives in the subsequent analysis of association studies. For example,
we would expect true positives to in general be more conserved than false positives
and for true positives to be more substantially enriched from within this group. The
fact that there is an apparent relationship between conservation and chi-square value
in our dataset suggests that there probably are indeed true positives within the set
of non-synonymous polymorphisms tested, however their effect on colorectal cancer
is limited and they can not be detected given the power of our study. (The polymor¬
phism in figure 5.7 with the highest chi-square value, that is also highly conserved,
is located in BRCA1 a gene already known to play an important role in various
cancers.)
Although our dataset is relatively sparse with SNPs of intermediate to high chi-
square values, the fact that polymorphisms with intermediate chi-square values in
figure 5.7 also show, at most, intermediate SIFT conservation scores, suggests that
more SNPs may be associated with colorectal cancer than is at first apparent. It may
be the case that some SNPs with relatively low chi-square scores show some level of
conservation as they have only a minor role or they interact epistatically with other
polymorphisms. We therefore tested the difference in SNP-SNP association between
cases and controls both through PLINK and using logistic regression with an additive
model (in both cases the results were similar). Although a number of SNP-SNP
comparisons displayed small p values in this analysis (down to 7x10 ~7), given the
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number of tests involved this is as would be expected. After Bonferroni, FDR and
permutation multiple test corrections no pairwise comparisons were significant at
greater than the 20% level.
5.3.4 Replication and comparison to further populations
If true positives do exist in a dataset they should replicate in other studies. As
previously mentioned tags in our study had been preferentially selected that had
previously been typed by the Gallinger group in Canada, and in total 433 SNPs had
been typed by both groups in a total of of 2207 cases and 2211 controls. Likewise
a number of our polymorphisms had been typed by the Houlston group in London
in a whole genome scan of 1585 people (620 cases and 965 controls). Although this
meant a reasonable proportion of SNPs could be directly validated in at least one
further population, through the use of data from our own whole genome scan, we
were also able to identify a further group of SNPs typed in the London population
that were in high LD with one of our polymorphisms. In this way we identified 84%
of our polymorphisms had been directly typed in the London dataset or could be
assigned a proxy with an r2 of at least 0.7. However substantially less SNPs could
be validated using the Canadian data for two reasons. Firstly their genome coverage
was more sparse than that of the Houlston group (they had only typed approximately
110k SNPs compared to over 500k typed in the London dataset). However perhaps
more importantly we also had to rely on HapMap data to calculate LD between our
SNPs and those typed by the Gallinger group. As 143 SNPs successfully genotyped
in our study had not been typed in the HapMap CEU population, we were unable
to identify tags for these polymorphisms. Consequently, to partly overcome this
relatively sparse coverage of the Gallinger data we allowed both single and multi-
marker tags to act as proxies (this was achieved by altering the Haploview source
code so that the best single or multi-marker test was outputted for each SNP). In
total 91% of our SNPs had been replicated (or pseudo-replicated by a proxy with an
r2>0.7) in at least one population and 53% were replicated in both.
If true positives existed within our dataset we would expect to see some enrich¬
ment of SNPs with low p values (the basis of an FDR analysis). However, as shown
in figure 5.6A no such enrichment was observed. The proportion of true negatives
estimated from this distribution using the qvalue R package was 99.5%. Our con¬
servation analysis however suggested that this may be an over-estimation and that
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some SNPs were indeed involved in cancer though their effects were probably small.
Consequently to enrich for any true positives we identified those SNPs that had a p
value of less than 0.1 in our analysis and that had been replicated in the Gallinger
dataset. As can be seen from the distribution of Gallinger p values of these SNPs,
an enrichment of low p values could now be observed (Figure 5.6C). Likewise the
estimation of the proportion of true positives among this subset of SNPs was now at
53%, compared to 15% among the Gallinger dataset as a whole. Consequently the
use of consecutive replication studies allowed us to enrich for potential true positives
among our dataset.
As shown in tables 5.3 and 5.4, 55 SNPs (or their proxies) had a p value less than
0.1 in at least two populations examined, with three SNPs, rsl2724233, rsl 1236164
and rs2247233, having a p value less than 0.1 in all three. Two of these SNPs,
rsl2724233 and rsll236164, are located in close proximity to known mismatch re¬
pair genes; the tumour associated tp73 and the polymerase POLD3 respectively. The
third SNP rs2247233, like rsll236164, is associated with a DNA polymerase (POLG).
It should be noted however that the best proxy of rsl2724233 in the Gallinger pop¬
ulation was in very limited linkage disequilibrium with the original SNP. This SNP
is therefore a poor tag of rsl2724233. However many SNPs in the region of tp73 dis¬
played a low p value in the Gallinger dataset and we therefore included this region
for further analysis. Figure 5.8 shows the odds ratios and corresponding confidence
intervals of SNPs rsl 1236164 and rs2247233. If none of the SNPs in our dataset with
an r2 of at least 0.7 in our replication datasets were truly associated with colorectal
cancer we would expect 1 SNP (or more precisely 0.85) to have a p value less than
0.1 in all three populations simply by chance. As we saw 2 it would be difficult to
say there is much meaningful enrichment in this analysis.
Further SNPs also had a p value less than 0.1 in all populations where a suitable
proxy was available. For example rsl6260 was untaggable in the Houlston population
and a had a relatively poor tag in the Gallinger dataset. However as it had previously
been associated with colorectal cancer this SNP is likely to be a strong candidate for
being associated with the disease.
Our SIFT analysis and examination of replication across studies consequently
suggests that a number of our repair loci may indeed be involved in colorectal cancer.
However our study is underpowered to detect them as a result of their attributable
risk being small (OR <1.2). The growth in the number of association studies pub¬
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Figure 5.8: Odds ratios for SNPs rsll236164 and rs2247233 in the Scottish popu¬
lation, as well as those of their corresponding proxies in the London and Canadian
datasets.
Both SNPs were typed in the Dunlop under 55 cohort initially however rsl 1236164
had also previously been genotyped in a second Dunlop cohort of older cases and
controls and these results were therefore included.
will have such small effects [209]. To overcome this, we are typing our strongest can¬
didates in a further 4000 individuals. Combined with the 2000 Canadian individuals
this should give us sufficient power to detect more marginal effects.
5.3.5 Tagging efficiency
It has been proposed from the examination of ENCODE data that picking HapMap
phase I tagging SNPs with an r2 threshold set at 0.8 should capture 75% of all
common variants in the human genome. Consequently, in association studies, only
a sub-set of all SNPs are selected to be genotyped based on the assumption that
typing SNPs in high LD will lead to unnecessary redundancy. This however is only
true if the p-value of the tag SNP is, as or more significant than the SNP it is meant
to be tagging. If a disease variant that is typed directly has a significant p value
but its proxies do not, then picking tagging SNPs may lead to this disease locus
being missed. We therefore tested the relationship between the r2 values observed
between SNPs typed in our study and their corresponding p values. To achieve this
we calculated the r2 between every pair of SNPs within 500kb (using the HapMap
CEU data) and then calculated the difference between the observed p values at each
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of these SNPs. Those pairs of SNPs with an r2 of approximately 0.8 differed in their
p values by on average 0.175. This is of course a large enough value for a disease
variant to not be detected through a tag. However a large difference in p values
between a pair of SNPs is only important if one of the polymorphisms is significant,
if large differences are generally only associated with polymorphisms of large p values
then they are of little concern. We therefore excluded all SNP pairs in which one of
the SNPs did not have a p value of less than 0.1. The average difference in p values
of the remaining SNPs whose r2 was between 0.8 and 0.9 was 0.065. Of those pairs
of polymorphisms (with an r2 greater than 0.8) where one of the SNPs had a p value
less than 0.05, in over a third of cases the p value of the second SNP was greater
than 0.05.
However perhaps more important than the relationship between the actual p
values observed between pairs of SNPs and their level of LD, is the relationship
between the r2 between pairs of SNPs and their rank among all SNPs tested. Of
those SNPs that had at least one proxy with an r2 of at least 0.8, and whose p
value were in the top 5% of all SNPs tested, approximately a third (31%) had a
corresponding tag outside the top 5%. For example the tag of the second most
significant SNP in the whole study, whose p value was 0.004, was not even in the
top 10% of all SNPs (r2 between these SNPs was 0.87, p of tag was 0.16). Similar
results were observed using the Canadian data. Those studies therefore that simply
select the top SNPs for further study irrespective of their p value (as done in our
whole genome scan) may still miss a substantial number of potential disease loci.
From these results we are able to determine what proportion of disease variants
we are able to detect through an association study such as ours. If we make a
naive assumption that there are 100 common disease variants within the human
genome whose p value would be at most 0.05 in a study of our size, we know that
approximately 25 of these polymorphisms will be missed simply due to the incomplete
nature of the HapMap data but that, on the other hand, 26 will be typed directly
due to having no suitable proxy (Figure 5.3). Tagging the remaining SNPs will
lead to approximately 16 disease variants being selected as tags by chance, and
of the remaining 33, 11 will not be detected at a significance threshold of 0.05.
Consequently, of the initial 100 disease variants, 36 will not be detected through an
association study such as ours. Although it may be possible to improve this figure
by biasing tag selection towards those SNPs that are more likely to be associated
with disease, for example by picking non-synonymous SNPs as tags where possible,
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most association studies are still likely to miss a substantial proportion of disease
variants.
One of the most likely factors leading to this relatively poor relationship between
r2 and p values is the HapMap data itself. Not only are the r2 values based on
the genotypes from relatively few individuals, but the HapMap Caucasian dataset
is likely to differ at least to some extent to the Scottish population. Calculating
r2 values based on the Canadian dataset, that contains genotypes for over 2000
individuals and that we have shown is highly similar to our population, does appear
to improve the relationship between the r2 and p values of pairs of polymorphisms.
Although allele frequency is also likely to explain some of the discrepancy between r2
and p values (SNPs of low minor allele frequency are more likely to have higher r2)
the majority of rare SNPs were excluded from our study (only rare non-synonymous
polymorphisms were retained).
5.3.6 Inter-chromosomal LD
It has been argued that when genes interact epistatically, evolutionary selection will
promote their genetic linkage as a means of enhancing the coinheritance of favourable
allelic combinations. This hypothesis has been supported by the observations of clus¬
ters of genes in eukaryotic genomes whose corresponding protein interact and/or are
coexpressed [210]. Although it was initially proposed that this may simply reflect
underlying gene duplications, it was shown by Pal and Hurst [211] that areas of the
genome containing clusters of essential genes display relatively low levels of recom¬
bination. Consequently there is support for the hypothesis, first proposed by Nei in
1967 [212], that high levels of linkage can be observed between interacting genes, so
that alleles that work well together will be maintained.
This hypothesis was further supported by observations in inbred mice of the coin¬
heritance of optimal sets of alleles among linked genes; recombination that broke up
these sets of alleles reduced the fitness of the corresponding mice and their ancestors
[213]. fn this study LD was also observed between markers on different chromosomes.
It has been previously observed that LD between unlinked (different chromosome)
markers in the human genome is higher than would be expected by chance (un¬
published communication), and we were therefore keen to test if these observations
were related. Do functionally related genes on separate human chromosomes display
higher levels of linkage than would be expected by chance? For example embryonic
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lethal combinations of genotypes between SNPs should not be observed, likewise
combinations that affect fertilisation success should be selected against. To test this
hypothesis we obtained 1030 interacting gene pairs from the EBI intact and MIPs
databases.
To identify whether genes whose products are known to interact display higher
levels of LD than we would expect by chance, we first calculated the LD observed
between interacting gene pairs located on different chromosomes. These results were
then compared to those obtained when the person ids were permuted in one of the
genes in each gene pair. This consequently provided us with an indication as to the
number of SNP comparisons we would expect to see above a certain r2 cutoff by
chance, given SNPs with the same alleles and minor allele frequencies.
Less than 4% of permutations based on the Chinese HapMap data displayed
more pairwise comparisons with an r2 of 0.4 than the real unpermuted data, with
none displaying more with an r2 greater than 0.5. Likewise only 6% of permutations
displayed more pairwise comparisons with an r2 of 0.4 when the HapMap Caucasian
data was used. These results therefore appear to suggest that genes whose protein
products interact may indeed display higher levels of LD between their SNPs than we
would expect by chance. However when r2 values were calculated using the Yoruba
HapMap data over 19% of permutations displayed more pairwise comparisons with an
r2 of 0.4 than the real data (though this did drop to 8% at an r2 of 0.5). Likewise the
figure at an r2 of 0.4 using the Japanese data was even higher at 31%. The Chinese
and Japanese populations are very similar, especially in their LD structures, and
therefore if we believe epistatically interacting genes do indeed show higher levels
of LD than we would expect by chance we would have expected the permutation
results to have been closer. However as we had observed potentially promising results
in at least two populations considering the limitations of the interaction dataset
(confidently identifying proteins that interact directly in humans can be difficult)
we decided to investigate the potential relationship between epistatically interacting
genes further. Although we had shown that genes whose products interact potentially
display higher levels of LD than we would expect by chance, we had not shown
that these levels of LD were any higher than we would expect between randomly
selected pairs of genes. For example, all pairs of genes may show higher levels of LD
than would be expected. However when random pairs of genes were selected they
generally showed at least ten times fewer SNP pairs with an r2 of 0.4 than the genes
known to interact, and fifteen times fewer with an r2 of 0.6 (Caucasian genotype
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data). It should be noted however that the majority of SNPs with an r2 of 0.4 are
from only a subset of genes whose products are believed to interact. For example,
although 65 SNP pairs display an r2 of 0.4 or greater these are all located in only 10
genes. Consequently rather than all epistatically interacting genes displaying higher
levels of linkage than would be expected by chance only a small proportion do and
consequently it is not possible to say that the high levels of LD observed in certain
populations are a result of the interaction between the genes.
One of the major limitations of using HapMap data for this type of analysis is
the relatively few individuals available. There were however over thirty times as
many people typed in our custom analysis than in the largest HapMap populations.
Likewise, as we had examined a candidate pathway, this set of genes was likely
to be enriched with those that interact epistatically. We consequently calculated
the r2 between all pairs of SNPs, located on different chromosomes, genotyped on
our custom array. After 100 permutations2 similar to those discussed above, only
one pair of SNPs remained significant (no permutations displayed a higher r2 value
at any pair of SNPs). This pair of non-synonymous SNPs were located in LIG4
and ATM. This pair of genes have previously been shown to interact epistatically
and are also known to be associated with embryonic lethality [214]. r2 may not
however be the most appropriate measure for this type of analysis, primarily as it
is based on predictions of phase between SNPs. When comparing SNPs on different
chromosomes phase, i.e. the parent of origin of each allele, is hard if not impossible to
determine. We therefore applied a simple chi square test to the observed frequencies
of genotypes between any pair of SNPs and those we would expect given random
associations. After permutation analysis the same pair of non-synonymous SNPs did
not remain significant array-wide. It is possible that any non-random association
between polymorphisms is simply the result of genome assembly errors or SNP mis-
annotation and therefore more analysis is required to try and understand why some
gene pairs show higher levels of linkage than would be expected by chance.





As highlighted in the previous chapter most association studies are by their nature
indirect. Disease variants are most often identified through their linkage disequilib¬
rium with a second, tag, variant. But what if it was possible to type disease variants
directly? Although this is impossible without knowing the location of each disease
variant, it is possible to make predictions as to which SNPs are potentially deleteri¬
ous. For example, coding SNPs make up the majority of disease alleles in Mendelian
disorders. Botstein et al. illustrated that of all mutations underlying disease phe-
notypes, 58.9% were missense or nonsense SNPs [192] despite coding SNPs making
up only a small proportion of known polymorphisms (approximately 1.5%). By typ¬
ing only coding variants it is therefore possible to significantly enrich for potential
disease SNPs. Even among coding SNPs many polymorphisms are more likely to
be deleterious than others and it is possible to prioritise those with strong evidence
of being potentially pathogenic. Although there is likely to be ascertainment bias
in the analysis of Botstein et al. (as most investigators preferentially look at non-
synonymous polymorphisms there is likely to be an artificially high proportion of
non-synonymous polymorphisms associated with disease), and complex diseases like
cancer are likely to differ from Mendelian diseases, it is still highly likely that coding
SNPs will be overrepresented among cancer disease variants.
All SNPs are not however functional and determining which are is not simple, es¬
pecially when their contribution to the disease may be small or when various SNPs are
in LD. However the polymorphisms most easily identified as potentially pathogenic
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are those that can be seen to dramatically affect the structure of a protein. For
example nonsense mutations often lead to a considerable truncation of the protein,
consequently it is relatively easy to hypothesise that the protein's function is being af¬
fected. Missense mutations on the other hand are less easily annotated as potentially
pathogenic; as not all amino acids in a protein are equally structurally or function¬
ally important. It has been shown however that changes at positions in proteins
that are conserved across species and multigene families are more likely to be detri¬
mental. Programs that utilise conservation to predict deleterious mutations/alleles
include SIFT [66], PolvPhen [215] and SNPs3d |207] that are discussed below. Like¬
wise changes between amino acids that are dissimilar in terms of their properties
(charge, side-chain length etc) are more likely to be potentially deleterious. Wang et
al. illustrated that 90% of pathogenic, missense mutations can be associated with a
predicted structural change, compared to only 30% of general polymorphisms [216].
Consequently, if a known structure is available, particular structural consequences
can be looked for. Programs that determine potential structural consequences of
amino acid changes include SNPs3d and PolyPhen.
Methods for identifying single nucleotide polymorphisms that affect splicing or
the expression of a gene have been less well characterised, partly due to the ambiguity
in splicing and regulatory motifs. However Clifford et al. showed that missense
mutations often adversely affect the score of Pfam domain predictions, and that the
magnitude of the change in the score is a good predictor of whether the mutation
is deleterious [217]. It may therefore be possible to apply a similar technique on
splicing and regulatory domains and programs such as FASTSNP [67] have begun
to adopt this approach using ESE and transcription factor motifs.
There has already been some notable successes of the use of SNP prioritisation
in the design of association studies. For example Begovich et al. [196] typed 87
polymorphisms in a study investigating rheumatoid arthritis that were selected not
on their tagging abilities but because they were located in candidate genes/regions
and were putatively functional. A study therefore that includes a combination of
both tagging and functionally important SNPs may provide the most power for
identifying disease variants.
The aim of this project was to develop an integrated analysis environment for
SNP prioritisation that could be used in both the design and analysis of both candi¬
date and whole genome association studies. This would be achieved partly through
the integration of a number of third party SNP prioritisation programs and the pre-
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sentation of SNP prioritisation results across the human genome. Below I discuss
the programs used during this project.
6.1.1 SNP Prioritisation Programs
6.1.1.1 SIFT
SIFT (Sort Intolerant From Tolerant) is a sequence homology-based program that
uses multiple sequence alignments to predict amino acid changes that will have a
phenotypic affect. It achieves this by first compiling an alignment of sequences
using the PSI-BLAST program. The database we used was the June 2006 release of
the SWISS-PROT/TrEMBL protein sequence database. Sequences from this PSI-
BLAST search that are more than 90% identical to one another are collapsed by SIFT
to a single consensus sequence with each sequence position represented by the amino
acid that occurs most frequently. PSI-BLAST is then again used to search among
these consensus sequences to find the top hit to the initial query sequence. These
sequences are subsequently aligned, conservation at each position in the alignment
calculated (see algorithm 4) and the median of these values determined. If this
value of median conservation is greater than a user defined cut-off, the sequence is
maintained in the alignment and a PSI-BLAST checkpoint file created. This file is
used to query the remainder of the consensus sequences and the process is repeated
until the sequence added falls below the median conservation cut-off. To prevent
contamination of the alignment with pseudogenes (or even the query sequence itself),
sequences with greater than 90% identity to the query sequence are excluded [218,
66].
Algorithm 4 Measure of conservation used by Ng and Henikoff.
Rc — /Of/220 E20aaPcalOQPca
pcais the frequency at which amino acid a appears at position c. Possible values for
median conservation range from 4.3 (sequences are 100% identical) to 0 (all amino
acids are found at almost all positions)
The prediction of an individual amino acid's affect on phenotype is a weighted
average of the observed frequencies of the amino acid and the Dirichlet estimation.
Dirichlet mixtures allow the probability of an amino acid at a position in the sequence
to be calculated based on prior information about what types of amino acid distribu¬
tions are reasonable in columns of alignments [219]. This allows amino acid probabil-
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ities to be adjusted according to the amino acids observed at that position and those
observed in databases of alignments. For further information on how the probabili¬
ties are calculated in SIFT see http://blocks.fhcrc.org/sift/SIFT_help.html.
Through comparisons to experimental data a probability of 0.05 has been shown to
be a reasonable cutoff for calling a change deleterious. SIFT also returns the median
conservation of the sequences in the alignment as predictions based on alignments
with high median conservation (>3.25) are thought unreliable. When tested on ac¬
tual SNPs annotated as associated with a disease in the SWISS-PROT database
(and not simply SNPs in genes associated with a disease), SIFT predicted 69% were
deleterious (i.e. a false-negative rate of 31%). Analysis of random SNPs from the
dbSNP database on the other hand resulted in 25% being predicted as deleterious,
however a proportion of these are likely to be pathogenic in some way [218].
6.1.1.2 Polyphen
The PolyPhen (POLYmorphism PHENotyping) program uses three sources of infor¬
mation to make its prediction of whether an amino acid change will be deleterious.
The first is whether the amino acid is located in a site annotated in the SWALL
database as functionally important. Features classified as important by PolyPhen
include active, binding and transmembrane sites, and any missense change at one
of these sites is predicted to be deleterious. The second source of data used by
PolyPhen is structural information. By comparing the query sequence to a database
of proteins with known structure PolyPhen attempts to identify whether the query
itself or a homologue with at least 50% identity has a known structure. If this is the
case, Polyphen makes predictions as to whether the amino acid change will affect
the hydrophobic core of the protein, electrostatic interactions, interactions with lig-
ands or other important features. This is achieved by calculating several structural
parameters and assessing the impact of the amino acids change on spatial contacts.
For example, changes that affect the residue's side chain volume or that disrupt an
interaction between subunits of a protein are predicted to be deleterious [215].
The final source of information used by PolyPhen is sequence conservation. In
a similar fashion to that of SIFT, PolyPhen uses BLAST to identify homologues
of the query sequence that display 30-94% identity over at least 50 base pairs. A
profile matrix is then calculated from this alignment using the PSIC software. Each
element of this matrix is a logarithmic ratio of the estimated probability of a given
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amino acid occurring at a site, given infinitely long evolution, against the background
frequency of that amino acid (derived from a database of proteins, see PSIC paper
for more details [220]). Polyphen then uses the absolute difference of these profile
scores to predict the affect of an amino acid change at a particular position. Like
SIFT the confidence of these predictions are determined by the quality of the original
alignment.
The performance of PolyPhen on known deleterious variants has been tested on
sets of disease causing (as annotated by Swissprot) and control variants (between-
species substitutions, fixed differences are thought unlikely to be pathogenic, no num¬
bers were reported). When only variants with strong evidence of being pathogenic
are examined, PolyPhen displays a false negative rate of 43% and a false positive
rate of 3%. Less strict criteria give rates of 18% and 8% respectively [215].
6.1.1.3 SNPs3d
SNPs3d, like PolyPhen, uses both structural information and sequence conservation
to predict the affect of amino acid changes. As briefly discussed previously, Wang
et al. illustrated that the majority (90%) of a subset of the known pathogenic
missense changes listed in HGMD could be associated with a predicted structural
change [216]. A subset of these factors, shown in table 6.1, are used by SNPs3d
to predict the structural consequences of an amino acid change. This is achieved
by training a Support Vector Machine with both pathogenic and control missense
changes, to determine the partitioning surface between these classes of changes in
the 15 dimensional parameter space (i.e. the 15 factors in table 6.1).
The prediction of deleterious mutations based on sequence conservation in SNPs3d
also relies on a SVM. Like SIFT and PolyPhen an alignment of sequences homolo¬
gous to the query is built using PSI-BLAST. Where two sequences in the alignment
are more than 90% identical one is removed. Sequences with less than 30% identity
to the query sequence are also excluded along with regions of the alignment where
more than 50% of the sequences have a gap. The SVM is subsequently trained on five
features associated with conservation; the probability of accepting the amino acid
substitution (derived from the BLAST position specific scoring matrix), the entropy
at the position in the alignment, the mean entropy across the whole sequence, the
standard deviation of the entropy across all positions and the entropy expressed as


















Breakage of a disulphide bond
Table 6.1: Factors affecting protein stability used by SNPs3d to investigate the
affects of missense changes. Taken from Yue, Li and Moult
In both the protein stability and conservation profiles the control variants used
to train the SVMs were non-synonymous base differences observed between human
sequences and their orthologues in closely-related mammals. The deleterious variants
on the other hand, were nonsynonymous polymorphisms previously associated with
monogenic diseases (obtained from the Human Gene Mutation Database). Random
subsets of each class of variant were used to train and test the SVMs so that false-
positive and false-negative rates could be estimated. In SNPs3d, variants with an
SVM score greater than 0.5 are annotated as non-deleterious and less than -0.5
as deleterious. Predictions between these scores are deemed unreliable. The false-
positive and false-negative rates obtained using these SVMs and parameters were 6%
and 16% for the conservation SVM, 12% and 21% for the stability SVM and 3% and
9% for both combined (i.e. where a variant is confidently predicted to be deleterious
by both methods). Therefore 6% of the variants annotated by the conservation SVM
as deleterious in test datasets were in fact not deleterious, and 16% of the variants
not annotated as deleterious were in fact pathogenic. It is hypothesised that the
error rates are higher when predictions are based on structural information alone
(than when based on sequence conservation or both combined) as many affects on
protein function such as post-translational modification will not be detected by this
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method. On the other hand the conservation profile should theoretically be able to
detect any deleterious affect on a protein's function [207].
These programs were used to prioritise SNPs in and around our genes of interest.
A number of points should be made about these programs. The first is that each
was tested on a different dataset so that the error rates reported above are not
comparable between programs. Likewise, all three of these programs were tested
and/or trained on disease variants associated primarily with Mendelian diseases.
Analysis of the performance of these programs on complex diseases such as cancer is
limited and often contradictory. It is likely that variants associated with cancer are
less strongly conserved than those involved in Mendelian diseases, not only because
of the complex nature of the disease but also the fact that the disease is generally
later in onset. However, this may simply mean that a less stringent cut off is required
for a polymorphism to be annotated as potentially pathogenic in cancer and other
complex diseases (at the expense of increasing the rate of false positives). Zhu et
al. have previously shown a weak but significant correlation (p = 0.002; r2 = 0.06)
between SIFT tolerance indices for 46 SNPs in human repair associated genes and
their corresponding odds ratios derived from cancer epidemiological studies [208].
This correlation was confirmed in a larger dataset in chapter 5. SNPs3d is most
likely to be affected by the lack of available data on complex diseases as it, unlike
SIFT and PolyPhen, is actually trained on Mendelian diseases (whereas the others
have simply had their cutoffs determined from Mendelian disease data). We have
therefore tried to use raw data where possible rather than predictions (e.g. benign,
deleterious etc) in this study.
6.2 Methods
6.2.1 SNPViewer
The SNPViewer program for prioritising SNPs, was implemented in the Java pro¬
graming language. A number of third party programs were included in the final
implementation of the program:
• EnsJ: An open source Java library providing access to current and archived
Ensembl databases. Developed by Ensembl and used in SNPViewer to retrieve
gene and SNP information. Now no longer supported by Ensembl.
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• MySQL Connector/J: For connecting to MySQL through Java. Required for
connection to Ensembl databases via EnsJ.
• Haploview: Haplotype analysis Java program. Code adapted to function within
SNPViewer. (adaptions to pass genotypes and to pass clicks)
SNPViewer web accessibility was implemented via Java web start. The class diagram
for SNPViewer is shown in figure 6.1 and the program is accessible at http://www.
hgu.mrc.ac.uk/Users/James.Prendergast/PolyAnalyser/SNPViewer.jnlp.
The graphical user interface of SNPViewer is split into four panels as shown in
figure 6.2. The control panel, located on the right of the GUI, contains a text area
that displays information on the currently selected SNP, checkboxes for selecting the
data to be displayed on the frequency plot and a spinner for selecting the repair gene
to view.
The main panel of the SNPViewer interface is the frequency plot. The frequency
plot displays minor allele frequencies (MAFs) and average heterozygosity for SNPs
where such information is available. This data was collected from four different
sources: Ensembl, HapMap, ABI, and NCBI. Data from each source is represented
by a different shape:
• Ensembl Minor Allele Frequency : o
• HapMap Minor Allele Frequency : □
• ABI Minor Allele Frequency : x
• NCBI average Heterozygosity : +
Each of these shapes is also colour coded according to the type of SNP it represents
(relative to the gene of interest only):
• Flanking SNP : Green
• UTR SNP : Blue
• Coding SNP : Red
• Intronic SNP : Orange
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Figure 6.1: SNPViewer class diagram.









Figure 6.2: Graphical User Interface of SNPViewer
In this plot the x-axis represents base position along the chromosome and exons (as
defined by Ensembl) are marked below it in red. Each time the plot is changed the
program retrieves the most up to date positions of these exons. The y-axis is either
MAF or average heterozygosity (depending on the data point) and is marked by 0.1
increments. The dashed line across the plot is at 0.3.
In order to select a SNP it can simply be clicked in the frequency plot. This will
lead to its information being displayed on the control panel where it can subsequently
be added to a list of chosen SNPs (or by right clicking). Those SNPs that have already
been chosen are coloured in black.
Directly below the Frequency plot is the SNP density plot. Each vertical line in
this panel represents a SNP and its height represents the number of known SNPs
within 2000bp. Both plots are aligned so that evidence for a particular SNP in
the SNP density panel will be directly above it in the Frequency panel. The y-
axis increments by 5 SNPs and the x-axis and colour coding are the same as for the
Frequency plot. This panel can be changed to display Ensembl genes and GENSCAN
predictions instead of SNP frequencies.
The conservation panel is shown at the bottom of the SNPViewer GUI. The initial
conservation trace implemented in the first version of SNPViewer was calculated
using the sum of pairs method. This involved creating an alignment between the
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human protein of interest and all predicted Ensembl orthologues using the t-coffee
alignment program. A suitable matrix was then used (in this case PAM120) to score
the similarity between all combinations of the residues observed at each position.
The sum of these scores consequently provides us with an indication of the level of
conservation observed at each amino acid. This initial conservation plot however had
two drawbacks. Not only was creating the alignments slow but conservation scores
were only available for coding amino acids. Therefore this trace was replaced by the
vertebrate multiz alignment from the UCSC genome browser.
6.3 Results and Discussion
The aim in developing SNPViewer was to provide a program that could be used to
identify functionally important SNPs to aid in the design and interpretation of our
association studies.
As mentioned above most association studies are by their nature indirect. Disease
variants are most often identified through their linkage disequilibrium with a second,
tag, variant. However we were keen to attempt to improve our association study
design by enriching for tags with potential phenotypic consequences. To test the
feasibility of using SNP prioritisation in designing association studies SNPViewer
was first trialled using the DNA repair genes examined in chapter 5.
Five initial sources of information were used:
1. SNPs3d.
2. SIFT.
3. Polymorphisms affect on GENSCAN prediction.
4. Polymorphism causes nonsense change (on Ensembl gene prediction).
5. Polymorphism in conserved region.
GENSCAN was written by Chris Burge and is a program designed to predict genes
and gene structures in DNA sequences |221, 222], On vertebrate sequences contain¬
ing short genes with simple exon structures GENSCAN has been shown to have a
sensitivity and specificity per nucleotide of 0.931. In SNPViewer a user is able to
1 Sensitivity and specificity was calculated by comparing GENSCAN predictions to a set of known
genes.
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compare GENSCAN predictions of DNA sequences containing the various alleles of a
polymorphism. If predictions differ depending on a SNPs allele we predict this vari¬
ant affects the ruRNA structure of a gene. GENSCAN prediction can however be
inaccurate and we therefore also compare the predictions to predicted gene structures
from Ensembl. Although Ensembl gene structures are partly based on GENSCAN
results we treat those exon predictions that match Ensembl genes as high quality.
If therefore a GENSCAN prediction that matches an Ensembl gene is affected by
an allele change we predict that this SNP is potentially deleterious. An example is
shown in figure 6.3.
To test the feasibility of using GENSCAN to predict splice changes in silico, the
G382D polymorphism of the MUTYH mismatch repair gene, predicted by GEN¬
SCAN to affect the mRNA structure of MUTYH in humans, was tested by Dr Susan
Farrington in vitro. cDNA analysis confirmed that this polymorphism did indeed
affect splicing and although far from a rigorous test this result seemed to confirm the
potential of using GENSCAN to predict polymorphisms that affect splicing [223].
As shown in chapter 5 the use of SIFT but not SNPs3d is also likely to be a viable
approach for prioritising tagging SNPs. SNPs with a high chi-square test statistic
appear to be, in general, well conserved. Although the use of programs such as SIFT
is restricted to missense polymorphisms, the conservation of the surrounding region
is a potential alternative measure that could be used for all classes of polymorphisms.
For example SNPs in key, well conserved motifs or domains are perhaps more likely to
be deleterious. However we could observe no relationship between a polymorphisms
test statistic and the average conservation of the surrounding region as measured
using the UCSC multiz 17 species alignment scores. It may simply be the case that
there are simply not enough true positives in our dataset to detect a relationship.
There is however no high-quality dataset of known cancer associated polymorphisms
available. As shown in chapter 5, few if any SNPs with a previous association to
colorectal cancer replicate in other populations.
PolyPhen, that predicts whether a particular polymorphism is likely to be delete¬
rious according to a range of criteria, also displayed no relationship to the chi-square
values of our non-synonymous repair SNPs (Kruskal-Wallis p=0.785). Consequently
although we had typed all known non-synonymous SNPs in a pathway critical to
tumour progression only SIFT displayed any substantial evidence of being a viable
approach to SNP prioritisation. However even its use is likely to provide at best a
modest enrichment. Programs such as SIFT, PolyPhen and SNPViewer may there-
124
n
.i uv ^ .u jrikf
S3





— — — u a nxiz
- - — mi m




(b) GENSCAN prediction of DNA containing allele2 of rs2066504
Figure 6.3: GENSCAN predictions in SNPViewer.
Note the missing exon in the GENSCAN prediction (green rectangles and lines) in
figure b. The Ensenibl gene structure is shown in red. The rs2066504
polymorphism is therefore predicted to affect splicing.
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fore be most useful in interpreting the results of association studies rather than in
their design, though it is still to be demonstrated that any programs except SIFT
are applicable to complex disorders.
6.3.1 SNP class and conservation
As previously stated it is widely assumed that non-synonymous polymorphisms, as
a class, are more likely to be associated with cancer than SNPs in general. Un¬
like synonymous or intergenic SNPs, non-synonymous polymorphisms can directly
affect a protein's structure. In this study, we had therefore typed all validated,
non-synonymous SNPs that were located in one of our repair genes of interest.
Although most polymorphisms that are associated with cancer are non-synonymous,
this is primarily the result of most studies, like us, preferentially studying non-
synonymous SNPs. However the whole genome study gave us the opportunity to
investigate whether non-synonymous polymorphisms were indeed more often associ¬
ated with cancer than other classes of SNPs.
We did this by first determining the class of each of the SNPs in the whole genome
study via the Ensembl Perl APIs. Allelic chi-square values for each whole genome
SNP were then calculated. Using this data we were able to compare classes of genes
and look at whether non-synonymous SNPs, on average, showed a higher chi-square
value than other types of SNPs. As can be seen in table 6.2 the average chi-square
value of non-synonymous polymorphisms was not significantly different from SNPs in
general. In fact the only class of SNPs that showed a significantly higher distribution
of chi-square values than the rest of SNPs was regulatory and 5'UTR polymorphisms
(p=0.049, Mann-Whitney U test, uncorrected for multiple testing). This result would
therefore seem to suggest that polymorphisms that control the expression of genes
are the most important in cancer with non-synonymous polymorphisms showing no
significant difference to intronic and intergenic polymorphisms.
However most polymorphisms in the genome are likely to be neutral with respect
to cancer. Any signal from functionally important non-synonymous SNPs is therefore
likely to be drowned out by the large number of functionally neutral SNPs. We
therefore attempted to enrich for polymorphisms that were likely to be functionally
important by examining only those polymorphisms in genes previously associated
with cancer (list obtained from the cancer gene census [224]). As shown in figure
6.4 synonymous and intronic polymorphisms located within cancer genes, in general,
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SNP type SNP count Mean chi-sq
SYNONYMOUS_CODING 2024 0.888









Table 6.2: Mean chi-square by SNP class
show no significant difference in their chi-square values than synonymous and intronic
polymorphisms located in other genes. A significant difference is however observed
when non-synonymous SNPs are examined. Although strictly the difference is not
large enough to survive a Bonferroni multiple test correction (a p value of 0.017
would be required) these data are based on only one study and the addition of
results from further studies and cancer types may improve this analysis. There is
also likely to be some bias in this analysis as many cancer genes will have been
annotated as involved in cancer through a non-synonymous polymorphism. However
the extent of this result is perhaps surprising. We would expect linkage disequilibrium
between polymorphisms to break down the association between a SNPs type and
its association with cancer. For example, we would expect many synonymous and
intronic SNPs to be in strong LD with non-synonymous polymorphisms nearby (as
the non-synonymous SNPs were added as additional content and not as tags). If this
was the case we may expect some difference between the synonymous polymorphisms
in the cancer genes and those in the whole genome (in the same way as the non-
synonymous polymorphisms) however this is not observed.
There is therefore at least some evidence that SNP prioritisation may be a viable
approach to association study design and interpretation. The test statistic of regu¬
latory SNPs is on average 14% higher than intronic and intergenic SNPs. Likewise,
when only genes previously associated with cancer are examined, non-synonymous
SNPs display on average a 35% higher test statistic than intronic SNPs (and regu¬
latory SNPs 70%, though when based on limited numbers). Perhaps unsurprisingly
therefore the best approach to designing cancer association studies is to preferentially
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Figure 6.4: Mean chi-squares, by SNP type, for polymorphisms in both cancer genes
and the entire genome.
Mann-Whitney values comparing the medians of each group are also shown. (Only
ten regulatory SNPs were present in this dataset; genome mean chi-sq: 1.06, cancer
genes mean chi-sq: 1.56; Mann-Whitney p=0.12)
select regulatory and non-synonynrous tags. Where more than one non-synonymous
SNP is in high LD SIFT could then be used to identify the strongest tag. No further
methods of SNP prioritisation examined showed any evidence of being applicable to
cancer association studies.
To make SNPViewer fully functional it would require a number of additions and
alterations. Firstly most results are pre-computed. The time required to make SIFT,
SNPs3d and GENSCAN predictions makes it unfeasible for predictions to be made ab
initio. This does however mean the displayed results are restricted to known SNPs,
and therefore a final version of SNPViewer would require the ability for the user
to input novel polymorphisms for prioritisation. The implementation of this ability
could be achieved by setting up SIFT, SNPs3d and GENSCAN Web Services that
could be queried from the Java application. However this is implemented, retrieval
of results would be slow and it would therefore be necessary that the query occurred
in the background and results could be saved.
SNPViewer is also currently gene-centric. It would however be simple for SNPViewer
to be made analogous to a genome browser so that the user could enter regions to
be viewed. This would simply require the predictions to be stored in a database
128
that was queried from the Java application. At present there is the ability to open
a genes Ensembl GeneView page from the application, this would have to also be
changed to the corresponding Ensembl ContigView page.
We would also add more functionality to the program. For example we could
determine the affect of polymorphisms on motif scores. As mentioned previously
Clifford et al. showed that missense mutations often adversely affect the score of
Pfam domain predictions, and that the magnitude of the change in the score is a
good predictor of whether the mutation is deleterious. The impact of polymorphisms,
on domain, transcription factor and splice enhancer motifs could therefore also be
displayed by SNPViewer.
The wrong approach was however probably adopted in the design of SNPViewer.
At present the third party, open source Haploview program was integrated into a
novel Java browser. However a far simpler approach would have been to adapt the
Haploview program alone. The core of association studies is LD structure that is
well handled by Haploview. Likewise the design of Haploview allows new tracks
to be added relatively easily, so that SNP prioritisation results could be simply
presented. By adapting Haploview to work via Web Start and to read information
from a remote database (that we have already implemented) Haploview could have
the same functionality of SNPViewer in a far more integrated package. This is
therefore the route forward for this project.
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Chapter 7
Whole Genome Association Study
7.1 Introduction
In chapter five a candidate gene association study was discussed, however this is only
one approach to identifying potential disease genes through the use of association
studies. An alternative is to scan the whole genome for potential disease variants
rather than simply a number of key candidate regions. The major difference between
these two approaches is that a candidate gene association study is hypothesis driven,
we are only testing regions of the genome we believe likely to be associated with the
disease, whereas no such specific hypothesis is being tested in a whole genome study.
Each approach has distinct advantages and disadvantages. A major advantage of
candidate region association studies is that it would be hoped that disease variants (or
SNPs in LD with disease variants) are enriched among the set of markers being tested
so that the number of true positives per SNP tested will be higher (though this of
course is not guaranteed). Likewise it should be easier to detect these true positives as
the background noise of false positives should be lower, and therefore disease variants
of more marginal affects may be detected. Candidate region association studies are
also simply cheaper, with large whole genome scans being prohibitively expensive
(although the cost per SNP is less). Whole genome studies are not however limited
to only detecting associations between a disease and regions with some previous
evidence of being associated with the disorder, completely novel associations can be
detected. Consequently in the Dunlop lab both approaches were adopted.
In recent months a number of whole genome association studies have been pub¬
lished. One notable success has been the identification of a region on 8q24 by Gud-
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mundsson et al. [225] and Yeager et al. [226] that was independently shown to be
associated with prostate cancer risk. A third study that had fine mapped this region
as a result of prior admixture mapping also found evidence of an association be¬
tween this region and prostate cancer [227). In total 21,063 cases and controls from
a variety of ethnic backgrounds had been examined across the three studies. Closer
examination of this region suggested that a number of loci are involved in prostate
cancer risk in this region, as multiple association signals were detected that were sep¬
arated by regions of high recombination |228[. However none of the polymorphisms
displaying the strongest association with the disease are located in known genes and
the nearest candidate gene, MYC, is approximately 260kb telomeric [228]. Conse¬
quently it is unlikely this region would have been detected by the use of candidate
gene studies.
Subsequent examination of a single SNP in this region in breast cancer did not
replicate the results observed in prostate, leading the authors to hypothesise that
this region does not harbor a region associated with all types of hormone-related
cancer [229]. However, even the association between this region and prostate can¬
cer is not straightforward. It appears that at least three independent regions at
this locus modify cancer risk, with little linkage disequilibrium observed between
them. The combined affect of these regions appear to follow a multiplicative model
[228]. Consequently further examination of this region is required to try and further
characterise the role of this region in cancer.
7.2 Methods
Genotype, person and SNP information data were stored in three MySQL tables.
The Haploview source code was adapted to calculate single and multi-marker LD
values between SNPs/haplotypes. Missing genotypes were predicted using the IM¬
PUTE program [209]. IMPUTE works by predicting the probability of observing
each possible genotype at each unknown polymorphism given the observed alleles
surrounding it and the known haplotype structure and recombination rates of the
region (both of the latter obtained from HapMap). Due to the uncertainty in geno¬
type calls arising from IMPUTE we used the SNPTEST program to analyse the
resulting data. SNPTEST simply converts those genotypes with a maximum pos¬
terior probability greater than 0.9 to the respective genotype and leaves the rest
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uncalled (i.e. null) and then performs standard frequentist association tests (addi¬
tive, dominant, recessive, general and heterozygote models) [230, 209]. The Illumina
Beadstudio software was used for the examination of copy number changes. Case
control matching and Hardy-Weinberg equilibrium analysis were performed by Dr
Tenesa. Resequencing was carried out by Dr Farrington.
7.3 Results and Discussion
The whole genome association study being carried out within the Dunlop lab will
ultimately consist of three phases. Phase I, that has already been completed, in¬
volved the typing of 555,512 SNPs in approximately 1,000 cases and 1,000 age and
sex matched controls. Only cases aged under 55 were typed in this phase in an
attempt to enrich for individuals with a larger genetic contribution to their disease.
Phases II and III will involve the typing of the most significant polymorphisms from
each previous phase in further cohorts of individuals. In total the most significant
1,000 SNPs should be typed in approximately 8,000 Scottish individuals. Although
currently only the first two phases of this study have been completed, the availability
of genome-wide case control data on a large number of individuals did provide us
with the opportunity to collaborate with other groups and combine data.
This collaboration was initially led by the Gallinger group in Canada. Through
their own two stage study consisting of typing 99,632 SNPs in 1226 cases and 1239
controls followed by typing the best 1,143 of these polymorphisms in a further cohort
of 1,139 cases and 1,055 controls, they had identified 76 SNPs potentially associated
with colorectal cancer (see [231] for more details). To determine which of these
polymorphisms were true risk variants we identified which of these SNPs had been
typed in our own whole genome study (the Gallinger group had been using Affymetrix
SNP arrays and consequently there was only limited direct overlap between our two
studies). Of the 76 Canadian variants 28 were present on either the 317k or 240k
Illumina array and had consequently been genotyped directly in our study in phase
I. Through the adaptation of the tagger algorithm implemented in Haploview we
identified the best single or multi-marker tag for each of the remaining SNPs. Allelic
chi-square p values were subsequently calculated for each of these tags/variants in
our dataset. The results can be seen in tables 7.1 and 7.2. The best tag of 7 of the 76
variants was in only limited linkage disequilibrium (r2 < 0.7) and consequently these
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variants were typed directly in our cohort by Dr Farrington. Of the 76 Canadian
polymorphisms 9 (or their corresponding tag) had a p value < 0.1 in our Scottish
population. These 9 polymorphisms were subsequently genotyped in our phase 2
cohort of 1,910 cases and 1,985 controls. After this phase only two variants remained
significant (allelic p < 0.05). The London dataset was not used in this study due to
a potential conflict of interests with their own publication [232].
The first of these variants, rs719725, is located on chromosome 9 approximately
34kb downstream from the nearest known gene, the protein kinase TPD52L3. TPD52L3
is a paralogue of the tumour protein TPD52, displaying approximately 26% conser¬
vation at the protein level. TPD52 was initially identified in 1995 by Byrne et al.
due to its overexpression in breast carcinomas [233] and is believed to be involved in
calcium-mediated signal transduction and cell proliferation [234].
However the nearest gene downstream of this locus, the E3 ubiquitin ligase NIRF
(rs719725 is located ~50kb 5' of this gene), has also been associated with cancer.
NIRF is expressed abundantly during cell proliferation but suppressed during cell
arrest. Likewise tumour cells have been shown to constitutively express NIRF, and
consequently NIRF has been associated with having a role in cell cycle progression
[235]. The rs719725 polymorphism is in LD with both of these loci, likewise rs719725
is situated only approximately 15kb from a DNAse I hypersensitive region [236], and
only 20kb from a CCCTC-binding factor region [237], suggesting regulatory sites
may also be located in close proximity.
Further examination of this locus in French and European cohorts of individuals
by the Canadian consortium (a total of 2199 cases and 2401 controls) did not support
its association with colorectal cancer. However as copy number changes at this region
of chromosome 19 have previously been associated with cancer in a number of studies
(e.g. [238, 239, 240]) this locus has not been completely disregarded.
The second polymorphism, rs 10505477, is located on chromosome 8q in the intron
of a gene of unknown function that was first identified last year as a result of an
investigation into an association between this locus and prostate cancer [241], A
second gene, POU5F1LR is also located within 20kb. At present little is known as
to the function of either of these genes however POU5F1L1 appears to have arisen
through retrotransposition relatively recently in the primate lineage [242]. Its parent
gene, the transcription factor POU5F1, may play a role in tissue differentiation
and early mammalian development [243]. (Multiple test corrections, haplotype and
epistasis analysis and Hardy-Weinberg equilibrium checks at these loci were carried
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Arctic SNP Best tag r2 Arctic p p (of tag) p (of Arctic SNP)
rsl0489565 rs3795357 0.656 0.0044 0.0270 0.0220
rsl0516168 rsl 2186237,rsl3130037 12 0.433 0.0016 0.5592 0.0370
rsl0493889 rsl2024594 0.73 0.0008 0.0213 0.0410
rsl1236164 rs3902018,rsl0219203,rs7932922 242 0.967 0.0299 0.0544 0.0436
rsl0491268 rsl422446,rsl 1742783,rs247205 421 1 0.0072 0.0629 0.0799
rs3743262 rs7162336 0.285 0.0953 0.2938 0.1089
rsl0512472 rs9897552 1 0.0027 0.2647 0.2488
rsl0769224 rsl0742787 1 0.0097 0.2677 0.2797
rs4931434 rs1084388 l,rs4031375 11 0.502 0.0730 0.7458 0.2917
rsl454027 rsl869472 1 0.0036 0.3646 0.3137
rsl0484791 rsl523932,rs7746943,rs2204285 243 1 0.0057 0.4279 0.3706
rs9328033 rs6596783,rsl997773 24 0.758 0.0082 0.5574 0.3786
rs2853129 rs2458416 0.483 0.0816 0.2966 0.4545
rsl0280428 rs2214726,rs7794797 33 0.451 0.0055 0.3182 0.5255
rs2278170 rsl 1032345 1 0.0079 0.5994 0.5774
rs9898 rs3733159,rs3733011 44 0.884 0.0081 0.4694 0.5814
rsl0489525 rsl2408865,rs8453,rs2144428 131 0.884 0.0067 0.8401 0.5814
rs945881 rsl0747482,rsl 1165879,rs7517433 132 0.709 0.0275 0.8976 0.6424
rsl402582 rs1081896, rs1402578,rs614673 112 0.994 0.0016 0.6282 0.6533
rsl504175 rs3788982,rsl 1903014,rsl504188 212 0.867 0.0075 0.7240 0.6723
rs2049064 rs955988 1 0.0020 0.7323 0.6803
rs2320590 rs3767248,rs4654873,rs9426736 134 0.949 0.0037 0.9584 0.6933
rs6601328 rs4841171 1 0.0056 0.8142 0.7183
rs444772 rsl45290 1 0.0131 0.5524 0.7393
rsl0499162 rs6935162,rs9321172 32 0.329 0.0007 0.0242 0.8032
rs7939226 rs4944925,rs4145953,rsl 0899013 134 1 0.0779 0.9969 0.8541
rsl0498243 rsl549567 1 0.0036 0.9461 0.9374
rs812824 rs1081896, rs614673 12 1 0.0058 0.9052 0.9640
rsl0483802 rs910315 0.743 0.0067 0.0025 #N/A
rs719725 rs7857628,rs2066362 13 1 0.0046 0.0025 #N/A
rsl0505477 rs6983267 0.935 0.0030 0.0310 #N/A
rs850470 rs850476 0.961 0.0069 0.0669 #N/A
rs797206 rs797208 0.951 0.0047 0.1099 #N/A
rsl0517602 rsl7031957 1 0.0063 0.1375 #N/A
rs2963765 rs751485,rs269511 23 0.967 0.0029 0.1415 #N/A
rsl0507308 rs9578469 0.487 0.0073 0.1658 #N/A
Table 7.1: Top SNPs from the ARCTIC (Assesment of Risk of Colorectal Tumours
In Canadians) whole genome association study with corresponding Dunlop study
tags and p values I.
(Arctic p corresponds to the the p value of the ARCTIC SNP in the ARCTIC study,
p of tag corresponds to the p value of the best Dunlop tag of the ARCTIC SNP, p of
ARCTIC SNP corresponds to the p valu^c^ the ARCTIC SNP in the Dunlop study
if genotyped.)
Arctic SNP Best tag r2 Arctic p p (of tag) p (of Arctic SNP)
rs572619 rs568306,rs491111 23 1 0.0063 0.1769 #N/A
rsl0512404 rsl7204340 0.308 0.0061 0.1950 #N/A
rs377685 rsl2482714 1 0.0022 0.2158 #N/A
rs2355084 rs7783055,rs7782151 44 1 0.0060 0.2171 #N/A
rsl0518098 rsl398982 1 0.0073 0.2288 #N/A
rsl994967 rsl495271,rsl 108993 23 0.821 0.0083 0.2308 #N/A
rs946807 rsl0867398 0.536 0.0053 0.2476 #N/A
rsl0494240 rs720899 1 0.0030 0.2607 #N/A
rs4484159 rs4858703 0.825 0.0076 0.2837 #N/A
rs798893 rsl03294 0.945 0.0071 0.2957 #N/A
rsl0503122 rs677592 1 0.0038 0.3209 #N/A
rsl399176 rsl514203 0.959 0.0007 0.3419 #N/A
rsl0505685 rsl514203 1 0.0040 0.3497 #N/A
rs4372639 rs6496067 1 0.0076 0.3636 #N/A
rs4133195 rsl2694428,rsl0804264,rs4674259 343 0.948 0.0049 0.3858 #N/A
rsl057083 rs4961323 1 0.0995 0.3986 #N/A
rs360659 rs360622 1 0.0057 0.4336 #N/A
rs431319 rsl 1913109,rs933582,rs6005625 244 1 0.0071 0.4618 #N/A
rsl0503262 rsl0089026 0.958 0.0033 0.4675 #N/A
rs3864498 rs4725830 0.052 0.0017 0.5874 #N/A
rsl0512028 rs6560355 1 0.0041 0.6003 #N/A
rs2469583 rs2433363 1 0.0013 0.6214 #N/A
rs4404442 rs4583651 1 0.0031 0.6444 #N/A
rsl0497667 rs6434164 1 0.0010 0.6479 #N/A
rs9830734 rsl0513799 0.636 0.0098 0.6484 #N/A
rs4944051 rs4145953 1 0.0468 0.6634 #N/A
rs723142 rs796398 0.959 0.0034 0.7253 #N/A
rsl087 rs9316180 0.961 0.0260 0.7443 #N/A
rs26764 rs26762 1 0.0045 0.7512 #N/A
rs508106 rs796398 0.958 0.0016 0.7687 #N/A
rs4941537 rs4942460 1 0.0593 0.8272 #N/A
rs724667 rs3136559 1 0.0039 0.8442 #N/A
rsl0510558 rsl872143,rs322706,rsl561115 243 0.999 0.0048 0.8505 #N/A
rsl0502694 rsl0502692 1 0.0029 0.8671 #N/A
rsl963296 rsl 1869275,rs4792347,rs2674958 112 1 0.0058 0.8917 #N/A
rs890248 rs977439 1 0.0057 0.9064 #N/A
rs973128 rs975951 1 0.0015 0.9666 #N/A
rs7200548 rs2118014 0.812 0.0030 0.9670 #N/A
rsl988515 Untaggable 0 0.0061 #N/A #N/A
rs2075322 Untaggable 0 0.0526 #N/A #N/A
Table 7.2: Top SNPs from the ARCTIC study with corresponding Dunlop tags and
p values II (as above)
out by the Canadian ARCTIC consortium and can be viewed in [231]).
This polymorphism on 8q is located in the same region as that associated with
modifying risk in prostate cancer. There was therefore a requirement to try and
narrow down the region of 8q associated with colorectal tumours as no genes in the
region had a strong previous association with cancer (the nearest strong candidate,
the oncogene MYC, is approximately 340kb telomeric and is separated from the locus
by high levels of recombination).
Our first approach was to compare the results from the three cancers exam¬
ined to date; prostate, breast and colon. The genotyping results of the prostate
and breast studies have been made publicly available (http://cgems.cancer.gov)
allowing us to make a direct comparison between tumour types (the breast and
prostate scans, like our colon study, had been carried out using Illumina arrays). To
compare datasets we first calculated the odds ratio at each SNP and then combined
the corresponding probabilities across datasets using a method developed by Fisher
(—2YlnP). Of all the ~500,000 SNPs present in all three studies, the top three most
significant polymorphisms were all located on 8q24 (p ~ 10 ~7). Shown in figure 7.1
are the combined p values for each SNP across this locus.
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Figure 7.1: Colon, prostate and breast combined p values across the 8q24 locus.





































As can be seen in figure 7.1 the middle of the three independently associated
regions determined by Witte et al. appears to show the strongest association with
cancer risk when all three tissue types are examined. Table 7.3 illustrates that SNPs
in this region are significantly associated with cancer risk in all three individual
tissue types with the strongest signal in the prostate study. This is however not the
case in the other two regions, with the centromeric region showing no association
in prostate tumours and the telomeric region showing no association with breast
tumours. It should be noted however that the signal from the colon study is weak
in the telomeric region and the signals from both the breast and colon analyses are
weak in the centromeric region. Consequently only the central portion of this locus
is convincingly associated with all three tumour types. This result is in contradiction
to the result of Shumacher et al. [229] who were unable to identify an association
between this locus and breast cancer. However this is a result of the fact that they
had only typed one polymorphism that was located within the telomeric region of
the locus.
Region rs Id Pos Breast p Prostate p Colon p Combined p
centromeric rsl456306 128185682 0.022 0.27 0.030 0.0085
middle rs7837328 128492309 0.0037 0.00053 0.0033 lxlO-6
telomeric rs!1988857 128601055 0.62 lxl0~6 0.047 6xl0~6
Table 7.3: Results of representative SNPs from each region
These results consequently argue for a factor within the central portion of this
locus that has a common affect on all three cancer types. Unfortunately further
analysis suggests that this is not the case. As shown in figure 7.2 those alleles
associated with an increased risk in colon and prostate cancers are associated with a
decreased risk to breast cancer. Consequently it appears alleles that are protective
in breast cancers are deleterious in colon and prostate malignancies (and vice versa).
Why this should be the case is unclear and requires further investigation. It may
be that the LD structure is different between these three Caucasian populations at
this locus. Or alternatively expression patterns of corresponding genes may differ
between the tissue types examined.
In order to further narrow down the key region within this locus, we fine-mapped
the central portion in our Phase II individuals. To combine the results from our
Phase I and II studies, as well as to further characterise the immediate region, we
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Figure 7.2: The odds ratios, at each SNP, within the middle region of the 8q24 locus.
All odds ratios were converted so that the protective allele in breast tumours was
examined.
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large proportion of high confidence genotypes were retained (>90% p>0.9). To sub¬
sequently calculate p values at each SNP the SNPTEST program was used. As can
be seen from figure 7.3 the strongest signal from the 8q24 locus is centred within an
LD block bounded by two recombination hotspots. This LD block is approximately
63kb in length and contains the POU5F1L1 gene that is located approximately 2kb
centromeric of the polymorphism displaying the strongest signal in our fine-mapping
analysis. However a further gene of unknown function, DQ515898, spans this region
and there is some EST and transcript evidence that further genes may exist within
this LD block. Consequently the exons of these genes are being sequenced by Dr
Farrington for new polymorphisms so that an even higher resolution scan can be
carried out.
7.3.1 Genome-wide Copy Number Variation Analysis
The use of genotype data to further characterise the mechanisms of disease is not
restricted to association studies. Genetic instabilities are a hallmark of the majority
of human cancers, and the availability of genome-wide genotype data provides a pow¬
erful opportunity to detect chromosomal aberrations such as copy number changes
and loss of heterozygosity (LOH). Although classical methods for determining ge¬
nomic rearrangements and copy number changes, such as FISH (Fluorescent In Situ
Hybridisation) and CGH (Comparative Genomic Hybridisation), have had a number
of notable successes in characterising genes associated with cancer (e.g. RBI [244]),
they lack the resolution now possible with genome-wide SNP genotype platforms.
We therefore examined the chromosomal aberrations observed in normal individuals
and those affected by cancer, in an attempt to determine genomic regions potentially
associated with the development of colorectal tumours.
Copy number scores for each SNP were calculated using the Beadstudio Geno-
typing module from Illumina. The underlying principle of this programs calculation
of copy number scores is that regions of abnormal copy number will also display
abnormal B allele intensities relative to A allele intensities. For example, in a region
with a standard copy number of 2, the B allele intensity relative to the A allele
intensity of the SNPs in that region can be thought of as either 0 (no B signal i.e.
a AA homozygote), 0.5 (50% B signal i.e. a heterozygote) or 1 (A BB homozy-
gote). However where a copy number of 1 exists only signals of 0 (A) and 1 (B)
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Figure 7.3: 8q24 locus fine-mapping results.
Displayed in the top panel are genotypic p values as calculated by SNPTEST. LD
structure and recombination hotspots obtained from HapMap are shown below.
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0 (AAA), 0.33 (AAB), 0.66 (ABB) and 1 (BBB). A suitable number of SNPs must
however be examined across each region; as if only 1 SNP is examined that displays
no B signal it is not possible to determine the copy number in that region (as it
could be A, AA, AAA etc). A balance is consequently required between examining
enough SNPs across each region to confidently determine that regions copy number,
and keeping the region small enough so that small areas of copy number variation
can be defined. Given approximately 300,000 SNPs had been typed in this study
and the fact that the human genome contains approximately 3 billion base pairs,
we had on average one SNP every lOkb. As the average MAF of these SNPs was
also around 0.23 we would estimate that approximately 35% of genotypes would be
heterozygous. Consequently a minimum sliding window size of 250kb (25 SNPs, 9
heterozygotes) appeared to give us sufficient power to confidently detect copy num¬
ber changes (though we plan, in the future, to examine more closely the affect on
the analysis of adjusting window size; it has been suggested by Illumina that window
sizes of lOOkb or even 50kb may be sufficient).
To determine regions displaying significantly different levels of copy number vari¬
ation between normal individuals and those with cancer, we first used the Fishers
exact test to determine those SNPs at which an unusual numbers of cases displayed
evidence of copy number variation. The most significant polymorphisms in this
analysis with a p value of 8xl0~5, that mapped to the small arm of chromosome
19, displayed evidence of copy number variation in only one case compared to 18
controls. Of these 18 controls 17 had a copy number of 1 at this region (Fig 7.4).
These results consequently suggest a copy number of one at this locus may provide
some form of protection from colorectal cancer.
This region, that spans approximately 350kb, is particularly gene dense and con¬
tains 15 Ensembl genes of which a number have previously been associated with can¬
cer. For example this locus contains both a ubiquitin gene as well as the leukaemia
associated RNA polymerase II elongation factor. However, perhaps the strongest
candidates within this region are the proto-oncogene JunD and the NSAID-regulated
protein MIC-1. JunD, that has been shown to have an antiapoptotic role within cells,
acts as a modulator of the pathways that links RAS to tp53 (OMIM). The potential
role of a proto-oncogene at this locus is supported by the observation of a protective
affect of a copy number of one at this region; the fewer copies of a proto-oncogene
present within an individuals genome, the lower the chance of one of the copies de¬

























Figure 7.4: Copy number variation across chromosome 19
The copy number variation observed across the whole of chromosome 19 (A) with
the most significant region shown in greater detail below (B). The average trendline
was calculated using a sliding window size of 5 SNPs.
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one copy of the gene is sufficient for life and that any deleterious mutations are dom¬
inant. MIC-1 on the other hand, that is located in the centre of this region, is a
member of the transforming growth factor-/? (TGF-/3) superfamily and has generally
been associated with antitumorigenic activity and the induction of apoptosis. This
would at first appear to contradict the observed enrichment of normal individuals
with a copy number of one at this locus, however MIC-1 has also been shown to
exhibit tumourigenic activity under certain conditions and tumour stages (Bauskin
et al. [107]). A number of genes in this region were also identified as differentially
expressed in tumours through our analysis of ESTs discussed in chapter 2, including





In this thesis I aimed to investigate the genetics of colorectal cancer using a variety
of approaches. These included the analysis of tumour gene expression across tissues
and platforms, the investigation of the association between chromatin structure and
cancer gene expression changes, the analysis of mutation and selection rates across
differing chromatin conformations as well as the identification and characterisation
of cancer risk variants through candidate and whole genome association studies. In
summary the main conclusions from this work are:
Chapter 2
• There is limited congruence in tumour gene expression changes observed across
different platforms and tissues.
• The human genome contains certain regions that are significantly enriched with
genes differentially expressed in tumours.
• The prioritisation of genes for analysis in association studies through the in¬
vestigation of gene expression changes can be a viable approach (as displayed
by the subsequent testing of EGR1).
Chapter 3
• Gene expression change in cancers is associated with chromatin structure.
• Genes in open chromatin show the largest increase in expression in cancer.
This is observed across platforms and tissues.
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• The relationship between chromatin structure and gene expression change ap¬
pears to be restricted to the later stages of tumourigenesis.
• Genes in more open chromatin display higher levels of general coexpression
than those in more closed regions.
• Consequently chromatin appears to be playing an important role in regulating
gene expression levels that is dysregulated in cancer.
Chapter 4
• Rates of mutation and selection in the human genome are associated with
chromatin structure.
• Background mutation rates are highest in relatively closed regions of the genome,
potentially as a result of being less accessible to repair mechanisms.
• Rates of synonymous site divergence are however highest in the most open
chromatin regions, a result of being under higher levels of selection in closed
regions.
• The more closed the local chromatin structure the greater the difference in the
levels of selection experienced by genes with and without CpG islands.
• The local chromatin structure of a gene may, in part, be governed by the rates
of mutation and selection it confers.
Chapter 5
• Few, if any, polymorphisms with a previous association to colorectal cancer
can be replicated.
• No polymorphisms in DNA repair genes that have a large contribution to col¬
orectal cancer could be identified.
• A weak correlation could be observed between a non-synonymous SNPs asso¬
ciation with colorectal cancer and its level of conservation across species.
• Concurrent replication studies can enrich for polymorphisms displaying the
strongest evidence of being associated with colorectal cancer, suggesting that
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a number of polymorphisms of low risk are likely to be present in DNA repair
genes.
Chapter 6
• The GENSCAN program can be successfully used to predict splice variants.
• The only class of polymorphisms that displays significantly higher associations
with colorectal cancer than SNPs in general are 5'UTR and regulatory SNPs.
Adding further support to the role of gene expression studies in association
study gene prioritisation.
• Non-synonymous SNPs in cancer genes do however display a significantly higher
distribution of chi-square values than those in genes in general.
• SNP/Gene prioritisation is likely to be limited by the number of true positives
among the original dataset.
Chapter 7
• A region on 8q is associated with colorectal, prostate and breast cancer.
• However various regions in this locus appear to modify risk differently in dif¬
ferent cancers.
• A copy number variation on chromosome 19 displays evidence of being associ¬
ated with colorectal cancer.
So what is the relationship between these results and what is their context in the
wider field? In this thesis I looked at two examples of prioritisation for association
studies; the prioritisation of genes through expression studies and the prioritisation
of SNPs by their genomic context. I showed that if different platforms are used to
measure expression changes in the same tumour types then there is some level of
overlap between the genes deemed differentially expressed. However likewise there is
a far greater proportion of genes that are deemed differentially expressed on only one
platform. Further work is required to determine whether there is an enrichment of
strong candidates among the overlap. With the increase in whole genome association
data, this should become increasingly feasible to test.
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The subsequent work on EGR1 does however hold at least some promise for the
use of gene expression studies in gene prioritisation. Those genes such as EGR1
that only have a small affect on cancer incidence (reflected in a small odds ratio)
will be hard to detect without some level of pre-prioritisation, as its p value will
never survive a multiple test correction if a large number of genes are tested (given a
realistic population size). EGR1 was after all not detected in the whole genome study
despite its subsequent replication in further populations examined by Dr Farrington.
On the other hand my examination into SNP prioritisation allowed me to repli¬
cate, in a substantially larger dataset, the findings of Zhu et al. that there is a weak
association between the test statistic of non-synonymous repair SNPs and their cor¬
responding level of conservation. This is despite none of the SNPs individually
reaching significance. This result is therefore promising for those association stud¬
ies which focus on non-synonymous SNPs, for example the recent publication by
the Wellcome Trust Case Control Consortium [230]. However when looking in a
genome-wide context, and not at candidate or known cancer associated genes, non-
synonymous SNPs as a class did not show substantially higher chi-square values than
the majority of SNPs. It appears therefore that typing only non-synonymous SNPs
genome-wide is not necessarily a strong strategy, and if only one class of SNPs is to
be typed other classes are potentially a better choice, for example 5' and regulatory
SNPs. This reflects back on the potential importance of gene expression data in gene
prioritisation.
The importance of gene expression in cancer was also reflected in the examination
of its relationship to chromatin structure. A number of studies, including that of
Zhou et al. [Ill], have looked in to the distribution of gene expression in cancer
and the results suggest chromatin structure may underlie at least part of the non-
random distribution found. I proposed that this was a result of common regulatory
control between genes in similar chromatin environments, and this hypothesis has
been partially supported by other recent studies. For example Stransky et al. [245]
looked at the strength of the correlation of each gene in 57 bladder tumours with
that of each its neighbouring genes and the genes that show the highest coexpression
with their neighbours in this study appear to lie in regions that correspond to areas
of open chromatin in the Gilbert et al. analysis [113]. As proposed by Stransky
et al. this may reflect common epigenetic alterations that lead to transcriptional
deregulation in cancers. Consequently further work is required to investigate this
relationship further.
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I also proposed that the increased deregulation in cancer in open chromatin re¬
gions may be the result of elevated rates of mutation. Loss of efficient DNA repair is
a hallmark of many cancer syndromes. However a thorough case control association
study of all known DNA repair genes did not produce any strong results despite
the use of a relatively large population and replication datasets. This may reflect
that although DNA repair loss may underlie many of the rare inherited syndromes
in colorectal cancer, the repair pathway may not have such a substantial affect on
inherited tumours in the general population.
On the other hand 1 did show that background mutation rates are likely not
constant across the human genome and that DNA repair may be less efficient in
closed chromatin. However applying these results directly to cancer will require
further work. The mutation spectrum in cancers is still unknown, especially when
efficient DNA repair has been lost. This could potentially be addressed by looking
at mutations identified through tumour EST libraries and the advent of large scale
sequencing technologies such as SOLEXA are likely to assist in investigations of this
sort. However we do know that genes in closed chromatin are more likely to undergo
mutation in the germ line than those in open chromatin and this consequently has
consequences for closed chromatin genes such as APC.
Thanks to the advent of the chimpanzee genome I was able to measure these fixed
mutation rates by measuring divergence at a number of regions likely to be under
little or no selection, including intergenic and intronic regions. However 1 showed the
traditional proxy for background mutation rate, dS, may be unsuitable for this use.
By comparing divergence in exons to those in neighbouring introns 1 showed that
divergence at synonymous sites is substantially lower than expected, and that the
level of difference is dependent on chromatin structure. Given the clearly defined drop
of divergence observed at intron-exon boundaries it is difficult to propose any other
explanation for this result than selection occurring at synonymous sites. However this
would suggest relatively strong selection is occurring at sites traditionally thought to
be under little if any selection, and that this selection is strongest in closed chromatin.
Further work is required to try and understand this contradiction.
In the final chapter of this thesis f showed how certain disease loci may be asso¬
ciated with multiple cancers, despite the key regions of these loci differing between
tumour types. Likewise 1 showed that certain changes in a region may be protective
in one tumour but deleterious in another. Having mined the results of three associ¬
ation studies pertaining to three different tumour types one locus, found on 8q, was
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shown to be associated with all three tumour types. However alleles found to be
protective in the breast study were deleterious in colon and prostate tumours.These
results illustrate the complex heterogeneity of tumour pathways.
Despite the results listed above this thesis has undoubtedly posed more ques¬
tions than it has answered. For example what underlies the associations between
chromatin structure, tumour gene expression and rates of inter-species divergence?
Why do genes in open chromatin display high levels of coexpression and low levels
of selection at their synonymous sites? What proportion of disease loci are both
protective and deleterious in different tumour types and what implications does this
have on selection and SNP prioritisation? Further research is consequently required





GO Description GO ID
-DNA repair G0:0006281
-base-excision repair G0:0006284
-base-excision repair\, AP site formation G0:0006285
-depurination G0:0045007
-depyrimidination G0:0045008
-base-excision repair\, base-free sugar-phosphate removal G0:0006286
-base-excision repair\, DNA ligation G0:0006288
-base-excision repair\, gap-filling G0:0006287
-bypass DNA synthesis G0:0019985
-DNA dealkylation G0:0006307
-DNA ligation during DNA repair G0:0051103
-base-excision repair\, DNA ligation G0:0006288
-DNA replication proofreading G0:0045004
-DNA synthesis during DNA repair G0:0000731
-DNA synthesis during double-strand break repair via homologous recombination G0:0043150
-DNA synthesis during double-strand break repair via single-strand annealing G0:0043151
-gene conversion at mating-type locus\, DNA repair synthesis G0:0000734
-meiotic DNA repair synthesis G0:0000711
-double-strand break repair G0:0006302
-double-strand break repair via homologous recombination G0:0000724
-DNA synthesis during double-strand break repair via homologous recombination G0:0043150
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GO Description GO ID
-double-strand break repair via break-induced replication G0:0000727
-double-strand break repair via synthesis-dependent strand annealing G0:0045003
-DNA double-strand break processing G0:0000729
-gene conversion at mating-type locus\, DNA double-strand break processing G0:0031292
-meiotic DNA double-strand break processing G0:0000706
-DNA recombinase assembly G0:0000730
-meiotic DNA recombinase assembly G0:0000707
-meiotic recombination nodule assembly G0:0007146
-early meiotic recombination nodule assembly G0:0042139
-late meiotic recombination nodule assembly G0:0042140
-heteroduplex formation G0:0030491
-meiotic heteroduplex formation G0:0000713
-strand displacement G0:0000732
-meiotic strand displacement G0:0000714
-strand invasion G0:0042148
-meiotic strand invasion G0:0000708
-double-strand break repair via nonhomologous end-joining G0:0006303
-double-strand break repair via single-strand annealing G0:0045002
-DNA double-strand break processing G0:0000729
-gene conversion at mating-type locus\, DNA double-strand break processing G0:0031292
-meiotic DNA double-strand break processing G0:0000706
-DNA strand renaturation G0:0000733
-DNA synthesis during double-strand break repair via single-strand annealing G0:0043151
-double-strand break repair via single-strand annealing\, removal of nonhomologous ends G0:0000736
-error-free DNA repair G0:0045021
-error-free postreplication DNA repair G0:0042275
-error-prone DNA repair G0:0045020
-error-prone postreplication DNA repair G0:0042276
-mismatch repair G0:0006298
-long patch mismatch repair system G0:0006300
-meiotic mismatch repair G0:0000710
-short patch mismatch repair system G0:0006299
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GO Description GO ID
-non-photoreactive DNA repair G0:0010213
-non-recombinational repair G0:0000726
-double-strand break repair via nonhomologous end-joining G0:0006303
-double-strand break repair via single-strand annealing G0:0045002
-DNA double-strand break processing G0:0000729
-gene conversion at mating-type locus\, DNA double-strand break processing G0:0031292
-meiotic DNA double-strand break processing G0:0000706
-DNA strand renaturation G0:0000733
-DNA synthesis during double-strand break repair via single-strand annealing G0:0043151
-double-strand break repair via single-strand annealing\, removal of nonhomologous ends G0:0000736
-nucleotide-excision repair G0:0006289
-nucleotide-excision repair\, DNA damage recognition G0:0000715
-transcription-coupled nucleotide-excision repair\, DNA damage recognition G0:0000716
-nucleotide-excision repair\, DNA damage removal G0:0000718
-nucleotide-excision repair\, DNA duplex unwinding G0:0000717
-nucleotide-excision repair\, DNA gap filling G0:0006297
-nucleotide-excision repair\, DNA incision\, 3'-to lesion G0:0006295
-nucleotide-excision repair\, DNA incision\, 5'-to lesion G0:0006296
-nucleotide-excision repair\, preincision complex formation G0:0006294
-nucleotide-excision repair\, preincision complex stabilization G0:0006293
-pyrimidine dimer repair via nucleotide excision repair G0:0000720
-transcription-coupled nucleotide-excision repair G0:0006283
-transcription-coupled nucleotide-excision repair\, DNA damage recognition G0:0000716
-postreplication repair G0:0006301
-error-free postreplication DNA repair G0:0042275
-error-prone postreplication DNA repair G0:0042276
-pyrimidine dimer repair G0:0006290
-photoreactive repair G0:0000719
-pyrimidine dimer repair via nucleotide excision repair G0:0000720
-recombinational repair G0:0000725
-double-strand break repair via homologous recombination G0:0000724
-DNA synthesis during double-strand break repair via homologous recombination G0:0043150
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GO Description GO ID
-double-strand break repair via break-induced replication G0:0000727
-double-strand break repair via synthesis-dependent strand annealing G0:0045003
-DNA double-strand break processing G0:0000729
-gene conversion at mating-type locus\, DNA double-strand break processing G0:0031292
-meiotic DNA double-strand break processing G0:0000706
-DNA recombinase assembly G0:0000730
-meiotic DNA recombinase assembly G0:0000707
-meiotic recombination nodule assembly G0:0007146
-early meiotic recombination nodule assembly G0:0042139
-late meiotic recombination nodule assembly G0:0042140
-heteroduplex formation G0:0030491
-meiotic heteroduplex formation G0:0000713
-strand displacement G0:0000732
-meiotic strand displacement G0:0000714
-strand invasion G0:0042148
-meiotic strand invasion G0:0000708
-regulation of DNA repair G0:0006282
-negative regulation of DNA repair G0:0045738
-positive regulation of DNA repair G0:0045739
-single strand break repair G0:0000012
-viral DNA repair G0:0046787
-recruitment of helicase-primase complex to DNA lesions G0:0046799
Table 9.1: DNA repair associated GO terms
Ensembl ID HGNC GO description
ENSG00000097007 ABL1 mismatch repair
ENSG00000100601 ALKBH DNA repair // DNA dealkylation
ENSG00000132466 ANKRD17 mismatch repair
ENSG00000100823 APEX1 base-excision repair
ENSG00000169188 APEX2 DNA repair
ENSG00000137074 APTX single strand break repair // base-excision repair
ENSG00000034533 ASTE1 DNA repair
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Ensembl ID HGNC GO description
ENSG00000149311 ATM DNA repair
ENSG00000175054 ATR DNA repair
ENSG00000085224 ATRX DNA repair
ENSG00000197299 BLM DNA repair
ENSG00000012048 BRCA1 DNA repair // positive regulation of DNA repair
ENSG00000139618 BRCA2 double-strand break repair via homologous recombination
// DNA repair
ENSG00000136492 BRIP1 double-strand break repair
ENSG00000159388 BTG2 DNA repair
ENSG00000134480 CCNH DNA repair
ENSG00000134058 CDK7 DNA repair
ENSG00000147400 CETN2
ENSG00000167670 CHAF1A DNA repair
ENSG00000159259 CHAF1B DNA repair
ENSG00000149554 CHEK1 DNA repair
ENSG00000183765 CHEK2
ENSG00000185043 CIB1 double-strand break repair
ENSG00000008405 CRY1 DNA repair
ENSG00000121671 CRY2 DNA repair
ENSG00000141551 CSNK1D DNA repair
ENSG00000100181 CSNK1E DNA repair
ENSG00000108055 CSPG6 DNA repair
ENSG00000198924 DCLRE1A DNA repair // nucleotide-excision repair
ENSG00000118655 DCLRE1B DNA repair
ENSG00000152457 DCLRE1C DNA repair
ENSG00000167986 DDB1 nucleotide-excision repair













ENSG00000012061 ERCC1 DNA repair // nucleotide-excision repair
ENSG00000104884 ERCC2 transcription-coupled nucleotide-excision repair
ENSG00000163161 ERCC3 transcription-coupled nucleotide-excision repair
ENSG00000175595 ERCC4 nucleotide-excision repair
ENSG00000134899 ERCC5 DNA repair // transcription-coupled nucleotide-excision
repair // nucleotide-excision repair
ENSG00000049167 ERCC8 DNA repair // transcription-coupled nucleotide-excision
repair
ENSG00000174371 EXOl DNA repair // mismatch repair
ENSG00000187741 FANCA DNA repair
ENSG00000181544 FANCB DNA repair
ENSG00000158169 FANCC DNA repair // nucleotide-excision repair
ENSG00000144554 FANCD2 DNA repair
ENSG00000112039 FANCE DNA repair
ENSG00000183161 FANCF DNA repair
ENSG00000165281 FANCG DNA repair
ENSG00000115392 FANCL DNA repair
ENSG00000134452 FBX018 DNA repair
ENSG00000168496 FEN1 DNA repair // double-strand break repair
ENSG00000198793 FRAP1
ENSG00000116717 GADD45A DNA repair
ENSG00000130222 GADD45G DNA repair
ENSG00000110768 GTF2H1 DNA repair
ENSG00000145736 GTF2H2 DNA repair
ENSG00000111358 GTF2H3 nucleotide-excision repair
ENSG00000137349 GTF2H4 DNA repair
ENSG00000185068 GTF2H5 DNA repair
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Ensembl ID HGNC GO description
ENSG00000188486 H2AFX double-strand break repair via homologous recombination
// DNA repair
ENSG00000100118 HMG1L10 DNA repair // base-excision repair, DNA ligation
ENSG00000189403 HMGB1 DNA repair // base-excision repair, DNA ligation
ENSG00000164104 HMGB2 DNA repair // base-excision repair, DNA ligation
ENSG00000172977 HTATIP double-strand break repair
ENSG00000136273 HUS1 DNA repair
ENSG00000178922 HYI
ENSG00000132740 IGHMBP2 DNA repair
ENSG00000161896 IHPK3 DNA repair
ENSG00000198690 KIAA1018 DNA repair
ENSG00000105486 LIG1 DNA repair
ENSG00000005156 LIG3 DNA repair
ENSG00000174405 LIG4 single strand break repair // DNA repair
ENSG00000116670 MAD2L2
ENSG00000129071 MBD4 base-excision repair
ENSG00000170430 MGMT DNA repair // DNA dealkylation
ENSG00000076242 MLH1 mismatch repair
ENSG00000119684 MLH3 mismatch repair
ENSG00000155229 MMS19L DNA repair
ENSG00000020426 MNAT1 DNA repair
ENSG00000103152 MPG base-excision repair // DNA dealkylation
ENSG00000020922 MRE11A double-strand break repair via nonhomologous end-joining
ENSG00000095002 MSH2 mismatch repair // postreplication repair
ENSG00000113318 MSH3 mismatch repair
ENSG00000057468 MSH4 mismatch repair
ENSG00000096474 MSH5 mismatch repair
ENSG00000116062 MSH6 mismatch repair // short patch mismatch repair system
ENSG00000172732 MUS81 DNA repair
ENSG00000132781 MUTYH base-excision repair // mismatch repair
ENSGOOOOO196535 MY018A
ENSG00000104320 NBN double-strand break repair
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Ensembl ID HGNC GO description
ENSG00000198646 NCOA6 DNA repair
ENSG00000140398 NEIL1 DNA repair
ENSG00000154328 NEIL2 DNA repair
ENSG00000109674 NEIL3 DNA repair
ENSG00000065057 NTHL1 base-excision repair // nucleotide-excision repair, DNA
incision, 5'-to lesion
ENSG00000106268 NUDT1 DNA repair
ENSG00000114026 OGG1 base-excision repair
ENSG00000143799 PARP1 DNA repair // base-excision repair
ENSG00000129484 PARP2 DNA repair // base-excision repair
ENSG00000041880 PARP3 DNA repair
ENSG00000102699 PARP4 DNA repair
ENSG00000132646 PCNA DNA repair // base-excision repair, gap-filling
ENSG00000032514 PGBD3 DNA repair // transcription-coupled nucleotide-excision
repair // pyrimidine dimer repair
ENSG00000064933 PMS1 mismatch repair
ENSG00000122512 PMS2 mismatch repair
ENSG00000078319 PMS2L1 mismatch repair
ENSG00000186704 PMS2L11 mismatch repair
ENSG00000127957 PMS2L3 mismatch repair
ENSG00000067601 PMS2L4 mismatch repair
ENSG00000039650 PNKP nucleotide-excision repair, DNA damage removal // DNA
repair
ENSG00000070501 POLB DNA repair // base-excision repair, gap-filling
ENSG00000062822 POLD1 DNA repair // base-excision repair, gap-filling // DNA
replication proofreading
ENSG00000077514 POLD3 DNA synthesis during DNA repair // mismatch repair
ENSG00000177084 POLE DNA repair
ENSG00000100479 POLE2 DNA repair
ENSG00000140521 POLG base-excision repair, gap-filling
ENSG00000136480 POLG2 DNA repair
ENSG00000170734 POLH DNA repair // regulation of DNA repair // pyrimidine
dimer repair // postreplication repair
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Ensembl ID HGNC GO description
ENSG00000101751 POLI DNA repair
ENSG00000122008 POLK DNA repair
ENSG00000166169 POLL DNA repair // nucleotide-excision repair
ENSG00000122678 POLM
ENSG00000130997 POLN
ENSG00000051341 POLQ DNA repair
ENSG00000121031 PRKDC double-strand break repair
ENSG00000110107 PRPF19 DNA repair
ENSG00000164611 PTTG1 DNA repair
ENSG00000113456 RAD1 DNA repair
ENSG00000152942 RAD 17 DNA repair
ENSG00000070950 RAD18 DNA repair
ENSG00000164754 RAD21 double-strand break repair
ENSG00000179262 RAD23A nucleotide-excision repair
ENSG00000119318 RAD23B nucleotide-excision repair
ENSG00000113522 RAD50 double-strand break repair
ENSG00000051180 RAD51 double-strand break repair via homologous recombination
// DNA repair
ENSG00000111247 RAD51AP1 double-strand break repair via homologous recombination
// DNA repair
ENSG00000108384 RAD51C DNA repair
ENSG00000182185 RAD51L1 DNA repair
ENSG00000185379 RAD51L3 base-excision repair
ENSG00000002016 RAD52 DNA repair // double-strand break repair via homologous
recombination // double-strand break repair
ENSG00000197275 RAD54B DNA repair
ENSG00000085999 RAD54L DNA repair
ENSG00000172613 RAD9A DNA repair
ENSG00000151164 RAD9B DNA repair
ENSG00000162521 RBBP4 DNA repair
ENSG00000101773 RBBP8 DNA repair
ENSG00000173959 RBM14 DNA repair
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Ensembl ID HGNC GO description
ENSG00000187456 RDM1
ENSG00000004700 RECQL DNA repair
ENSG00000160957 RECQL4 DNA repair
ENSG00000108469 RECQL5 DNA repair
ENSG00000135945 REV1L DNA repair // error-prone postreplication DNA repair
ENSG00000009413 REV3L DNA repair
ENSG00000111445 RFC5 DNA repair
ENSG00000132383 RPA1 DNA repair
ENSGOOOOOl 17748 RPA2
ENSG00000106399 RPA3 DNA repair
OTTHUMG00000021987 RPA4
ENSG00000048392 RRM2B
ENSG00000183207 RUVBL2 DNA repair
ENSG00000127922 SHFM1
ENSG00000065613 SLK nucleotide-excision repair
ENSG00000072501 SMC1L1 DNA repair
ENSG00000054796 SPOll
ENSG00000132207 SULT1A3 DNA repair
ENSG00000181625 SULT1A3 DNA repair
ENSG00000139372 TDG DNA repair // base-excision repair
ENSG00000042088 TDP1 DNA repair
ENSG00000026036 TNFRSF6B
ENSGOOOOOl 18245 TNP1 single strand break repair
ENSG00000141510 TP53 base-excision repair // nucleotide-excision repair
ENSG00000078900 TP73 mismatch repair
ENSG00000164053 TREX1 DNA repair // mismatch repair
ENSG00000183479 TREX2 DNA repair
ENSG00000077721 UBE2A postreplication repair
ENSGOOOOOl 19048 UBE2B DNA repair
ENSG00000177889 UBE2N
ENSG00000169139 UBE2V2 regulation of DNA repair
ENSG00000076248 UNG DNA repair // base-excision repair
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Ensembl ID HGNC GO description
ENSG00000152669 UNG2 base-excision repair
ENSG00000136709 WDR33 postreplication repair
ENSG00000165392 WRN
ENSG00000124535 WRNIP1 DNA synthesis during DNA repair
ENSG00000076924 XAB2 DNA repair // transcription-coupled nucleotide-excision
repair
ENSG00000136936 XPA nucleotide-excision repair
ENSG00000154767 XPC nucleotide-excision repair
ENSG00000073050 XRCC1 single strand break repair
ENSG00000196584 XRCC2 DNA repair
ENSG00000126215 XRCC3 DNA repair
ENSG00000152422 XRCC4 DNA repair // double-strand break repair
ENSG00000079246 XRCC5 regulation of DNA repair // double-strand break repair
via nonhomologous end-joining
ENSG00000196419 XRCC6 DNA repair // double-strand break repair via
nonhomologous end-joining

















Ensembl ID HGNC GO description
ENSG00000196120
ENSG00000196763 single strand break repair
ENSG00000197229 base-excision repair // nucleotide-excision repair
Table 9.2: DNA repair genes
SNP Gene Reference
rsl042522 TP53 Dumont P, 2003[246]
rsl045642 MDR1 Jamroziak K, 2004(247]
rsl047840 EXOl Wu Y, 2001(248]
rsl047972 AURKA Kemp Z, 2004(41]
rsl048943 CYP1A1 Kiyohara C, 2000(249]
rsl049654 CD36 Kemp Z, 2004(41]
rsl051740 mEPHX Harrison DJ 1999(250]
rs 1056827 CYP1B1 Kiyohara C, 2000(249]
rsl056836 CYP1B1 Kiyohara C, 2000(249]
rsl057910 CYP2C9 Kemp Z, 2004(41]
rsl059060 PMS2 -
rsl0735810 VDR Kemp Z, 2004(41]
rsl0916 CYP1B1 Kiyohara C, 2000(249]
rsl128503 MDR1 -
rsl 143627 IL1B El Omar, 2000(251]
rsll692021 UGT1A7 Strassburg CP, 2002(252]
rsl2917 MGMT Kemp Z, 2004(41]
rsl3181 XPD Yeh CC, 2005(253]
rsl503185 PTPRJ Kemp Z, 2004(41]
rsl566734 PTPRJ Kemp Z, 2004(41]
rsl6260 CDH1 Porter TR, 2002(254]
rsl650697 MSH3 Orimo H 2000(255]
rsl6944 IL1B Kemp Z, 2004(41]
rsl 75080 MLH3 de Jong MM 2004(256]
rsl7561 ILIA Yoshimura K, 2003(257]
rsl7868323 UGT1A7 Strassburg CP, 2002(252]
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SNP Gene Reference
rsl7879961 CHEK2 Kemp Z, 2004[41]
rsl799782 XRCC1 Shen H, 2000[258]
rsl799930 NAT2 Brockton N, 2000[259]
rsl799931 NAT2 Brockton N, 2000(259]
rsl799945 HFE Kemp Z, 2004(41]
rsl799977 MLH1 Bagnoli S, 2004(260]
rsl800562 HFE Kemp Z, 2004(41]
rsl800566 NQOl Kemp Z, 2004(41]
rsl800629 TNF -
rsl800795 IL6 Kemp Z, 2004(41]
rsl801131 MTHFR Kiyohara C, 2000(249)
rsl801133 MTHFR Kiyohara C, 2000(249]
rsl801278 IRS1 Slattery ML, 2004(261]
rsl801280 NAT2 Brockton N, 2000(259]
rsl801282 PPARG Landi S, 2003(262]
rsl801376 BUB1B Cahill DP, 1998(263]
rsl801394 FASTKD3 Kemp Z, 2004(41]
rsl805321 PMS2 -
rsl865434 IRS2 Slattery ML, 2004(261]
rs20417 PTGS2 Kemp Z, 2004(41]
rs2066844 NOD2 Hampe, 2002(264]
rs2066845 NOD2 Hampe, 2002(264]
rs2234922 mEPHX Harrison DJ 1999(250]
rs2273535 STK15 Ewart-Toland A, 2003(265]
rs2276331 CDH1 Kim HC, 2000(266]
rs2287498 TP53 Dumont P, 2003(246]
rs2303428 MSH2 Kolodner RD, 1994(267]
rs25487 XRCC1 Krupa R, 2004(268]
rs25489 XRCC1 Kemp Z, 2004(41]
rs2854744 IGFBP3 Slattery ML, 2004(2611
rs361525 TNF -
rs3750861 KLF6 Kemp Z, 2004(41]
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SNP Gene Reference
rs3808607 CYP7A1 Kemp Z, 2004 [41]
rs4073 IL8 Kemp Z, 2004[41]
rs4148323 UGT1A1 Kemp Z, 2004[41]
rs4149963 EXOl Wu Y, 2001 [248]
rs4149966 EXOl Wu Y, 2001[248]
rs429358 APOE Kemp Z, 2004[41]
rs4648298 COX2 Cox DG, 2004(269]
rs4988235 LCT -
rs649392 CCND1 Kong S, 2000[270]
rs689469 COX2 Cox DG, 2004(269]
rs735943 EXOl Wu Y, 2001(248]
rs7412 APOE Kemp Z, 2004(41]
rs7586110 UGT1A1 Kemp Z, 2004(41]
rs861539 XRCC3 Krupa R, 2004(268]
rs9350 EXOl Wu Y, 2001(248]

































Table 9.4: Non-repair candidate genes examined
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E Using a multistage genetic association approach comprising
= 7,480 affected individuals and 7,779 controls, we identified
3 markers in chromosomal region 8q24 associated with
£ colorectal cancer. In stage 1, we genotyped 99,632 SNPs in
3 1,257 affected individuals and 1,336 controls from Ontario.
jS In stages 2-4, we performed serial replication studies using
- 4,024 affected individuals and 4,042 controls from Seattle,
= Newfoundland and Scotland. We identified one locus on
chromosome 8q24 and another on 9p24 having combined odds
ratios (OR) for stages 1-4 of 1.18 (trend; P = 1.41 x 10"8)
■ and 1.14 (trend; P= 1.32 x 10"5), respectively. Additional
Manalyses in 2,199 affected individuals and 2,401 controls from
France and Europe supported the association at the 8q24 locus
(OR = 1.16, trend; 95% confidence interval (c.i.): 1.07-1.26;
P = 5.05 x 10"4). A summary across all seven studies at the
8q24 locus was highly significant (OR = 1.17, c.i.: 1.12-1.23;
P= 3.16 x 10"11). This locus has also been implicated in
prostate cancer1-3.
Colorectal cancer is a common cause of cancer death in developed
countries. Genetic susceptibility accounts for 35% of disease etiology4,
most of which remains to be explained. We studied 1,257 affected
individuals and 1,336 matched community controls (identified by
population-based random telephone dialing) provided by the Ontario
Familial Colorectal Cancer Registry (OFCCR)5. Affected individuals
with known germline APC, MSH2, MLH1, MSH6 or biallelic MUTYH
mutations were excluded. The initial screen involved three SNP
panels tested using three genotyping technologies: (i) 1,536 SNPs in
227 genes implicated in DNA repair, genome instability, folate
metabolism and other pathways implicated in carcinogenesis, which
we genotyped successfully on 1,226 affected individuals and 1,239
controls using the Illumina GoldenGate technology6; (ii) the Asyme¬
trix Gene Chip 10K coding SNP (cSNP) array containing approxi¬
mately 9,701 coding nonsynonymous SNPs, which we used to
genotype 1,135 affected individuals and 1,157 controls and (iii) two
Affymetrix Mendel arrays each containing approximately 50,000
genomic SNPs, which we used to genotype 960 affected individuals
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Figure 1 Study scheme. The experimental stage 1 and three
sequential validation stages (2-4) are illustrated, with the number of
successfully genotyped affected individuals and controls and the number
of analyzed markers. For OFCCR, the case-control numbers refer to the
lllumina custom array. Attrition of candidate markers of colorectal cancer
is indicated, with two SNPs remaining significantly associated with disease
after validation testing.
~ and 984 controls. After excluding SNPs with low allele frequency or
5 unreliable genotyping data (see Methods for details), we compared
j) 99,632 SNPs among affected individuals and controls (Supplementary
Fig. 1 online).
■j. To determine which associations identified in Stage 1 were true, we
Bjperformed sequential replication studies in independent case-control
series (Fig. 1). The first replication panel tested 1,143 markers selected
from the stage 1 SNP panels. We used different P value thresholds for
marker selection from the three Ontario genotyping data sets owing to
a priori considerations about the number of 'true' associations in
each data set7 (see Methods for details). Our approach for marker
selection was based on optimizing the strati¬
fied false discovery rate (FDR). We estimated
FDR to be 0.68, reduced from an estimate of
0.94 obtained by a naive selection based
on P values alone. We then tested the resul¬
tant SNP panel in two case-control sets, one
from Seattle (687/688) and another from
Newfoundland (452/367). To maximize
power yet allow for heterogeneity between
these two populations, disease-marker asso¬
ciations were estimated using a random effect
model for the log odds ratios8. Replication
was considered to have occurred when the
significance was <0.10 in both Ontario and
the combined validation data sets under the
same model (that is, dominant, recessive or
trend) and when the association was in the
same direction. We identified 76 markers that achieved this threshold
(Supplementary Table 1 online).
We then investigated the 76 putative associations identified in stages
1 and 2 in an early-onset colorectal cancer case-control set from
Scotland (mean age: affected individuals, 49.1 years; controls,
50.9 years). We generated genotypes (975 affected individuals, 1,002
controls) for each of the 76 SNPs either directly (n = 28) or through a
tagging strategy (n = 41) (r2 > 0.7) using data from a concurrent
genome-wide scan in this case-control set using Illumina Human-
Hap300 and HumanHap240S arrays genotyped on the Infinium
platform. The seven SNPs that were neither tagged nor genotyped
directly by this approach were genotyped using Applied Biosystems
(ABI) TaqMan in the same Scottish case-control sample set (see
Supplementary Table 2 online for all genotyping). We then assessed
all 76 putative associations from stages 1 and 2 using an allelic model
of inheritance for evidence of association between each marker or
tag(s) and colorectal cancer phenotype. We used a y} test of allelic
counts (one degree of freedom) unless two or more tagging SNPs were
needed, which required a x2 test using estimated counts of the tagging
haplotype, as implemented in Haploview2. Using a cut-off threshold
of P < 0.10, we found nine SNPs showing evidence for replication in
the Scottish stage 3 sample set (P values between 0.0025-0.0736;
Table 1). These nine loci were then tested for association (stage 4) in a
further, independent Scottish case-control series of older-onset cases
(mean age: affected individuals, 65.8 years; controls 67.9 years).
Excluding missing values, we generated TaqMan genotypes for 1,910
affected individuals and 1,985 controls for the corresponding SNP
identified in stages 1 and 2 (but not the tags used in stage 3). Two of
the associations identified in stage 3 were replicated further in this
stage 4 Scottish case-control sample set: rs 10505477 (tagged by
rs6983267 in stage 3, P = 0.03) and rs719725 (tagged by rs7857628
or rs206636213 in stage 3, P = 0.0025). Stage 4 associations detected
for rsl0505477 gave an OR of 1.16 (c.i. 1.11—1.21; P = 0.001), and for
rs719725, OR = 1.10 (c.i. 1.05-1.15; P = 0.037) in an allelic model.
Supplementary Table 2 contains data for these 76 markers from all
four stages.
To address issues of multiple testing in the four sequential stages
that we used, we evaluated by simulation the likelihood of achieving
the observed results by chance. All four stages of analysis and three
rounds of marker selection were incorporated into the simulation (see
Methods), and we obtained an empirical P value of 0.005, indicating
that identification of two markers in stage 4 with the observed P values
is highly unlikely to be a chance finding. Combining overall genotype
data for stages 1^1 gave an OR of 1.19 (P = 6.40 x 10~9) for the 8q24
Table 1 SNPs associated with colorectal cancer disease status in the stage 3 and 4 study sets
Stage 3 tag SNP Scotland stage 3 Scotland stage 4 Odds ratio
ARCTIC SNP (if used) P value P value (s.e.m.)
rs719725 rs7857628, rs206636213 0.0025 0.037 1.10 (0.05)
rsl0483802 rs910315 0.00317 0.705 1.05 (0.11)
rsl0489565 Direct genotype 0.0258 0.967 0.99 (0.07)
rsl0505477 rs6983267 0.0305 0.001 1.16 (0.05)
rsl0516168 Direct genotype 0.0484 0.105 1.12 (0.07)
rsl 1236164 Direct genotype 0.0506 0.168 0.94 (0.05)
rsl0493889 Direct genotype 0.0508 0.814 0.98 (0.09)
rs850470 Direct genotype 0.0661 0.761 1.02 (0.05)
rsl0491268 Direct genotype 0.0736 0.44 1.04 (0.05)
For each marker from the Ontario data set, the relevant tag SNPs are given, along with the P values for allelic tests of
association in stages 3 and 4. Stage 4 allelic odds ratios and standard error (s.e.m.) are also shown.
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Table 2 Genotyping results using the TaqMan assay at rs!0505477 and rs719725 at each stage of this study
Affected individuals Controls
rsl0505477 GG AG AA GG AG AA OR 95% c.i. P Phomo
Ontario 249 557 361 305 586 297 1.22 1.09-1.37
Newfoundland3 103 213 129 85 176 105 1.01 0.83-1.22
Seattle3 141 333 218 177 327 190 1.20 1.03-1.38
Newfou nd land/Seattle 1.11 0.94-1.31
Scotland-3 179 440 280 230 456 241 1.22 1.07-1.39
Scotland-4 384 970 556 483 988 514 1.16 1.06-1.27
France-Nantes 248 504 293 294 551 272 1.13 1.00-1.27
France-Familial 76 192 102 136 291 112 1.28 1.05-1.55
EPIC 167 372 222 189 365 195 1.13 0.98-1.31
Stages l^t 1.18 1.12-1.25 °PoX 0.74
French/EPIC 1.16 1.07-1.26 5.05 x 10-4 0.54
All cohorts 1-7 1.17 1.12-1.23 3.16 x 10"11 0.85
rs719725 CC AC AA CC AC AA OR 95% c.i. P Phomo
Ontario 138 502 508 159 581 439 1.20 1.07-1.36
Newfoundland 66 208 162 64 156 142 1.01 0.83-1.23
Seattle3 83 324 278 101 337 253 1.15 0.99-1.35
Newfoundland/Seattle 1.09 0.96-1.24
Scotland-3 117 410 353 139 447 314 1.17 1.02-1.34
Scotland-4 264 895 753 301 955 713 1.10 1.01-1.21
France-Nantes 165 510 363 175 537 389 0.99 0.88-1.12
France-Familial 60 175 144 78 249 220 0.92 0.77-1.12
EPIC 121 354 289 108 379 279 0.99 0.86-1.15
Stages 1^4 1.32 x 10"5 0.61
French/EPIC 0.61 0.80
All cohorts 1-7 0.023 0.11
In addition to the genotype counts, odds ratios (OR) based on a log-additive model are shown with their 95% confidence intervals (95% c.i.). Random effect model summary odds
ratios, confidence intervals and P values are also shown, along with P values for tests for homogeneity (Phomo)- Results from Newfoundland and Seattle were combined using a
random effect model, and the combination was considered to be the stage 2 result.
[J. locus (rsl0505477 or rs6983267) and 1.13 (P = 4.98 x 10"5) for the
M9p24 locus (rs719725 and rs7857826).
Communication among a number of groups investigating the
genetics of colorectal cancer led to sharing of data at the 8q24 and
9p24 loci. A consortium genotyped 20 of 76 SNPs from stages 1 and 2
(including rsl 0505477 from 8q24) in 2,199 affected individuals and
2,401 controls derived from the European Prospective Investigation
into Cancer and Nutrition (EPIC), Nantes and French Familial
Case Control studies, resulting in validation of the association
of rsl0505477 with colorectal cancer (log-additive OR = 1.16;
P = 5.05 x 10-4). None of the other 19 SNPs replicated any of the
putative associations from stages 1 and 2 (Supplementary Table 3
online). rs6983267 was also significantly different among affected
individuals and controls in this same group (log-additive OR =
1.16, P = 5.4 x 10-4). The choice of the 20 loci genotyped in these
cohorts was independent of the choice of the nine loci genotyped in
our stage 4. Hence, we do not expect a selection bias in the estimates
of the OR from cohorts derived from France and Europe as may be
true for our results from stages 1^.
To ensure technical consistency across all study sets, we genotyped
rsl0505477 (8q24) and rs719725 (9p24) using TaqMan assays in all
7,480 affected individuals and 7,779 controls. Genotype concordance
between Affymetrix and TaqMan was high (3,865/3,880 individuals, or
99.61%). As expected, rsl0505477 showed association with colorectal
cancer in each set of subjects and in a pooled data set (OR = 1.17,
95% c.i. 1.12-1.23, P = 3.16 x 10~u) (Table 2 and Fig. 2), and the
effect seems to be additive or log additive with each copy of allele A'.
Although the combined stages 1^1 provided evidence for an associa¬
tion with colorectal cancer at the 9p24 locus (OR = 1.14, P = 1.32 x
10~5), the association of rs719725 was not replicated in the EPIC and
French data sets individually. When combined with stages 1^, the
result was only marginally significant (OR = 1.08; P = 0.023) (Table 2
and Fig. 2). Despite this apparent lack of replication, it remains
possible that this marker is a susceptibility locus, but further replica¬
tion will be required in additional case-control sets.
Markers rsl0505477 and rs6983267 are located on chromosome
8q24 within a 17,196-bp region of high linkage disequilibrium (LD)
(Fig. 3). CEU HapMap estimates of LD between rsl0505477 and
rs6983267 (r2 = 0.94) seem robust, as r2 = 0.95 and D' = 0.98 in 325
Scottish subjects genotyped for both SNPs, indicating that both SNPs
efficiently tag each other. Indeed, there are effectively only two
common haplotypes (with frequencies of 0.552 and 0.435) because
there are very few recombinations in the 5,862 bp between rsl0505477
and rs6983267.
Chromosome 8q24 polymorphisms have recently been reported to
be associated with prostate cancer risk. At least three risk-associated
regions, separated by sites of recombination, confer independent
risk' 3,9. The haplotype block containing SNP rs6983267, which we
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rs10505477Figure 2 Odds ratios associated with an
additional copy of allele A at rsl050477 or allele
A at rs719725 in samples of affected individuals
and controls from our four-stage analysis and
validation in several populations, assuming a
log-additive impact on disease risk. Ontario refers
to affected individuals and controls from the
OFCCR. Seattle/Newfoundland is the combined
result from the Seattle and Newfoundland data
sets. Scotland 3 refers to early-onset affected
individual and a matched control set from
Scotland. Scotland 4 refers to later-onset
affected individuals and matched controls.
France/Nantes refers to affected individuals
(n = 1068) and controls (n = 1113) from the
Nantes cohort, France/Familial refers to affected individuals (n = 370) and controls (n = 539) from the Familial Cohort. EPIC refers to affected individuals
(n = 761) and controls (n = 749) from the European Prospective Investigation into Cancer and Nutrition. French/EPIC refers only to the combination of the
Nantes, Familial and EPIC study sets. Symbols are plotted proportionally in size to the number of affected individuals in each data set. Random effect




Ontario 1.20 0.062 ■
Seattle/Newfoundland 1.09 0.064 ■
Scotland3 1.17 0.070 ■
Scotland4 1.10 0.047 ■
France/Nantes 0.99 0.063 ■
France/Familial 0.92 0.096 ■
EPIC 0.99 0.074 ■
Summary-all 1.08 0.033
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identified as conferring risk of colon cancer, also confers prostate
cancer risk with an OR of 1.58 for subjects homozygous for the
risk allele3.
The colon and prostate cancer risk locus at 8q24 contains two
ORFs. One, DQ515897, is an uncharacterized gene with multiple
alternatively spliced products, and rsl0505477 lies within intron 6.
The biological relevance of this alternatively spliced gene product is
unknown. The second ORF, DQ486513, is located 20,414 bp telomeric
to rs 10505477 and is currently categorized as a putative pseudogene
of the transcription factor POU5FP1. There are several regions
of sequence homology with DQ486513 in the human genome,
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Figure 3 LD and locus map of 8q24. LD coefficients (i2) of stage 1 SNP are indicated.
The position and transcription orientation of DQ515897 and DQ486513 mRNA are indicated.
SNPs rsl0505477 and rs6983267, found within the indicated region of LD, are associated with
the colon cancer phenotype.
a 50-bp sequence centered on rs 10505477 appears unique to the
chromosome 8q locus.
In addition to its close proximity to DQ515897 and DQ486513,
rs 10505477 is also 340,873 bp telomeric to the oncogene MYC, which
has a known role in colon cancer biology. We performed immuno-
histochemistry on formalin-fixed paraffin embedded tumor tissue
from genotyped individuals (« = 86) from the OFCCR to assess
MYC protein expression in affected individuals. However, there was
not a statistically significant relationship between genotype and MYC
expression (Supplementary Table 4 online).
The Canadian and French groups initiated their projects with a
hypothesis-driven candidate gene approach. They selected a common
set of 1,536 SNPs using an early version of the
HapMap for 227 candidate genes, of which
138 are implicated in DNA repair and the
remainder in apoptosis, chromosome stability,
cell cycle control or nucleotide metabolism.
The lack of significant hits in an early joint
analysis led to a change in strategy toward a
genome-wide approach. Although 330 SNPs
from this set were investigated in the New¬
foundland and Seattle samples, and a subset
of these moved to later stages, the two loci
that were subsequently replicated in Scotland
were from the genome-wide SNP panels and
not from the hypothesis-based list of genes.
Using our four-stage strategy, the power in
this study was excellent for detecting a locus
with the observed magnitude of effect, assum¬
ing that at least five true loci of such magni¬
tude were in strong LD with our markers.
However, we acknowledge that the strate¬
gy used here may miss variants that influence
colorectal cancer risk, if such variants are rare,
if they exert very small effects, if they interact
with environmental factors or other genes or
if our markers are not in sufficiently strong
LD with such risk variants. Further studies,
using higher-density SNP arrays to increase
genome coverage, are ongoing, which may
lead to the identification of additional com¬
mon risk alleles for colorectal cancer.
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This study shows definitively that a locus on chromosome 8q close
to SNPs rs 10505477 and rs6983267, within a small region of tight
LD, is associated with colorectal cancer susceptibility. This is common
genetic variant was identified by a genome-wide scan using genetic
association to successfully identify and validate a genetic risk factor for
large bowel malignancy. Although it is unlikely that this finding in
itself will have direct clinical relevance for the individual, this
discovery will lead to better understanding of colorectal cancer biology
and disease causation. Furthermore, this marker, in conjunction with
</) others yet to be discovered, could be used in a population setting to
'*£ stratify risk. Groups with marginally elevated risk could be identified
g so that they might benefit from a tailored approach to screening
S? and/or preventative interventions.
1 METHODS
^ Study populations. Individuals with colorectal cancer and population controls
j|j participating in three familial cancer registries (two in Canada, one in the US)
3 were used in the initial phases of this study. Cases and controls from the
<2 Ontario Familial Colorectal Cancer Registry (OFCCR) were used for the initial
> analyses that detected associations, and then the Newfoundland Familial
g Colorectal Cancer Registry (NFCCR) and the Seattle Familial Colorectal Cancer
== Registry (SFCCR) were used to assess consistency in different populations.
Stage 3 and 4 validation studies were performed on samples from the Scottish
c Colorectal Cancer Genetic Susceptibility Study (COGS) cohort. Further
validation was performed using the Nantes, the EPICS and the French Familial
O Cohort. Details of these populations are provided in Supplementary
D Methods. All subjects provided written informed consent. This study was
approved by the ethics review boards of the Toronto Academic Health Sciences




L SNP panels used by study stage. Stage 1 genotyping used three separated SNP
E panels. The first included 1,502 SNPs from 227 genes, and 34 random SNPs
3 (http://fisher.utstat.toronto.edu/~celia/index.php) anticipated to be of rele-
Z, vance to colorectal cancer biology (Supplementary Table 5 online). Panel 2
^ SNPs involved the Affymetrix GeneChip Human Panel 1 10K array, that
3 included nonsynonymous double-validated public cSNPs, from approximately
^ 8,000 genes10. The complete SNP and gene list can be found at http://
www.affymetrix.com/products/reagents/specific/application_specific.affx.
Panel 3 SNPs on the Affymetrix GeneChip Human Mapping 100K set
Sjkwere selected by the manufacturer (http://www.affymetrix.com/support/
Sjftechnical/manual/taf_manual.affx), producing an average distance between
markers of 26 kb1'.
In stage 2, when selecting markers for the first validation, we allowed our
significance thresholds to vary by platform. We expected differing rates of true
positive associations to occur across the three data sets used in stage 1, owing to
marker selection. For example, we expect more true positive associations in the
Illumina custom set (selected at candidate gene loci) than in the Affymetrix
100K set. We identified the optimal configuration of markers to minimize the
expected false discovery rate7. Markers (1,152) were selected for validation, of
which 1,143 were successfully genotyped: 330 from the Illumina GoldenGate
platform, 142 from the Affymetrix 10K cSNP platform and 671 from the
100K Affymetrix GeneChip. In stage 3, genotypes (76) were obtained from
a concurrent genome-wide scan and by direct genotyping. The early onset
case-control set were genotyped using Illumina HumanHap300 and
HumanHap240S arrays genotyped on the Infinium platform and by TaqMan
assay for sites not represented on these panels. In stage 4, genotypes (9) in the
Scottish cohort, which was unrestricted by age, were measured by TaqMan
assay. Selection of SNPs and genotyping of the Nantes, EPICs and French
Familial study were based on the Illumina HumanHap300 and Human-
Hap240S arrays.
Statistical analysis. To obtain the Ontario data, using 10,000 permutations of
case-control labels, disease-marker associations were calculated for each marker
by calculating the empirical significance associated with the largest of three test
statistics: dominant, recessive and a test for trend12. False discovery rates were
estimated13. Markers were selected for replication in the Seattle and New¬
foundland datasets by minimizing the platform-stratified false discovery rate8
(see SNP panels, Stage 2, above). This led to different P-value selection
thresholds for the three genotyping datasets on the Ontario data.
For the first replication, data from two sources, Seattle (698 affected
individuals, 700 controls) and Newfoundland (452 affected individuals,
367 controls), were combined. For each marker and each population, dominant,
recessive and trend log odds ratios and empirical estimates of each s.e.m. were
obtained, the latter by dividing the log odds ratio by the normal statistic
associated with the empirical Rvalue obtained from 10,000 permutations. Stage
2 disease-marker associations were estimated by combining the two population-
specific log odds ratios using random effect models8. The P value for association
was obtained by testing whether the summary log odds ratio was zero.
Model-specific odds ratios were compared between stage 1 and stage 2 to
determine direction of effect. To obtain an odds ratio measure corresponding to
the trend test, we calculated the log-additive odds ratio corresponding to a
linear coding of the number of high-risk alleles in a logistic model.
For stages 3 and 4, tests of disease-marker associations were calculated
using allelic models. The probability that two markers remain significant
after three consecutive rounds of (i) selection of a subset of significant
markers and (ii) testing in new independent data was evaluated via a
simulation study. Specifically, at each stage j of the selection process, we
generated Nj P-values and Nj 'directions', where Nj is the number of markers
genotyped in stage j, N\ = 99,632, N2 = 1,143, N3 = 9 and N4 = 2. The
P values were generated from the uniform distribution, assuming that no
markers were associated with disease, and the 'directions', representing which
allele was the higher risk allele, were generated from Bin(0.5). We sorted the
P values and selected the Nj + 1 smallest P values with a matching direction of
effect. After selecting N4 = 2, we counted the number of simulations where the
first three P values for these two markers were <0.10, the last (in stage 4) was
less than 0.05 and all four directions matched. This empirical significance was
P = 0.005, implying that these two markers are unlikely to be significant by
chance alone.
We calculated power assuming there were one, five or ten loci in strong LD
with one of our markers, with the same differences in allele frequency as
observed at rs10505477 (49% versus 55%). Our power simulations used a
similar design as the type 1 error calculations described in the previous
paragraph, framed around our four-stage analytic strategy, including the
selection at each stage, but including these fixed numbers of true positives.
For only one true positive locus, the most significant marker is likely to be the
true locus only 43% of the time. For five true positives, in 90% of simulations,
the most significant marker will be a true locus, and for ten true positives, the
estimated power is 100% (out of 150 simulations).
Note: Supplementary information is available on the Nature Genetics website.
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Abstract
Background: Evolutionary rates are not constant across the human genome but genes in close
proximity have been shown to experience similar levels of divergence and selection. The higher-
order organisation of chromosomes has often been invoked to explain such phenomena but
previously there has been insufficient data on chromosome structure to investigate this rigorously.
Using the results of a recent genome-wide analysis of open and closed human chromatin structures
we have investigated the global association between divergence, selection and chromatin structure
for the first time.
Results: In this study we have shown that, paradoxically, synonymous site divergence (dS) at non-
CpG sites is highest in regions of open chromatin, primarily as a result of an increased number of
transitions, while the rates of other traditional measures of mutation (intergenic, intronic and
ancient repeat divergence as well as SNP density) are highest in closed regions of the genome.
Analysis of human-chimpanzee divergence across intron-exon boundaries indicates that although
genes in relatively open chromatin generally display little selection at their synonymous sites, those
in closed regions show markedly lower divergence at their fourfold degenerate sites than in
neighbouring introns and intergenic regions. Exclusion of known Exonic Splice Enhancer hexamers
has little affect on the divergence observed at fourfold degenerate sites across chromatin
categories; however, we show that closed chromatin is enriched with certain classes of ncRNA
genes whose RNA secondary structure may be particularly important.
Conclusion: We conclude that, overall, non-CpG mutation rates are lowest in open regions of
the genome and that regions of the genome with a closed chromatin structure have the highest
background mutation rate. This might reflect lower rates of DNA damage or enhanced DNA repair
processes in regions of open chromatin. Our results also indicate that dS is a poor measure of
mutation rates, particularly when used in closed regions of the genome, as genes in closed regions
generally display relatively strong levels of selection at their synonymous sites.
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Background
Regions of open and closed chromatin structure have
recently been defined across the human genome [1], Gil¬
bert et al showed that regions of open chromatin are often
gene dense and appear to correlate well with clusters of
broadly expressed genes. They suggested that open chro¬
matin fibre domains provide a chromatin environment
more conducive to transcriptional activation. However,
many genes are also found in regions of closed chromatin
structure. This raised the question as to why would genes
be maintained in closed chromatin if this meant they were
simply less accessible for transcription. One possibility is
that they need to be subject to especially tight transcrip¬
tional regulation, and that their aberrant or leaky expres¬
sion in inappropriate cells cannot be tolerated. However,
it has also been proposed that open chromatin structure
may make the underlying DNA sequence more suscepti¬
ble to DNA damage [2].
Although some studies have predicted that rates of muta¬
tion are relatively constant across mammalian genomes,
analysis of human-mouse alignments has suggested that
there may be as much as a 3-fold difference in substitution
rates across chromosomes [3], with regions containing
genes involved in extracellular communication displaying
unusually high levels of synonymous substitutions [4].
Previous studies have also shown that, in mammals, genes
within close genomic proximity undergo similar rates of
neutral divergence and evolution [4-6], For example, Wil¬
liams and Hurst showed that the mean difference between
the Ka values (substitution rate at non-synonymous sites)
of 176 pairs of linked genes was significantly lower than
would be expected by chance [5], Similar results were also
observed with Ks (substitution rate at synonymous sites)
and Ka/Ks (often used to infer the mode and strength of
selection). Consequently they proposed that the murid
genome was split into domains of evolution. The reason
for this was unknown, but it is possible that some aspect
of chromatin structure over different genomic regions
influences the rate of DNA damage or its repair.
The availability of a map of long-range chromatin struc¬
ture across the human genome [1] allows us to assess this
idea and, through the comparison of various measures of
neutral variation, we have identified those forms of chro¬
matin structure associated with the highest rates of back¬
ground mutation.
Results and discussion
Non-dS measures ofmutation are highest in closed
chromatin
In order to determine whether background mutation rates
are associated with chromatin stmcture we first deter¬
mined intergenic divergence rates, using human versus
chimpanzee whole genome alignments, in regions whose
chromatin environment in human lymphoblastoid cells
had been determined. The majority of intergenic bases
should be under little or no selection and therefore inter¬
genic divergence should be approximately analogous to
background mutation rates. As shown in Figure 1A, we
found a negative correlation between intergenic diver¬
gence and chromatin structure at non-CpG sites. As open
chromatin is generally more gene rich than closed (and
may therefore contain more regulatory elements than
intergenic regions) we also examined divergence rates in
ancient repeats only. However, these also displayed the
lowest divergence rates when in open chromatin (Figure
IB).
It has previously been proposed that DNA sequences
nearer the centre of the nucleus may be protected from
DNA damage by those on the periphery (the "bodyguard
hypothesis"). Likewise, the chromosomes most enriched
with open chromatin are generally situated towards the
centre of a nucleus [2|. The correlation observed between
divergence rates and chromatin structure may therefore be
an indirect result of these phenomena. We therefore inves¬
tigated whether a correlation between intergenic diver¬
gence and chromatin structure could be observed within
chromosomes. Although chromosomes themselves have
been shown to display some level of polar organization
(such that their most gene-poor regions are those closest
to the nuclear periphery [7]) adjacent intergenic regions
within chromosomes often have very different chromatin
structures despite displaying approximately the same
nuclear localisation. If the observed correlation between
intergenic divergence and chromatin structure reflects the
predictions of the bodyguard hypothesis we would expect
to see no such correlation within chromosomes. This,
however, is not the case. For example, as shown in Figure
1C, there is a significant negative correlation between
intergenic divergence and chromatin structure within
chromosome 1 (r2 = 0.053; p = 0.0043). The two outlier
clones observed in this figure, with a divergence greater
than 0.025, could represent mutational hotspots in the
genome. However, the degree of difference between the
divergence observed in these clones compared with the
rest of the chromosome suggests to us that the alignments
in these regions are more likely be of poor quality.
Removal of these clones increases the significance of the
correlation observed between divergence and chromatin
stmcture (r2 = 0.113; p = 2.5e-05). In total 7 out of 22
chromosomes display a significant negative correlation (p
< 0.05) between clone intergenic divergence and chroma¬
tin stmcture (Chromosomes 1, 2, 5, 8, 12, 17 and 20).
These data therefore argue against the bodyguard hypoth¬
esis being solely responsible for these observed correla¬
tions between chromatin stmcture and intergenic
divergence rates.
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Increased mutation rates in closed chromatin at non-CpG sites. (A+B) Mean intergenic and ancient repeat divergence
observed across chromatin categories (Intergenic r2: = 0.87, p = 9.1 e-05; Intergenic repeats only r2: = 0.93, p = 7.3e-06;
Ancient repeats only r2: = 0.93, p = 6.1 e-06). (C) Intergenic divergence of each I Mb clone from chromosome I against their
corresponding chromatin score (10 clones containing less than 10,000 intergenic bases were excluded). (D) Mean human SNP
densities (SNPs/bp) observed across chromatin categories (All SNPs r2: = 0.89, p = 0.016; Single random detection protocol
(TSCM0019) SNPs only r2: = 0.93, p = 0.008).
Another measure often used to predict mutation rate is
SNP density [8,9], It is predicted that as a large proportion
of intergenic sequence is non-functional and that there
has been little time for selection to act on SNPs, their den¬
sity along the genome should generally reflect underlying
mutation rates. A further benefit of the use of SNPs in this
way is that mutation rates can he predicted without rely¬
ing on sequence comparisons with other species. We con¬
sequently determined the mean intergenic SNP densities
observed across chromatin categories. As shown in figure
ID the mean SNP density was also lowest in the most
open regions of the genome.
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There is therefore strong evidence that mutation rates are
associated with chromatin structure. Not only are inter-
genic, intronic (Figure 2A) and ancient repeat divergence
rates highest in closed chromatin but the density of SNPs
is also elevated in the most closed regions of the human
genome. Thus we hypothesise that closed regions of the
genome are simply less accessible to DNA repair mecha¬
nisms.
It should be noted however that chromatin stmcture is
likely to be only one ofseveral factors associated with neu¬
tral divergence rates in the human genome. This is most
apparent on chromosome 19, and to a lesser extent chro¬
mosome 8, which show substantially higher mean inter-
genic divergence rates in our analysis than the other
autosomes. Whereas chromosome 19 and chromosome 8
display mean intergenic divergences of 1.5% and 1.3%
respectively, the divergence rates of all other autosomes
fall between 1 and 1.2%. As chromosome 19 is particu¬
larly enriched with open chromatin [1], its high diver¬
gence levels are contrary to what is generally observed
across the autosomes. The high levels of divergence
observed along chromosome 19 are consequently likely
to be a result of factors other than chromatin structure.
Gene distribution and chromatin structure
As shown in figure 3A, housekeeping genes are generally
located in the more open regions of the genome and tis¬
sue-specific genes in the most closed regions. This is in
agreement with a previous analysis that illustrated that
nucleosome formation potential is negatively correlated
with expression breadth [10]. Consequently a recent study
by Gazave et al. [11], that showed that the levels of
human-chimpanzee divergence observed in the introns of
housekeeping genes is significantly lower than in other
genes, is in broad agreement with the analysis presented
here. Although CpG dinucleotides were not excluded in
Gazave et al's analysis this is only likely to have led to an
increase in the estimation of divergence in housekeeping
genes due to the enrichment of CpG dinucleotides in
open chromatin. However, intriguingly, when human-
mouse alignments are examined, the introns of tissue-spe¬
cific genes have been shown to contain a greater propor¬
tion of conserved sequence than those of housekeeping
genes 112 ] (in contradiction to what is observed in
human-chimpanzee alignments). We believe this appar¬
ent discrepancy is likely to be the result of the difference
in evolutionary distance investigated, with the examina¬
tion of human-mouse alignments potentially leading to
the identification of regions under (stabilising) selection.
For example, we may expect that closed regions of the
genome contain more DNA elements involved in regulat¬
ing the surrounding chromatin structure whose conserva¬
tion becomes apparent across larger evolutionary
distances.
Through the use of the DAVID program [ 131 that deter¬
mines those biological terms and annotations (for exam¬
ple GO terms) enriched among a set of genes, we
identified further classes of genes most over-represented
in closed chromatin, and therefore likely to be experienc¬
ing the highest mutation rates. Of the 148 genes in the
most closed regions of the genome, 40 encode glycopro¬
teins (p for enrichment: 0.000074) and 22 were associ¬
ated with the G-protein coupled protein signaling
pathway (p = 0.00011). Glycoproteins and G-protein cou¬
pled receptors are involved in immune response and cell
signaling and it has previously been proposed that such
genes are likely to evolve quickly in response to changing
stimuli [4]. Being located in closed regions of the genome
(where we have observed background mutation rates
(intergenic divergence and SNP density) are particularly
high) will allow this more rapid evolution. Housekeeping
genes, on the other hand, that are enriched in open chro¬
matin, have previously been shown to evolve relatively
slowly [14], The location of a gene in the genome and its
subsequent local chromatin stmcture may therefore, at
least partly, be governed by the suitability of the local
mutation rate it confers.
dS, unlike dN and dNIdS, is highest in regions of open
chromatin
dS has historically been used as a further surrogate meas¬
ure of basal mutation rates, as synonymous sites were
believed to be under little or no selection. Changes at syn¬
onymous sites, unlike at non-synonymous sites, do not
affect the encoded amino acid. In addition, due to the rel¬
atively small effective population sizes of mammals, a
synonymous site would have to experience relatively
strong selection to evolve in a non-neutral manner [15].
As shown in Figure 4A, the average rate of non-synony¬
mous changes (dN) observed in human mouse align¬
ments is 51% higher in the most closed chromatin regions
of the genome than in the most open regions. Similarly,
the ratio of non-synonymous to synonymous substitution
rates (dN/dS), which is frequently used as a measure of
selection, is 61% higher (Figure 4B). However, the average
synonymous rate (dS) for genes in relatively open chro¬
matin is higher than that for genes in a more closed chro¬
matin structure (Figure 4C). This is consistent with the
reported high Ks for human chromosome 19, the human
chromosome with one of the most open chromatin struc¬
tures of all [ 16]. The observation by Hurst et al. of similar
levels of human-mouse dS, dN and dN/dS in linked genes
is likely therefore to be the result of linked genes being
from similar chromatin environments. To ensure the con¬
verse is not true, and that the results observed in this study
are not the result of linked genes, we randomly selected
only one gene from each clone (so that all genes analysed
were approximately 1 Mb apart and therefore unlinked).
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Figure 2
Comparison of splice site divergence observed across chromatin categories. (A) The divergence at non-CpG four¬
fold degenerate and intronic sites on autosomes only, with the divergence observed across the splice sites of the most closed
(B) and open (C) genes shown below. (Closed exonic vs. closed intronic Mann-Whitney U test: p = 4.4e-l6; open exonic vs.
open intronic Mann-Whitney U-test: p = 0.053)
With this selection strategy we still observed similar corre¬
lations to those shown in Figure 3 (not shown).
Although we would expect the enrichment of housekeep¬
ing genes in relatively open regions of the genome as
shown in figure 3A (as open chromatin is likely to pro¬
vide a more conducive environment for transcription),
the lower average dN/dS observed in open chromatin may
simply be a consequence of this higher number of house¬
keeping genes (which are known to evolve slowly) in
these regions. The exclusion of housekeeping genes from
the analysis, however, has little effect on the correlations
in Figure 4 (not shown). Even the exclusion from the anal¬
ysis of all genes whose 5' end is associated with a CpG
island (which includes almost all housekeeping genes
[17] and that are also enriched in open chromatin, Figure
3B) does not lead to the loss of the correlations between
chromatin structure and dN, dS and dN/dS. In fact the rate
of dN in CpG island genes, unlike that in genes not asso¬
ciated with a CpG island, is relatively constant across
chromatin categories and does not show a significant cor¬
relation with chromatin. Consequently selection appears
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Number of tissues Chromatin structure (log2(Open:lnput))
Figure 3
The distribution of gene expression profiles and CpG island genes across chromatin categories. (A) The mean
chromatin structure (log2(Open:lnput)) of genes of differing expression breadth across normal tissues (Kruskal-Wallis p =
7.5e-6) (B) The percentage of genes across chromatin categories that are associated with a CpG island.
to maintain similar levels of dN in genes associated with
a CpG island irrespective of their local chromatin struc¬
ture.
To ensure these results were not confounded by CpG asso¬
ciated or sex chromosome specific factors (sex chromo¬
somes have been shown to display abnormal rates of
divergence when compared to the autosomes [18]), we
calculated divergence rates at non-CpG, fourfold degener¬
ate sites in genes on autosomes only. We also used
human-chimp alignments instead of human-mouse
alignments as the chromatin structure of the chimp
genome should be more similar to that in humans (and
consequently the species of origin for each change is less
important). However, as shown in Figure 2A, the highest
rates of divergence are still observed in genes from the
most open regions of the genome.
Genes in closed chromatin display the highest levels of
selection at synonymous sites
Although historically the synonymous substitution rate
(dS or Ks) has been used as a measure of the rate of muta¬
tion, there is increasing evidence that selection may be
occurring at synonymous sites [15]. To investigate the
potential role of any selection on synonymous sites in the
disparity between dS and other measures ofmutation, we
analysed the rates of divergence observed across intron-
exon boundaries [18], As shown in Figure 2, the rates of
intronic divergence in open regions of the genome are
comparable to those observed at corresponding exonic,
fourfold degenerate sites. This would suggest that genes in
open chromatin display little if any evidence for selection
at their synonymous bases. However, genes in closed
chromatin display markedly higher rates of divergence at
their intronic sites than at corresponding fourfold degen¬
erate sites. Genes in closed chromatin therefore, unlike
those in open, display strong evidence for synonymous
site selection.
Although the rate of selection against both synonymous
transitions and transversions is highest in closed chroma¬
tin, only the rate of synonymous transitions is strongly
positively correlated with chromatin structure (Figure
5A). The rate of transversions at fourfold degenerate sites
shows no obvious trend across chromatin categories (Fig¬
ure 51?) and consequently selection against transversions,
unlike transitions, appears to be independent of any fac¬
tors associated with chromatin structure. We are not aware
of any reason for the observed association between rates
of transitions at non-CpG fourfold degenerate sites and
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Figure 4
Human-mouse divergence across chromatin categories. Mean dN (A), dN/dS (B) and dS (C) in human/mouse coding
sequence alignments. (All protein coding genes dS r2: = 0.99, p = 0.001; dN r2: = 0.92, p = 0.01; dN/dS r2: = 0.92, p = 0.009.
Genes associated with a CpG island dS r2: = 0.72, p = 0.07; dN r2: = 0.17, p = 0.5; dN/dS r2: = 0.64, p = 0.1. Genes not associ¬
ated with a CpG island only dS r2: = 0.84, p = 0.03; dN r2: = 0.95, p = 0.005; dN/dS r2: = 0.92, p = 0.01.).
chromatin structure, but it could reflect constraint in
motifs whose distribution are not uniform across the
genome.
As previously shown, open regions of the genome are par¬
ticularly gene dense whereas closed regions are relatively
gene poor (1 ]. Consequently, the use of dS as a measure of
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The effect of ESEs on fourfold degenerate site divergence and the ncRNA gene distributions observed across
chromatin categories. (A+B) The observed rate of transitions and transversions respectively, at fourfold degenerate sites
with and without ESE sites excluded (Fourfold degenerate site transversions r2: = 0.02, p = 0.69; fourfold degenerate site trans-
versions at non-ESE sites r2: = 0.1 3, p = 0.30; intergenic transversions r2: = 0.92, p = l.2e-05. Fourfold degenerate site transi¬
tions r2: = 0.78, p = 0.001; fourfold degenerate site transitions at non-ESE sites r2: = 0.67, p = 0.004; intergenic transitions r2: =
0.81, p = 4.0e-04). (C+D) The percentage of genes in each chromatin category that are of each Ensembl ncRNA class. Only the
distributions of rRNAs and snRNAs show a significant negative correlation with chromatin structure (rRNA r2: = 0.96, p =
0.004; snRNA r2: = 0.92, p = 0.01)
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mutation rate may be appropriate for a large proportion
of genes. However, the use of dS as a surrogate measure of
mutation rate for genes in closed chromatin will lead to
the under-estimation of the true mutation rate in these
regions and also the miscalculation of the levels of selec¬
tion when used to measure dN/dS.
Exonic Splice Enhancers and RNA secondary structure
It has been proposed that synonymous sites may experi¬
ence constraint because they play a role in controlling
splicing or RNA stability [15]. For example, synonymous
sites may be part of an exonic splice enhancer (ESE) motif
or lead to a more stable base-paired RNA that is less sus¬
ceptible to degradation. Although codon usage bias
(resulting from unequal abundances of tRNAs and subse¬
quent selection at synonymous sites in favour of codons
corresponding to the most abundant tRNAs) has also
been proposed as an explanation of synonymous site
selection, the evidence for this in mammals is weak [19].
We therefore looked at the distribution of each predicted
ESE motif across chromatin categories to see if their rela¬
tive densities could explain the high levels of synonymous
selection in closed chromatin. The density of a large pro¬
portion of ESE hexamers (44%) displayed a significant
negative correlation with chromatin structure. However,
given the base composition of ESE hexamers and coding
regions across chromatin categories, we actually observed
far fewer hexamers displaying a negative correlation than
we would expect by chance (66%). This is because coding
sequence base composition is itself correlated with chro¬
matin structure and ESEs also show biases in their base
composition. As shown in Figure 5A, excluding all sites
from coding regions that overlap a predicted ESE hexamer
leads to only a small increase in the rate of transitions
observed at fourfold degenerate sites. Consequently,
either there are many ESE motifs that are yet to be deter¬
mined, or selection at synonymous sites is at most only
partly the result of exonic splice enhancers.
We also compared the distribution of gene types across
chromatin categories. If genes whose RNA structure is
important were preferentially located in closed chromatin
we may expect an over-representation of non-protein cod¬
ing genes in closed regions. As shown in figures 5C+D,
certain classes of non-protein coding genes are indeed
over-represented in closed chromatin (rRNAs and
snRNAs), while the distribution of other types of genes
such as miRNAs and snoRNAs show no relationship with
chromatin stmcture.
Further analysis is therefore required to determine why
protein coding genes in closed regions of the genome dis¬
play such comparatively high levels of selection at their
synonymous sites. If it is indeed because of a requirement
for a more stable secondary stmcture, then we may expect
that the predicted stability ofmRNAs from closed regions
would be greater than those in open [20], Future tests of
this kind may help determine the reasons behind the
enrichment of selection at synonymous sites in closed
chromatin observed in this study.
Conclusion
We have shown that rates of mutation (intergenic,
intronic and ancient repeat divergence as well as SNP den¬
sity) and synonymous selection are correlated with chro¬
matin stmcture. Regions of open chromatin display the
lowest mutation rates and the least constraint at the syn¬
onymous sites of genes. Consequently previous observa¬
tions of mutational hotspots in the human genome, high
mutation rates around classes of genes involved in extra¬
cellular communication, the low dN/dS observed in
housekeeping genes and the clustering of genes with sim¬
ilar divergence levels can all also be associated with chro¬
matin structure. These correlations are observed despite
the relatively low resolution of the chromatin dataset. The
average length of the clones used in this analysis was 146
kb but the average human exon is approximately a thou¬
sand times smaller than this. There is consequently a dis¬
parity between the DNA regions whose rate of change we
are measuring and the regions whose chromatin stmcture
is known. The ability to measure chromatin stmcture at a
higher resolution in the future may help increase the
strength of these observed correlations.
We believe the lower background mutation rate observed
in open regions of the genome in this study is likely to be
a result of these regions being more accessible to repair
mechanisms. Indeed it is known that sites of transcrip¬
tion-coupled repair are clustered in the gene dense (and
therefore) open chromatin regions of the genome [21],
that chromatin remodelling is a precursor to DNA repair,
and that efficient DNA lesion detection is associated with
relaxed chromatin stmctures [22-24]. However, contrary
to mutation rate, we believe it unlikely that chromatin
stmcture mediates selection on synonymous sites directly.
Rather, it is more likely that genes that display a high level
of selection at their synonymous sites are preferentially
located in closed regions of the genome. It may be that
these genes in general require especially tight transcrip¬
tional regulation, with a consequence being they are less
accessible for DNA repair.
Chromatin structure is likely, however, to be only one of
a number of factors that are associated with the variance
in divergence rates observed across the human genome.
This is supported by the fact that the levels of intergenic
divergence of chromosome 19 are substantially higher
than other autosomes, despite being gene dense and rela¬
tively open in stmcture. Most notably, both the chromatin
dataset used in this analysis, as well as nucleosome forma-
Page 9 of 12
(page number not for citation purposes)
BMC Evolutionary Biology 2007, 7:72 http://www. biomedcentral.com/1471 -2148/7/72
tion potential [ 10], have previously been associated with
GC content. Although this agreement between the lym-
phoblastoid chromatin dataset used in this analysis and
other more general datasets is reassuring, GC content has
previously been associated with rates of mutation and
selection. However, although the mechanisms underlying
the appearance of GC variability and isochores along the
human genome remain controversial, it has been pro¬
posed that they may be a result of selection for the struc¬
tural requirements of DNA. For example, an increase in
GC content has been associated with an increase in bend-
ability of DNA and a decrease in curvature, properties
associated with more open chromatin [25]. Further anal¬
ysis is consequently required to determine the complex
interplay between the various factors involved in rates of
mutation and selection across the human genome.
Methods
The abundance of open chromatin fibre structure in lym-
phoblastoid cells, at clones spaced approximately 1 Mb
apart along the human genome, was determined as previ¬
ously described [1], Relative chromatin structure was rep¬
resented in this analysis by log2(open chromatin:input
chromatin) values (determined by cohybridising differen¬
tially labelled "open" and input chromatin fragments to a
human genomic DNA microarray). A large
log2(open:input) value in this analysis indicates a region
enriched with open chromatin (see Gilbert et al. for fur¬
ther details). Clones with similar log2(open:input) values
were binned for analysis (with bin sizes adapted to the
amount of data available). The 2,787 human protein cod¬
ing genes that mapped to each of these clones and their
corresponding mouse orthologues were obtained from
Ensembl (unique best reciprocal hits were taken where
possible then reciprocal hits based on synteny). Coding
sequence alignments of each of these orthologous pairs
were derived via protein alignments (using the MUSCLE
[26] and tranalign [27] programs). The codeml program
of the PAML package [28] was used to calculate dN, dS
and dN/dS using the F3 x 4 codon evolution model. Gene
pairs with anomalously high dS values (> 1.270 i.e. twice
the median dS of all human vs. mouse pairs) were
excluded [29],
Gene expression breadth was determined through the
analysis of the Gene Expression Atlas Affymetrix U133A
dataset of Su et al. [30], Intensity levels were averaged
across arrays derived from the same tissue and all tumour
derived arrays were excluded. A gene was defined as
expressed if its mean signal level across all its correspond¬
ing probes exceeded that of the data set median [12], To
identify potential genes with CpG islands, the positions of
predicted CpG clusters were obtained from the UCSC
genome browser [31]. Of these islands, any that were less
than 500 bp long, had a G+C content less than 55 or had
a CpG to expected CpG ratio of less than 0.65 were
excluded [32]. Those genes whose 5' end was within 2 kb
of one of these islands were determined to be potential
CpG island genes.
Human chimpanzee divergence was determined through
the use of the chained and netted human-chimpanzee
alignments available at the UCSC website (hgl7-
panTrol) [33], Ensembl gene predictions were used to
identify intronic, intergenic and protein coding regions.
All exclusively intergenic and intronic regions found
within clones were identified, and divergence measured in
the corresponding sections of the human-chimpanzee
alignment using PAML's baseml with the REV model [28].
Before calculating divergence all sequence from the same
chromatin category was concatenated, in order to mini¬
mise the problems inherent in accurately measuring low
divergence levels in regions of finite length. All bases that
overlapped a CG dinucleotide in either species were
removed from the alignments to conservatively calculate
non-CpG rates of divergence [18].
Intergenic repeats were identified through UCSC's Repeat-
Masker annotation. Ancient repeats were defined as in
Gibbs et al [29] and Taylor et al. [34] as repeats from the
same RepeatMasker subfamily conserved between mouse
and human in the same orientation. Simple repeats and
regions of low complexity were excluded.
The SNP Consortium data were used to calculate SNP den¬
sity across chromatin categories [35]. To ensure these den¬
sities were not biased as a result of the variety of protocols
used to detect SNPs (some of which were chromosome
specific), SNP densities across chromatin categories were
also calculated using only SNPs randomly identified via
theTSCM0019 protocol (a panel of 24 DNAs sequenced
by the Sanger Centre, for more details see: [36]). The loca¬
tion of TSC SNPs was determined by mapping their sslds
to current rslds via data available at dbSNP.
Predicted Exonic Splice Enhancer (ESE) hexamers were
obtained from Fairbrother et al. [37]. The occurrence of
each of these hexamers in the coding regions of each of
the genes that mapped to a 1 Mb clone was determined.
In order to identify the number of hexamers we would
expect to detect by chance given the base composition of
the genes and hexamers, we randomly shuffled the bases
in each of the coding regions 100 times and recalculated
the occurrence of each of the hexamers. The distribution
of non-protein coding genes across chromatin categories
was determined through Ensembl annotations.
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Germline Susceptibility to Colorectal Cancer Due to Base-Excision Repair
Gene Defects
Susan M. Farrington,1'4'* Albert Tenesa,1,4'* Rebecca Barnetson,1,4 Alice Wiltshire,1-4
James Prendergast,1,4 Mary Porteous,1,2 Harry Campbell,1-3 and Malcolm G. Dunlop1,2
'Colon Cancer Genetics Group, School of Clinical and Molecular Medicine, 2Clinical Genetics Department, and 'Public Health Sciences,
University of Edinburgh, and "Medical Research Council (MRC), Human Genetics Unit, Edinburgh
DNA repair is a key process in the maintenance of genome integrity. Here, we present a large, systematically
collected population-based association study (2,239 cases; 1,845 controls) that explores the contribution to colo¬
rectal cancer incidence of inherited defects in base-excision repair (BER) genes. We show that biallelic MUTYH
defects impart a 93-fold (95% CI 42-213) excess risk of colorectal cancer, which accounts for 0.8% of cases aged
<55 years and 0.54% of the entire cohort. Penetrance for homozygous carriers was almost complete by age 60
years. Significantly more biallelic carriers had coexisting adenomatous polyps. However, notably, 36% of biallelic
carriers had no polyps. Three patients with heterozygous MUTYH defects carried monoallelic mutations in other
BER genes (OGG1 and MTH1). Recessive inheritance accounted for the elevated risk for those aged <55 years.
However, there was also a 1.68-fold (95% CI 1.07-2.95) excess risk for heterozygous carriers aged >55 years,
with a population attributable risk in this age group of 0.93% (95% CI 0%-2.0%). These data provide the
strongest evidence to date for a causative role of BER defects in colorectal cancer etiology and show, to our
knowledge for the first time, that heterozygous MUTYH mutations predispose to colorectal cancer later in life.
These findings have clinical relevance for BER gene testing for patients with colorectal cancer and for genetic
counseling of their relatives.
Introduction
The role of base-excision repair (BER) in the mainte¬
nance of genome stability is primarily to counter oxida¬
tive DNA damage, which generates 8-oxoguanine prod¬
ucts (8-oxoG). In humans, MYH (MIM 604933), OGG1
(MIM 601982), and MTH1 (MIM 600312) function in
consort to identify and repair 8-oxoG incorporated into
DNA, as well as to remove modified nucleoside. Re¬
cent studies have identified biallelic germline defects
in MUTYH, in a proportion of families with multiple
colorectal polyposis, that are not due to germline APC
(MIM 175100 and 608456) mutations (Al-Tassan et al.
2002; Sieber et al. 2003). Although these studies provide
indirect evidence, it is important to establish whether
BER gene defects predispose to colorectal cancer (MIM
114500), to estimate the level of associated risk, and to
determine the attributable contribution of such defects
to overall disease incidence. Previous studies have pro-
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vided some supporting evidence that biallelic mutations
are associated with excess cancer risk (Croitoru et al.
2004; Fleischmann et al. 2004). Here, we present an
analysis of the largest cohort study to date, thereby af¬
fording the opportunity to assess the effect of homo¬
zygous and heterozygous BER gene mutations on colo¬
rectal cancer risk. We assembled a large, systematically
recruited prospective cohort of patients from across
Scotland, shortly after diagnosis of colorectal cancer and
irrespective of family history. We also systematically re¬
cruited healthy Scottish population control individuals
through the central National Health Service (NHS). Us¬
ing this population-based resource, we set out to deter¬
mine, by a genetic association strategy, the role of BER
genes in colorectal cancer susceptibility.
Subjects and Methods
Assembly of the Cohort and Sample Collection
A populationwide accrual of prospective colorectal
cancer cases has been in progress since 1999. Cases are
ascertained through direct contact with every surgical
and pathology department in Scotland. All cases had
histologically confirmed adenocarcinoma of the colon
or rectum. Blood DNA samples were obtained from pa¬
tients after counseling and receipt of informed consent.
Population-based and age- and sex-matched controls were
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systematically identified, and blood DNA samples were
obtained from them. A questionnaire about family infor¬
mation and lifestyle and medical history was completed
for patients and controls. Dietary risk-exposure data
were also collected by use of a validated food-frequency
questionnaire. For cases, tumor stage, pathology, clinical
presentation, as well as the presence of synchronous pol¬
yps were documented. These studies are subject to all
necessary approvals from local ethics research committee
(LREC), multicenter research ethics committee (MREC),
and NHS research and development management in ev¬
ery participating hospital.
Analysis of MUTYH Variants Y165C and G382D
A two-stage approach was used to efficiently identify
subjects carrying heterozygous or homozygous BER gene
variants. In the first step, assays were designed using
Primer Express v2.0 software (Applied Biosystems [AB])
for the two commonly reported variants, Y165C and
G382D, in patients with multiple polyposis. Allelic dis¬
crimination for each variant employed allele-specific Taq-
Man MGB probes (AB), resolved on an ABI 7900 An¬
alyzer, by use of SDS v2.1 software. Probe and primer
details are available on request. Each Y165C and G382D
variant identified by the TaqMan approach was con¬
firmed by repeat DNA sequence analysis. In the second
phase, all subjects heterozygous for Y165C and G382D
underwent sequence analysis of the entire coding re¬
gion of MUTYH, and the heterozygote cases were also
screened for OGG1 and MTH1 gene variants. GenBank
accession numbers for the genes are AF527839, NT_
022517, and NT_007819, respectively. PCR products
were treated with Exonuclease 1, shrimp alkaline phos¬
phatase (Amersham Biosciences) and then were se¬
quenced using ABI Big Dye terminator V3.0 chemistry,
with precipitated products separated on an ABI 3700.
Details of primer sequences are available on request.
Using this approach, we identified all homozygotes or
compound heterozygotes and any subjects in whom at
least one allele was either Y165C or G382D. However,
it should be noted that we could have missed some bial-
lelic carriers who did not have these two common vari¬
ants. Hence, if anything, our estimates may underrep-
resent the contribution of BER genes, but we consider
this to be a marginal effect.
Assessment of Variants of BER Genes
Each variant identified by sequencing was confirmed
by repeat sequence analysis. Allele frequency for each
newly identified variant was then determined in at least
340 control chromosomes, to confirm that the variant
was not simply a common polymorphism. Any common
polymorphic variants were discarded, after which each
identified variant was subjected to rigorous bioinfor-
matic analysis. We used SIFT, which predicts deleterious
coding variants on the basis of cross-species conserva¬
tion; PolyPhen, which predicts the effect by use of con¬
servation and any protein structure available in the pub¬
lic domain; T-Coffee, which aligns closely related En-
sembl orthologues; protein domains predicted using Pfam;
assessment of potential splicing effects by use of GEN-
SCAN; ESEfinder; and Berkeley Drosophila Genome
Project splice-site prediction.
Functional Analysis of MUTYH nt 9639 a~^g Variant
A variant was identified that was predicted to affect
splicing (MUTYH; nt 9639 a->g). In this case, RNA was
extracted from blood leukocytes by use of Tri-reagent
(Sigma) and was processed to cDNA (Boeringer Mann¬
heim First Strand Synthesis kit). A transcript product of
475 bp was amplified using exonic primers in exons 10
and 14 (primer details available on request). The product
was cloned using the Topo cloning kit (Invitrogen), and
positive colonies were amplified and sequenced. Similarly,
a genomic amplicon covering the nt 9639 a->g change
and the G382D locus was cloned to demonstrate reces¬
sive inheritance of the two variants.
Test for Association
Association was tested using Fisher's exact test in a
3x2 table of genotype by colorectal cancer status,
thereby making no prejudgment on potential mode of
inheritance.
Estimate of Genotype Relative Risk
As an adaptation of the method of Hugot et al. (2001),
the genotype relative risk (GRR) is defined as follows:
GPPMAI Pr(DlAA) 1RR(AA) -
pf(D|AA) - 1 ,
GRR(Atf)
Pr(D\Aa)
_ Pr(Aa\D) x Pr(AA)
Pr(D|AA) ~~ Pr (AA|D) x Pr (Aa)
and
GRR(IM) =
Pr (D\aa) Pr (aa\D) x Pr(AA)
Pr (D\AA) Pr (AA|D) x Pr (aa)
where Pr(G|D) is the frequency of genotype G among
cases and Pr(G) is the expected Hardy-Weinberg equi¬
librium proportion, as obtained from the allele frequency
in the control population. The control population was
assumed to be a representative sample of the general
population. The 95% CIs for the GRRs were obtained
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Table 1
Population GRR Associated with MYH Y165C
No. of Subjects
with Genotype
Population and Genotype Case Control GRR 95% CI
Entire cohort (P = .228):
GG 0 0 .00 .00-.00
AG 17 8 1.76 .90-4.16
AA 2,202 1,824 1.00 1.00-1.00
U55 (P = 1.000):
GG 0 0 .00 .00-.00
AG 7 4 1.08 .37-3.72
AA 867 535 1.00 1.00-1.00
055 (P = .180):
GG 0 0 .00 .00-.00
AG 10 4 2.42 .96-8.71
AA 1,335 1,289 1.00 1.00-1.00
dence rates, Pr(AJ, were obtained from Scottish Health
Statistics, and the sex-average incidence rates were used.
Then
Pr(AJG)
= Pr(G|A,) x Pr(AJ
Pr(AJG) Pr(G|AJ x Pr(AJ '
Pr (AJG)
_ Pr(G|Av) x Pr(At)
1 -Pr(A,|G) Pr(G| Ax) x [1 -Pr(AJ] '
and
Pr(g|A,)xPf(A,)
p ,r, _ Pr|C|T)«|l-PfM.ilrrj/l^lCj; - Pr(G|A,) x Prj/I.) '
Pr(G|A,)x[l-Pr(A,)J
by bootstrapping 1,000 independent samples. For each
of the samples, the GRR was estimated, then the same
1,000 samples were ordered within each genotype, and
the 50th and 950th estimates were taken as the lower
and upper limits of the 95% CI.
Penetrance Estimates
Penetrance for colorectal cancer at a given age is de¬
fined as the probability that a randomly selected indi¬
vidual with genotype G will develop the disease by that
age, with the assumption that that individual does not
die of another cause. If Ax is the event "affected at age
x:x + 1, given being disease-free at x," then the prob¬
ability that an individual is affectedly age x, given the
genotype G, is Pr (AJG). Similarly if Ax is the event "not
affected at age x:x + 1, given being disease-free at x,"
then the probability that an individual is not affected by
age x, given genotype G, is Pr(AJG). Population inci¬
There were not enough observations for each age,
so Pr (G|Av) was estimated using logistic regression (i.e.,
age was used as a predictor of genotype). Similarly,
Pr(G|Av) was estimated from controls. The penetrance
for genotype G is then defined as:
x
Pc = 1 "lltl -Pr(AJG)] .
1
Estimate of CIs
The 95% CI for the estimate of the penetrance was
obtained by bootstrapping (i.e., by sampling with re¬
placement) samples of cases and controls. A total of 500
independent samples were obtained of size equal to the
total number of cases and controls. Penetrance was es¬
timated for each sample, and mean penetrance over rep-
Table 2
Population GRR Associated with MYH G382D
No. of Subjects
with Genotype
Population and Genotype Case Control GRR 95% CI
Entire cohort (P = .010):
AA 8 0 121.23 44.48-325.10
GA 35 20 1.46 .93-2.43
GG 2,181 1,808 1.00 1.00-1.00
U55 (P = .402):
AA 4 0 146.69 26.71-998.71
GA 12 6 1.24 .54-3.42
GG 864 531 1.00 1.00-1.00
055 (P = .049):
AA 4 0 102.19 22.09-333.10
GA 23 14 1.60 .93-2.95
GG 1,317 1,277 1.00 1.00-1.00
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Table 3
Population CRR Associated with MUTYH Gene
No. of Subjects
with Genotype
Population and Genotype" Case Control GRR 95% CI
Entire cohort (P = .001):
MM 12 0 92.65 41.60-213.20
WM 45 28 1.35 .92-2.07
WW 2,160 1794 1.00 1.00-1.00
U55 (P = .976):
MM 7 0 91.73 22.53-293.41
WM 14 10 .87 .43-1.72
WW 851 523 1.00 1.00-1.00
055 (P = .014):
MM 5 0 77.26 20.51-208.98
WM 31 18 1.68 1.07-2.95
WW 1,309 1,271 1.00 1.00-1.00
W = wild-type allele; M = mutant allele.
licates and standard deviation (SD) were obtained. The
95% CI was calculated using the mean ± 1.96 SD.
Results
Analysis of MUTYH Variants Y165C and G382D
All variants detected by TaqMan analysis were con¬
firmed by genomic sequencing. Eight (0.36%) of the pa¬
tients were homozygous for G382D. There were no ho-
mozygotes for Y165C, but three Y165C/G382D com¬
pound heterozygotes were identified. There were no bial-
lelic defects in any control samples. Association was first
tested, using Fisher's exact test in a 3 x 2 table of ge¬
notype by colorectal cancer status, thereby making no
prejudgment on potential mode of inheritance. Next,
GRR was calculated using the method of Hugot et al.
(2001), because the usual method, estimated by odds
ratio, is not possible because there were no homozygote
controls. The frequency of Y165C and G382D alleles
in cases and controls is presented in tables 1 and 2,
respectively.
The data presented in table 2 establish the fact that
the G382D locus is associated with colorectal cancer in
the complete cohort (P = .0104; GRR 121; 95% CI 44-
325 for the G382D/G382D genotype). To explore any
age-specific effect, the cohort aged <55 years at diagnosis
(U55) was compared with those aged >55 years at diag¬
nosis (055) (table 2). Because of the lower number of
U55 subjects, there was no statistically significant asso¬
ciation with G382D for the U55 cohort, whereas asso¬
ciation for the O55 cohort remained statistically signifi¬
cant (P = .0494). There was no association with the
Y165C locus (table 1), possibly because of the rarity of
the mutant variant in the Scottish population. We con¬
sider the lack of association in the early-onset cohort to
be due primarily to the low allele frequency of these
individual variants and the resultant lack of statistical
power, even though this study involved large case and
control cohorts.
Significance of Other Variants in BER Genes
In light of prior genetic and functional evidence of an
additive effect of G382D and Y165C alleles (Al-Tassan
et al. 2002; Sieber et al. 2003), we next determined the
overall prevalence of biallelic defects, using a pragmatic
approach. To find second BER gene defects, DNA from
all carriers of monoallelic Y165C or G382D mutations
(n = 74) was sequenced for each exon and intron/exon
boundary of MUTYH. BER genes OGG1 and MTH1
were also sequenced in cases with heterozygous Y165C
or G382D MYH alleles. All identified variants were ex¬
cluded as polymorphisms by confirmation of wild-type
sequence in at least 340 control chromosomes and likely
functional relevance assessed by bioinformatic analysis,
as described in the "Subjects and Methods" section.
In addition to the eight G382D/G382D homozygotes
and the three Y165C/G382D compound heterozygotes
described above, we identified a further patient with a
heterozygous G382D mutation who had a second ge¬
nomic MUTYH defect (nt 9639 a->g) that we consider
to be pathogenic. This variant was confirmed to reside
on the wild-type allele by genomic DNA cloning and
sequencing. The variant was predicted to affect splicing.
This was confirmed by cDNA analysis, which showed
only mutant G382D transcript and no wild-type tran¬
script. Thus, the patient was hemizygous for G382D at
the RNA level. The TbgMan approach used for the
G382D variant identified all nt 9639 a->g variants, so
we have systematically screened all samples for this vari¬
ant. Thus, the genotyping strategy would have identified
the MUTYH defect nt 9639 a-*g variant with equal sen¬
sitivity in cases and controls. Hence, we have included
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this variant in further analyses of the effect of overall
MUTYH genotype, for a total of 12 biallelic carriers (all
cancer patients) and 73 subjects (45 patients and 28
controls) with monoallelic MUTYH alleles that we are
confident are pathogenic (table 3).
We next considered other samples that might have a
second BER gene defect. In all, there were an additional
three samples with heterozygous G382D or Y165C al¬
leles that had another BER gene defect that we consider
likely to be pathogenic, but we cannot confirm or refute
this. Hence, we did not include these other BER alleles
in the analysis of the overall effect of putative BER gene
defects (table 3). Two patients with Y165C or G382D
mutations (one of each) had a second allelic variant in
MTH1 (R31Q) that has been reported elsewhere in mul¬
tiple polyposis (Sieber et al. 2003). Codon 31 ofMTH1
is evolutionarily conserved, and bioinformatics interro¬
gation suggests that the R31Q mutation affects protein
function. Furthermore, we identified the variant in a to¬
tal of 2 of 84 patient chromosomes, compared with 0
of 368 control chromosomes, which suggests that this
is not a common polymorphic variant in the population
(although we cannot directly compare R31Q prevalence,
because these are two different groups). Taken together
with previously published studies, we consider that the
MTH1 R31Q variant is likely to be functionally im¬
portant and consequently is likely to be a pathogenic
mutation. One patient with an MTH1 R31Q variant
also had a P391L variant in MYH that is at a highly
conserved residue and is predicted to affect protein func¬
tion. However, the significance of this variant is unclear,
in light of the above discussion. A third patient with a
monoallelic MYH G382D allele also had a variant in
OGG1 (R197W). The variant is at a highly conserved
codon, and bioinformatics analysis predicts a profound
effect on protein function; again, the significance of this
cannot currently be determined.
Analysis of the MUTYH Gene and Colorectal Cancer
Risk
To assess biallelic inactivation of the entire gene, we
calculated the combined risk for all significant MUTYH
variants that had been analyzed in the complete cohort.
This analysis included eight G382D/G382D homozy-
gotes, three Y165C/G382D compound heterozygotes,
and one nt 9639 a~>g /G382D compound heterozygote,
as discussed above. The data presented in table 3 con¬
vincingly establish the fact that the MUTYH gene is sig¬
nificantly associated with colorectal cancer (P = .0012).
Biallelic inactivation imparts an overall 93-fold excess
risk (GRR 93; 95% CI 42-213). As was the case for
analysis of the G382D variant alone, the reduction in
numbers for the U55 cohort resulted in loss of statistical
power to detect association with the gene in that group,
although the 055 group remains significant (P =
.0138).
Separation of the cohorts by age reveals an age-specific
risk effect and shows, for the first time, a significant mono¬
allelic effect for late-onset disease when the empirical
CIs produced by bootstrap analysis are used. There was
a 1.68-fold excess risk (95% CI 1.07%-2.95) for het¬
erozygous carriers aged >55 years and a population-
attributable risk in this age group of 0.93% (95% CI
0%—2.0%). However, these results should be taken with
some caution, because the significance was marginal,
despite the fact that we have studied large case/control
cohorts. Furthermore, analysis by use of standard CIs
for the odd ratios in testing for association gave an al¬
most significant result (P = .085; 95% CI 0.93-3) for
a monoallelic effect. It was only with bootstrap analysis
that this effect was significant at the 5% level. None¬
theless, these are novel observations that suggest that het¬
erozygous MUTYH variants impart a modest increased
risk later in life.
Estimate of Penetrance for MUTYH Gene Defects
We first estimated penetrance for G382D alleles at the
MUTYH locus using the method of Satagopan et al.
(2001), modified for application to a recessive trait. Fig¬
ure 1 shows age-specific penetrance and 95% CIs for the
G382D/G382D genotype alone. Of G382D/G382D car¬
riers, ~55% developed colorectal cancer by age 40 years,
and cancer had developed in all G382D/G382D carriers
by age 65 years. Next, we estimated age-specific pene¬
trance for all systematically determined biallelic defects
identified in MUTYH (fig. 2). This analysis suggests that
biallelic inactivation of the gene is highly penetrant, with
all homozygous carriers developing cancer by age 60
years.
These findings establish the fact that there is a sub¬
stantially elevated colorectal cancer risk early in life for
people with biallelic MYH defects.
Synchronous Polyps in Biallelic MUTYH Cancer
Patients
Data on polyp prevalence in cancer patients by geno¬
type are presented in table 4. It is noteworthy that 4
(36%) of the 11 biallelic carriers with cancer for whom
we had reliable polyp information had no concurrent
metaplastic or adenomatous polyps. This emphasizes the
fact that using polyp presence as a surrogate to enrich
for MUTYH mutation carriers is quite insensitive. The
data presented in table 4 show that there was a clear
relationship between synchronous polyps and MUTYH
genotype (all polyp types P = .025; adenomatous pol¬
yps P = .007; multiple adenomas P < .0001 [with use
of Fisher's Exact Test]). In all, 64% of biallelic carriers
had polyps; in all cases, these were multiple adenomas.
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Figure 1 Penetrance curve of the MYH G382D locus. Age-related penetrance was estimated and plotted for all three genotypes, including
95% CIs.
The same analyses were performed, but with comparison
of only the heterozygotes and wild-type genotypes, using
2x2 contingency tables; there were no significant re¬
sults for presence of polyps with a heterozygote genotype
(P > .24).
Discussion
Taken together, these data establish conclusively that de¬
fects in BER genes predispose to colorectal cancer. The
findings provide robust evidence of causal involvement
of biallelic BER gene defects in early-onset colorectal
cancer, given the fact that there was complete penetrance
by age 60 years. These findings substantially extend pre¬
vious indirect evidence of involvement in colorectal can¬
cer susceptibility through study of families with multiple
polyposis (Al-Tassan et al. 2002; Sieber et al. 2003) and,
combined with our findings of an excess of adenomatous
polyps, suggest that polyps in such cases are premalig-
nant. Our findings are also supported by previous sug¬
gestive evidence from smaller studies that lacked power
to definitively establish whether there is an association
between biallelic MUTYH variants and colorectal cancer
(Enholm et al. 2003; Fleischmann et al. 2004; Wang et
al. 2004).
There is only one previous study (Croitoru et al.
2004) that has shown an association between biallelic
MUTYH variants and colorectal cancer. In that study,
the authors proposed indirect evidence of a heterozy¬
gous effect because they observed nonrandom loss of
heterozygosity of the wild-type allele in colorectal can¬
cer. The findings presented here do, in fact, support their
view and provide the first evidence of a modest colo¬
rectal cancer risk associated with heterozygousMUTYH
mutations later in life. It is noteworthy that we found
evidence of a significant excess risk associated with het¬
erozygous MUTYH gene defects only when we consid¬
ered the entire gene effect, and, importantly, this effect
emerged only for late-onset disease. The effect was small
and only just significant, and the results should be taken
with some caution. Bootstrapping CIs are generally more
robust than asymptotic CIs; however, it must be noted
that asymptotic CIs for the odds ratio gave a slightly
less significant result for the same data set. It is also
possible that some of the excess risk we are detecting
in heterozygotes is due to variants on the other allele
that we have not detected. Data from mouse models
indicates that, on an ApcM,n/+ background, monoallelic
Myh inactivation does not increase tumor burden or the
signature G-T transversions of the remaining Ape allele
in the mouse tumors (Sieber et al. 2004). However, the
study presented here is the largest to date, and previous
studies have concentrated on early-onset disease or
mixed cohorts (Fleischmann et al. 2004; Wang et al.
2004). Thus, only studies involving even larger numbers
of later-onset cancer cases might be able to confirm our
evidence of a monoallelic effect.
The study presented here emphasizes the requirement
for very large population-based cohorts for robust as¬
sessment of the role of putative colorectal cancer sus-
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Figure 2 Penetrance curve of the MUTYH gene. All systematically verified and functionally deficient variants were included in the
calculations, to estimate the penetrance of the entire gene. This therefore includes variants G382D, Y165C, and nt 9639 a->g. W = wild-type
allele; M = mutant allele.
ceptibility alleles by genetic association strategies, even
when relative risk is high. The relatively low allele fre¬
quency is likely to be a feature of many other cancer
susceptibility alleles and raises some concerns for future
power to detect associations where there is no prior
biological hypothesis behind locus selection.
For clinical purposes, it is interesting to note that
more than one-third of biallelic carriers did not have any
synchronous polyps. This emphasizes the fact that use
of polyps as an approach to enrich for MUTYH carriers
with cancer is quite insensitive, in contrast with the find¬
ings of ATC-negative multiple polyposis cases (Sampson
et al. 2003; Sieber et al. 2003). Overall, there was an
excess of synchronous polyps in biallelic carriers com¬
pared with others in this cohort, especially when ade¬
nomatous lesions were considered. Interestingly, mono-
allelic carriers did not appear to have an excess of
polyps, suggesting the possibility that the excess cancer
risk for heterozygotes later in life might be through a
different mechanism.
Data presented here indicate that 1 of 50 patients who
are diagnosed with colorectal cancer at age <40 years
and 1 of 150 patients aged <55 years carry biallelic
mutations in BER genes that are causally linked to can¬
cer development. In defining the mutation carrier fre¬
quency for MUTYH and other BER genes, the present
work informs future decisions about offering genetic
testing to patients with early-onset colorectal cancer.
Furthermore, the findings also have substantial clinical
importance for the siblings of carriers, who have at least
a 1/4 risk of colorectal cancer by age <60 years, by
nature of the recessive genetic trait segregating in the
family. Very large studies of late-onset disease-carrier
status are required to replicate or refute the evidence
Table 4
MUTYH Genotype and the Presence of Synchronous Benign Polyps
No. (%) of Subjects with
Genotype No Polyps All Polyp Types Multiple Polyps Adenomas Multiple Adenomas
MM (n = 11) 4 (36) 7 (64) 7 (64) 7 (64) 7 (64)
WM (n = 44) 31(70) 13(30) 5(11) 8(18) 3(7)
WW (n = 1,167) 859 (74) 308 (26) 100 (9) 224 (19) 54 (5)
Note.—Adenomas were either tubular or tubulovillous subtypes. Other polyps were metaplastic/hyper¬
plastic. Three or more polyps were categorized as "multiple." Reliable concurrent polyp-prevalence data
were not available for all patients with cancer, so the numbers for whom information was available are
provided for each genotype.
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presented here that monoallelic MUTYH defects con¬
tribute to colorectal cancer incidence.
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